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v 
Sudha Satish Savant 
Elucidating the role of Smad7 in pancreatic cancer through in vivo studies 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death with a 
mere 9% survival rate. PDACs harbor KRAS (92-95%) and CDKN2A (90%) mutations, 
overexpress tyrosine kinase receptors, their ligands, and transforming growth factor-β 
(TGF-β) isoforms. Canonical TGF-β signaling is mediated via Smad2, Smad3 and 
Smad4, whereas inhibitory Smad6 and Smad7 attenuate TGF-β signaling. Smad7 is 
overexpressed in PDAC and blocks TGF-β-mediated growth inhibition in vitro. However, 
the exact role of Smad7 in PDAC is not known. We have established a genetically 
engineered mouse model of PDAC in which conditional expression of Smad7 and 
oncogenic KrasG12D are driven in the pancreas by Pdx1-Cre. These LSL-
KrasG12D;SMAD7;Pdx1-Cre(KS7C) mice exhibit accelerated progression of pancreatic 
intraepithelial neoplasia (PanIN) to PDAC by comparison with LSL-KrasG12D;Pdx1-Cre 
(KC)  mice harboring the KrasG12D mutation alone, whereas in the absence of oncogenic 
Kras, pancreatic histology remains normal in spite of a 9- fold increase in Smad7 mRNA 
levels. KS7C pancreata exhibit increased PanIN and pancreatic cancer cell proliferation, 
and these changes are recapitulated in a tetracycline (tet) inducible mouse model of 
Smad7 (KtetS7C). In both models, pre-neoplastic lesions and PDACs exhibited 
increased levels of anterior gradient 2 (AGR2), hyper-phosphorylated retinoblastoma 
protein (p-pRb) and p-Smad2, but low levels of p-Smad3 and p21. Smad7 
overexpression in human pancreatic cancer cells (hPCCs) results in downregulated p21 
and upregulated AGR2 mRNA and protein levels, and decreased binding of Smad3/4 
complex to the AGR2 promoter. Smad3 silencing in hPCCS also resulted in 
downregulated p21 mRNA and upregulated AGR2 mRNA levels. These findings indicate 
that Smad7 blocks TGF-β pathways, in part, by preferentially decreasing Smad3 
vi 
phosphorylation and enhancing AGR2 expression in PDAC, and suggest that targeting 
Smad7 may constitute a novel therapeutic approach in PDAC.  
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1 
1. Introduction 
1.1. Pancreatic cancer 
Cancer is the disease of abnormal cell division and growth with the capacity to spread to 
other parts of the body. Pancreatic cancer (PC) is the cancer of the pancreas and can 
arise in the endocrine (account for 6% of total PC) or exocrine portion (94% of total PC) 
of the pancreas[1-3]. Exocrine tumors of the pancreas include acinar cell carcinoma, 
adenosquamous carcinoma, mucinous cystadenocarcinoma and pancreatic ductal 
adenocarcinoma (PDAC)[3]. PDAC is the most common form of pancreatic cancer which 
accounts for ~85% of total pancreatic tumors[1, 3]. In PDAC the cancer cells appear 
ductal like and bear ductal markers. It is the third leading cause of cancer related deaths 
in the United States with an over-all survival rate of 8%[4]. When presented with 
pancreatic cancer, less than 20% of the patients qualify for surgical resection [1, 3, 5, 6]. 
The dismal statistics associated with PDAC are consequences of late diagnosis of the 
cancer (~91% of the patients present with distant metastasis) due to lack of specific 
diagnostic measures and marked resistance to chemotherapy. Almost 50% of the 
patients diagnosed with metastatic disease have a 5-year survival of only 3% [3]. 
Gemcitabine had been a long standing standard of care for treating pancreatic cancer 
patients [2]. The slight improvement seen in the overall survival rate over the years is 
because of the adjunct therapy with FOLFIRINOX (a combination of fluorouracil, 
leucovorin, irinotecan and oxaliplatin) and nab-paclitaxel [2, 7]. However, these drugs do 
not prolong survival substantially and affect healthy cells adversely, thus decreasing 
quality of life.  
In 2000, Hanahan and Weinberg, described the model of hallmarks of cancer [8] which 
gave a concept based on existing literature about how cancer is a multistep process and 
the ability of a normal cell to acquire capabilities like self-sufficiency in growth signals, 
insensitivity to growth, evading apoptosis, sustained angiogenesis, limitless replicative 
potential and ability to metastasize. Within a decade, further understanding of cancer 
and the microenvironment associated with it, resulted in additional cancer hallmarks like 
deregulation of metabolism and immune system, and tumor promoting inflammation [9]. 
Next generation sequencing has also revealed the presence of heterogeneity in cancers, 
which further adds to the complexities of cancer biology [10-12].  
PDACs are characterized by desmoplasia as a consequence of the aberrant activation 
of pancreatic stellate cells into cancer associated fibroblasts (CAFs) that deposit 
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excessive amounts of extracellular matrix (ECM) components such as collagens and 
fibronectin [13]. In addition, the tumor microenvironment (TME) in PDAC harbors a 
variety of immune and inflammatory cell types that combine to suppress cancer-directed 
immune mechanisms [14] (Figure 1.1).Tumor progression is enhanced through autocrine 
and paracrine signaling cascades activated by growth factors and cytokines.   
 
Figure 1.1 Schematic representation of PDAC desmoplasia 
Schematic representation of PDAC desmoplasia, depicting pancreatic cancer cell and stellate cells 
which secrete cytokines and growth factors, including TGF-β. These cytokines through autocrine and 
paracrine signaling stimulate the stellate and cancer cells, resulting in an activated stroma rich 
environment, increased cancer cell proliferation, migration and invasion. Together these outcomes 
further contribute to PDAC progression. 
 
PDAC is also associated with a high frequency of major driver mutations, most notably 
oncogenic KRAS (95%), CDKN2A (90%), TP53 (70%) and SMAD4 (55%) as well as 
over-expression of tyrosine kinase receptors and ligands that bind to these receptors[11, 
15-21].  
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Understanding the physiology and genetic makeup of pancreatic cancer cells over the 
last two decades has resulted in testing of a wide variety of therapeutics which target all 
the cancer capabilities described above [3, 7, 22, 23]. However, the complexities 
associated with PDAC also result in failure of most of the therapeutics at pre-clinical 
stages [24]. Altogether, while efforts are being made to develop better diagnostic and 
screening methods for PDAC, there is an urgent need for novel therapeutics to improve 
the current therapy and clinical outcome for PDAC[7, 25].   
Transforming growth factor-β (TGF-β) isoforms belong to a large family of cytokines that 
bind and activate a family of serine threonine kinase receptors [26]. Previously, we have 
shown that all three mammalian TGF-β isoforms are over-expressed in PDAC, which 
correlates with decreased survival [27]. In cancer, TGF-β has been shown to play a role 
in tumor-promoter and tumor suppressor activity[28, 29]. TGF-β inhibits cell growth of 
epithelial cells [30, 31] and can also induce senescence and apoptosis and result in cell 
growth inhibition, thus acting as a tumor suppressor. However TGF-β can induce 
Epithelial to Mesenchymal Transition (EMT) of cells, (which is an important characteristic 
of cancer cells) angiogenesis, suppression of immune system and deposition of ECM 
which altogether support tumor growth [32-34].   
Many reports have described the potential of targeting TGF-β in PDAC. TGF-β pathways 
have been targeted by (a) antisense oligonucleotides against the ligand (b) treatment 
with monoclonal antibodies which absorb TGF-β ligands and, (c) blocking the TβR1 
receptor which prevents ligand interaction [35-37]. However, targeting TGF-β alone has 
not shown any promising results, probably due to; 1) mutations in the key components of 
the pathway; 2) the complex interaction and cross talks between the microenvironment 
and cancer cells and; 3) due to the large number of normal physiological functions of 
TGF-β and its context dependent effects[35, 38, 39]. Understanding the molecular 
mechanisms of the TGF-β pathway and its role in PDAC may help develop targets for 
attenuating specific functions of TGF-β. 
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1.2. Risk Factors for PDAC 
There are inherited mutations associated with pancreatic cancer and 10% of pancreatic 
cancer patients have a familial history of the disease. The risk of being diagnosed with 
pancreatic cancer increases with advancing age [2, 25]. Other risk factors are mainly 
related to lifestyle and chronic medical conditions which include obesity, poor diet, heavy 
alcohol consumption and tobacco smoking. Diabetes mellitus and chronic pancreatitis 
(CP) are medical conditions that have also been associated with PDAC[40, 41]. CP is 
the inflammation of the pancreas and it may be due to hereditary factors like gene 
mutations or due to alcohol consumption [23, 42, 43]. The risk ratio (RR) for PDAC 
associated with CP is 2[44]. Studies on pancreatitis as risk factor for PDAC using mouse 
models will be discussed in a later section.  
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1.3. Pancreas 
The pancreas is a retroperitoneal organ, located behind the stomach. The head of the 
pancreas sits in the loop of the duodenum and its neck, body and tail slope upwards and 
extend to the left side[45, 46] (Figure 1.2).  
 
Figure 1.2 Anatomy of the Pancreas 
Figure illustrates location of the pancreas in the “C” loop of the duodenum. The endocrine portion of 
the pancreas encompasses the pancreatic islets which secrete the pancreatic hormones insulin and 
glucagon,that regulate blood glucose levels. The exocrine portion is made up of the acinar cells 
which secrete digestive enzymes that are secreted into the small intestine via the pancreatic duct. 
Figure is adapted from [47]. 
 
~ 95% of the pancreas is made up of ducts and acini which synthesize and secrete 
enzymes that aid digestion[46-48]. The remaining portion of the pancreas is made up 
islets of Langerhans (~1-2%), which functions as the endocrine portion of the pancreas 
consisting of blood vessels, nerves, and connective tissue. The islets secrete hormones 
such as, insulin, glucagon, somatostatin and pancreatic polypeptide which regulate 
blood glucose levels, and exert other metabolic effects[47, 48].  
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1.4. Exocrine Pancreas 
The exocrine pancreas is a compound gland made up of lobules and intralocular ducts 
which drain into the main pancreatic duct. A lobule is a collection of multiple acini or the 
secretory units along with interlobular ducts. Each secretory unit is made of an acinus 
which secretes zymogen granules into an intercalated duct. An acinus is a collection of 
15-100 polarized acinar cells which are the units synthesizing the enzymes and 
releasing them into the intercalated ducts that are lined with centroacinar cells[47, 48] 
(Figure 1.3). 
 
Figure 1.3 Cellular organization of the exocrine pancreas 
Figure illustrates the organization of the exocrine pancreas which is a collection of the pancreatic 
acinar and centroacinar cells and intercalated ducts. The pancreatic acinar cell is made up with 
zymogen granules which produce and secrete enzymes including amylase that aid in digestion. Figure is 
adapted from [49] 
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1.5.  TGF- β signaling  
Transforming Growth Factor Beta (TGF-β) is a cytokine that relays signals to regulate 
cellular processes like; proliferation, differentiation, apoptosis and to maintain 
homeostasis [50-53]. There are 3 isoforms of the TGF-β ligand; TGF-β1, TGF-β2 and 
TGF-β3. These ligands are associated with latent TGF-β binding protein (LTBP)[54]. Of 
the three, TGFβ1 binds to the receptor with highest affinity. Upon activation, the TGF-β 
ligand dissociates from the LTB protein, and binds to the type II TGF-β receptor (TβRII). 
TβRII is a trans-membrane receptor with a serine/threonine protein kinase domain. 
When the TGF-β ligand binds to TβRII, it recruits TβRI and phosphorylates the hydroxyl 
(OH) group of serine and threonine residues on it[55]. The receptors form an activated 
heterodimeric complex and are internalized by endosomes. Within the endosomes, the 
Smad anchor for receptor activation (SARA) protein helps TβRI recruit the Smads to the 
complex[55, 56]. 
Receptor-regulated Smads (R-Smads) are key transcription factors, downstream of the 
TGF-β receptor signaling cascade. TβRI specifically recruits Smad2 and Smad3 to the 
complex and phosphorylates them on serine residues present on their C-terminus. The 
phosphorylation event changes their conformation and increases their affinity for the Co-
Smad4[57]. The heterodimeric complexes of the R-Smads and Smad4 then are 
translocated to the nucleus where they act as transcriptional regulators of genes that 
regulate cell differentiation, migration, growth, apoptosis and extracellular matrix (ECM) 
deposition[58](Figure 1.4). 
TGF-β increases deposition of fibronectin, laminin and collagen[59, 60]. Simultaneously 
it also downregulates expression of ECM proteases and upregulates upregulation of the 
ECM protease inhibitors like Plasminogen Activator (PAI-1) thereby increasing ECM 
deposition[60]. TGF-β inhibits cell growth in epithelial cells while it increases proliferation 
of cells that are mesenchymal in origin [61]. The role of TGF-β’s growth inhibitory actions 
on epithelial cells with respect to cell cycle will be discussed in later section.   
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Figure 1.4 Schematic representation of Canonical TGF-β signaling 
TGF-β ligand binds to TβRII, which then hetero dimerizes with TβRI, resulting in activation of downstream 
signaling. The phosphorylated receptor complex then recruits the receptor Smads, Smad2 and Smad3, and 
phosphorylates them. These then interact with Smad4, a Co-Smad, and are translocated to the nucleus, 
where they bind to promoter regions of target genes, along with transcriptional co –activators and 
repressors to upregulate or inhibit genes, respectively, that regulate cell processes like proliferation, 
migration and angiogenesis. Figure adapted from [26] 
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1.6.  Smad7  
Smad7 is an inhibitory Smad and a potent inhibitor of the TGF- β pathway which was 
first discovered in endothelial cells [62]. The SMAD7 gene is located on Chromosome 18 
in humans and its expression is regulated primarily by Smad2/3 along with a variety of 
transcriptional activators [63, 64]. Smad7 is a ~46 kDa protein and has a conserved Mad 
homology-2 (MH2) domain in its C-terminal that helps it to bind to DNA [65, 66]. Its N-
terminal has minimum homology to the MH1 domains of the receptor or co-Smads. The 
N-terminus of Smad7 allows it to exert its inhibitory effects on TβRI by physically 
interacting with the MH2 domain[67].Smad7 also has a short proline rich linker that 
allows it to interact with other proteins that contain WW domains, a short 40 amino acids 
long protein module [68-70](Figure 1.5). 
 
 
Figure 1.5 Schematics of structure of Smad7 
Smad7 is made up of 426 aa residues in length represented with key regions highlighted. Smad7 
contains a conserved MH2 domain similar to other Smads and has a nuclear localization sequence (NLS) 
at its N terminus. The linker region of Smad7 contains the PY motif, made up of proline rich residues 
which allow it to interact with and bind to other proteins with WW domains. 
 
Smad7 is primarily located in the nucleus and upon activation of the TGF-β signaling 
cascade, it gets translocated to the cytoplasm where it inhibits the pathway by key 
mechanistic features, which include the following: [71](a) Smad7 has been shown to 
recruit phosphatases to the TβRs to dephosphorylate them [72, 73]. (b)It can also bind to 
TβRI and inhibit the recruitment of the R-Smads to the activated receptor complex and 
inhibit their phosphorylation [74, 75]. (c) Previous studies have shown Smad7 to recruit 
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ubiquitin ligases such as Nedd4L and Smurf1/2 to the TβRI, Smad2 and Smad4 to 
promote their degradation [76-78]. (d) NuclearSmad7 has been shown to interact with 
HDAC-1 to modulate gene expression[79].  
1.7.  Cell Cycle 
Cell cycle or cell division is an important cell process that results in duplication of the 
DNA, followed by division of the cell into two daughter cells. When the cell cycle gets 
hijacked, a normal cell is able to avert growth inhibitory signals, impede apoptosis and 
undergo uncontrollable growth, resulting in cancer. The cell cycle is divided into 4 
stages: Gap1 (G1), Synthesis (S), Gap2 (G2) and Mitosis (M). G1, S and G2, together 
are known as interphase where the cell grows and replicates its DNA. Mitosis is the 
phase of cell cycle, where the cell divides to form two daughter cells. Cyclins and cyclin 
dependent kinases (CDK) are important proteins required for the cell to go through 
interphase and reach the mitosis stage. The cyclin-CDK complex phosphorylates target 
substrates to activate or inactivate them, resulting in transcription of genes important for 
cell cycle progression[80, 81]. The retinoblastoma protein (pRb) is an important tumor 
suppressor[82], which is also a substrate for the cyclin-CDK complex[83]. pRb, when 
unphosphorylated, is active and remains bound to the transcription factor E2F[84], 
preventing it’s transactivation. pRb gets phosphorylated (p-pRb) by the CyclinD-CDK4/6 
complex in the G1 phase[85]resulting in the rapid phosphorylation of pRb at other sites 
by other Cyclin-CDK complexes which are phase specific, that result in the hyper 
phosphorylation of pRb. Cyclin E-CDK2 complexes are activated during late G1 and 
early S phase, Cyclin A-CDK2 complexes during early S to mid G2 and Cyclin A/B-
CDK1 complexes during late G2 to M phases (Figure 1.6). Synthesis and degradation of 
each of these complexes are phase specific and tightly regulated. The pRb when 
completely phosphorylated, becomes inactive and dissociates from its complex with E2F 
allowing the latter to bind to the DNA to synthesize proteins important for cell cycle 
progression[86-88]. The cyclins, CDKs, DNA replication and repair proteins are some of 
the known targets for E2F[89]. While the cyclin – CDK complexes drive the progression 
of the cell cycle; they are regulated by the cell cycle inhibitors (CKI’s)[90, 91]. The 
proteins that serve as CKIs belong to two family of proteins – the Inhibitor of CDK4 
(INK4) and the kinase inhibitor protein (KIP/CIP) family[92]. The proteins of the INK4 
family, which includes p16, p15, p18 and p19, are expressed in the early G1 and inhibit 
CDK4/6 activity specifically [93-96]. The CIP/KIP family comprises of p21, p27 and p57 
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[97-101]. These proteins inhibit all the cyclin-CDK complexes, specifically in late G1 and 
S phases to inhibit them and result in cell cycle arrest.  
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Figure1.6 Schematic representation of cell cycle 
The cell cycle is divided into four phases and is governed by the synthesis of cyclins and their 
binding to the cyclin-dependent kinases (CDKs). The early Gap 1 or G1 phase involves Cyclin D and 
CDK4/6 complex. Cyclin E –CDK2 complex control transition of G1 to S phase. Cyclin A-CDK2 then 
drive progression through S and into G2 phase, which is followed by activation of Cyclin A-CDK1 
through G2 phase and mitosis. These complexes phosphorylate pRb at specific residues, resulting in 
its confirmation change, which results in its dissociation from the E2F transcription factor. The 
unbound E2F then binds to the DNA to regulate transcription of genes required for the cell cycle, 
including cyclins. The activity of the CDKs is regulated by the INK4 and KIP/CIP family members 
which comprises of p15, p16, p21 and p27. TGF-β upregulates expression of p15,p21 and p27, thus 
inhibiting G1 phase and resulting in cell cycle arrest.  
 
TGF-β is a growth inhibitory cytokine for epithelial cells. TGF-β can either induce p15, 
p21 and p27 or downregulate expression of c-Myc and Inhibitor of differentiation (Id) -1 
and 3; which then results in inhibition of cyclin D1, cyclin A and cyclin E [102-105]. 
Altogether, the inhibition of the cyclins induces cell cycle arrest by blocking progression 
of late G1 into S phase. 
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1.8.  KRAS mutations in PDAC 
Kras is a small GTPase that is encoded by the KRAS gene. Guanidine nucleotide 
exchange factors (GEFs) facilitate activation of the Kras protein by aiding the exchange 
of GDP with GTP [106]. GTPase-activating proteins (GAPs) facilitate hydrolysis of GTP 
bound to Kras, which results in its activation [107]. KRAS is mutated in 92 to 95% of 
PDAC patients [11, 108]. Mice expressing oncogenic Kras alone (KC), have 
development of pancreatic intraepithelial neoplasia (PanIN) [109]. PanIN are classified 
into various grades depending on their structure and degree of nuclear atypia (Figure 
1.7). PanIN-1A lesions consist of cuboidal to columnar epithelial cells that produce 
mucin and have basal nuclei.  As KC mice age, these PanIN lesions progress towards 
PanIN-2 and PanIN-3 lesions which are characterized by loss of cell polarity and nuclear 
atypia. As they continue to age, the pancreas contains excessive ductal-like lesions 
associated with fibrous stroma[109, 110]. Previously, studies with transgenic mouse 
models expressing oncogenic Kras in an inducible manner have demonstrated that Kras 
is important in PDAC initiation and maintenance [111]. Induction of pancreatitis in the 
presence of Kras mutation accelerates PDAC progression in mice [111, 112]. 
Conditional deletion of tumor suppressors like Rb1, p53, SMAD4 and INK4A have been 
shown to have no effects in PDAC initiation unless supplemented with oncogenic 
Kras[113-117]. Thus, Kras is an important oncogenic driver of PDAC and hence, it is 
important to study effects of other genes in the presence of Kras mutation to understand 
their role in PDAC. The KC model will be used as a control is our studies, and effects of 
Smad7 will be analyzed in the presence of oncogenic Kras.  
14 
 
Figure 1.7 Initiation and progression of PDAC 
Expression of oncogenic Kras in acinar cells of the pancreas results in Acinar to Ductal reprogramming 
(ADM). The ADM lesions then progressively develop into pancreatic intraepithelial neoplasia -1 (PanIN-
1) where the cuboidal cells become columnar but with nuclei basal in position. Age, environmental 
insults, loss of tumor suppressor genes or mutations in pro-cancerous genes can result in progression 
of PanIN-1 to PanIN-2 and PanIN-3 lesions which are characterized by excessive mucin production, loss 
of cell polarity, atypical nuclei, and increasing desmoplasia. PanIN-3 progresses into PDAC with 
uncontrolled cell proliferation and invasion into the surrounding stroma. Adapted from [110].  
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1.9.  Need for better understanding Smad7 in Pancreatic Cancer 
In PDAC, there is aberrant signaling of TGF-β [26, 118] and it has been shown in mouse 
models that targeting TGF-β in PDAC results in decreased tumor growth [119]. However, 
Smad7, an inhibitor of the TGF-β pathway, is also over-expressed in PDAC, [120, 
121]and its overexpression in hPCCs blocks TGF-β mediated growth inhibition that 
culminates into increased tumor growth[121-123]. Smad7 also interacts with p38 MAPK, 
resulting in the inactivation of GSK-3β and accumulation of adenomatous polyposis coli 
(APC) protein, which binds to the microtubule system and contributes to TGF-β-
mediated cell migration [79, 124, 125]. The overexpression of Smad7 has been shown to 
be associated with poor survival in patients with endometrial, esophageal, colorectal, 
gastric, breast, skin and liver cancers[126]. Contrary to these findings, Smad7 has been 
shown to block TGF-β-mediated EMT and migration in HCC (liver cell lines) and lower 
levels of Smad7 correlate with longer survival in patients with liver cancer[127]. In 
prostate cancer cell lines, Smad7 has been shown to promote migratory responses in 
PC-3U cells [124] on one hand, while in another study using the same cells it has been 
shown to play an important role in apoptosis [128]. 
In pancreatic cancer, specifically, Wang et al demonstrated that low Smad7 levels 
correlated with lymph node metastasis and poor prognosis in pancreatic cancer patients 
[129]. Previously the Korc lab has demonstrated that Smad7 blocks TGF-β mediated 
growth inhibition by keeping pRb hyper-phosphorylated and functionally inactivating it 
without blocking activation of p-Smad2 levels[123]. We also demonstrated that Smad7 
allows TGF-β to modulate the expression of genes such as PAI-1 and thioredoxin which 
enhance tumor growth [121, 122]. Xenograft models with COLO-357 cell lines 
overexpressing Smad7 demonstrate increased tumorigenicity. Findings from the Korc 
lab suggest a tumor enhancing function for Smad7, while clinical study suggests 
otherwise (Figure 1.8). Therefore, it is unclear if targeting Smad7 would be beneficial in 
PDAC.   
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Figure 1.8 Yin and Yang model for dual role of Smad7 expression in PDAC 
Smad7 plays a dual role in PDAC. On one hand Smad7 is overexpressed in hPDAC and its 
overexpression blocks TGF-β mediated cell growth inhibition, increases tumorigenicity inactivates p-Rb 
and increases expression of PAI-1 and thioredoxin.  On the other hand low levels of Smad7 in hPDAC 
are associated with increased metastasis to the lymph nodes and liver. Overexpression of Smad7 in 
mouse model of chronic pancreatitis reduced activation of stellate cells, collagen deposition and 
fibrosis.  
 
To better understand the role of Smad7 in context of pancreatic cancer, we have now 
developed a transgenic mouse model with conditional expression of Smad7 in the 
pancreas. In this thesis I intend to accomplish the following specific aims.  
Primarily, I will focus on observational outcomes of overexpression of Smad7 (Smad7 
OE) in the pancreas of mice and its effects in the presence of oncogenic Kras. This will 
elucidate the role of Smad7 in PDAC progression. Based on the previous studies in the 
lab [121-123] and by others [130] we expect Smad7 to accelerate PDAC progression. 
The goal is to determine the effects on canonical signaling pathways in the mouse 
tissues and see if the TGF-β pathway is attenuated by Smad7.  
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Secondly, my goal is to understand the mechanisms by which Smad7 inactivates pRb 
without attenuating p-Smad2 levels in COLO-357 cells. The effects of Smad7 on 
transcription of TGF-β mediated genes and its effects on p-pRb suggest alternative roles 
for Smad7, e.g. protein-protein interactions and or transcriptional co-activator or 
repressor effects without affecting TGF-β canonical signaling. Thus the goal is to unravel 
the mechanisms by which Smad7 modulates TGF-β to regulate gene expression.  
1.10 Pancreatitis, TGF-β and Smad7 
Chronic Pancreatitis (CP) is an important risk factor for PDAC [44]. Previous studies 
have shown that CP combined with genetic mutations in mouse models or with 
increased exposure to high fat diet, alcohol and tobacco smoke can lead to PDAC[131, 
132].TGF-β1, -2 and -3 expression is increased in humans with acute pancreatitis [133] 
and after induction of acute pancreatitis in rats [134]. When wild-type mice are subjected 
to acute pancreatitis, it results in damage to acinar cells, increased inflammatory 
response, infiltration of lymphocytic infiltrates and increase in serum amylase and lipase 
[135].  Simultaneously when transgenic mice expressing heterozygous expression of 
dominant negative TβRII were subjected to acute pancreatitis, it blocked caerulein 
induced tissue damage and attenuated infiltration of neutrophils and macrophages [136]. 
When the dominant negative TβRII transgenic mice were subjected to chronic 
pancreatitis, they exhibited decreased fibrosis when compared to wild type mice [136, 
137]. Smad7 overexpressing transgenic mice also displayed decreased collagen and 
alpha smooth muscle actin (α-SMA) [138, 139] when compared with wild type mice. Anti-
inflammatory treatment in mice induced with chronic pancreatitis and expressing 
oncogenic Kras, resulted in prevention of PanIN progression to PDAC[131, 140]. 
Induction of acute pancreatitis in the presence of oncogenic Kras results in accelerated 
PanIN progression to PDAC [111, 112] Thus we hypothesized that overexpression of 
Smad7 will protect against caerulein-induced acceleration of PanIN progression in the 
KC genetically engineered mouse models (GEMM).  In this thesis, we will compare and 
contrast the KC and KS7C mice subjected to caerulein-induced acute pancreatitis. 
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2. Materials and Methods 
2.1 LSL-SMAD7 Transgene Generation 
The pBTG (plasmid #15037, depositing investigator D. Melton) and pRosa26PAM1 
(plasmid #15036, depositing investigator D. Melton) vectors were obtained from 
Addgene.  These vectors are modifications of vectors originally created by F. Constantini 
(Srinivas et al. [141] and P. Soriano [142], respectively. The pBTG vector has a multiple 
cloning region upstream of IRES-eGFP. A previously cloned HA-SMAD7 cDNA was 
cloned into pBTG using the NheI/SalI restriction sites. After screening the resulting 
clones for successful integration, the entire HA-SMAD7-pIRES-eGFP portion was cloned 
into pRosa26PAM1 using the PacI/AscI restriction sites.  There was appreciable 
recombination observed with amplification of the final product. The final full-length 
(>15Kb) plasmid was linearized using PacI, gel-purified and submitted to the Dartmouth 
Transgenic Mouse Facility for Embryonic Stem (ES) cell electroporation and selection. 
2.2 ES Cell Electroporation, Selection, Injection and Screening 
All ES cell electroporation and the selection was performed by the Dartmouth 
Transgenic Mouse Facility. Following transduction, ES cell pools were selected for 
neomycin resistance and cloned into parallel 96-well plates. The genomic DNA was 
isolated from >250 clones using proteinase K digestion, phenol/chloroform extraction 
and ethanol precipitation. Successful integration events in ES clone genomic DNA were 
first screened en masse using PCR analysis to detect 5’ and 3’ portions of the LSL-
SMAD7 transgene. At least 3 sets of primers were used at each end. For clones that 
amplified both ends of the transgene, a more rigorous PCR analysis was performed. The 
forward primer hybridized to an area within the Rosa26 locus upstream from where the 
5’ arm was homologous and the reverse primer amplified from within the transgene, 
close to the LSL region (refer Table 2.1, Primer 1 and 2).The PCR reaction included 10X 
MGB reaction buffer (0.6M Tris pH8.8, 0.167M (NH4)2SO4, 0.0066M MgCl2 and 0.5% 
gelatin), 10µM dNTP, Dimethyl sulfoxide (DMSO), primers, beta-mercaptoethanol (β-Me) 
and Qiagen HotStar Taq polymerase. The successful product from this PCR was 1.5Kb. 
ES cell clones that had positive signals from all three screening PCRs were then 
screened using standard Southern blot analysis.  Briefly, ten micrograms of genomic 
DNA from each ES clone was run on a 1% agarose gel and transferred overnight to a 
Hybond-XL (GE Healthcare, US) membrane by alkaline capillary transfer.  The 
membrane was then dried and prehybridized with FBI buffer (1.5X SSPE, 10% 
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Polyethylene glycol (PEG) 8000 and 7% Sodium Dodecyl Sulfate (SDS)) at 65C for at 
least 1 hour prior to overnight hybridization. To screen the 5’ integration event, the rosa-
5’ probe was digested from the pROSA26-5’ plasmid (a gracious gift from P. Soriano), 
32P-dCTP labeled and hybridized overnight at 65C. To screen the 3’ integration event, 
the eGFP probe was 32P-dCTP labeled and hybridized overnight at 60C. Following 
hybridization, the membranes were washed extensivelyas follows: 2XSSC briefly, 2x20 
minutes with 2XSSC, 0.1%SDS at 65C, 20 minutes with 0.5XSSC, 0.1%SDS at 65C, 
20 minutes with 0.25XSSC, 0.1%SDS at 65C, and a final 20 minutes with 0.1XSSC, 
0.1%SDS before exposing to film for 48 to 96 hours at -80C.  Targeted clones were 
expanded for blastocyst injection. 
2.3 Generation of SMAD7 overexpressing transgenic mice 
A lox-stop-lox (LSL) SMAD7 transgene was created using the Soriano Rosa26 gene trap 
strategy [141, 142]. The transgene includes selection components for screening ES cell 
recombinants; neomycin (NeoR) and Diphteria toxin A (DT-A), a HA-tagged human 
SMAD7 cDNA, and an IRES driving eGFP (Figure 2.1A). Using these materials, the 
transgene was inserted in a manner that allows expression to be driven by the 
endogenous ROSA26 promoter. Integration of the transgene was 85% in ES cell clones 
screened (Figure 2.1B) with the correct position and orientation within the Rosa26 locus 
(Figure 2.1C, 2.1D).  As can be seen, clones #68, 69 and 71 had proper integration of 
the entire transgene, while #72 had a partial recombination event and was not at the 
correct position (Figure 2.1E). Clones #68 and 69 were used for blastocyst injection and 
subsequent Rosa-LSL-SMAD7 mouse generation.  
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Figure 2.1 Generation a of SMAD7 overexpressing transgenic mice 
This figure describes the generation and validation of the Rosa-LSL-SMAD7 (S7) mice.  (A) The S7 
transgene was designed using Soriano Rosa26 gene trap constructs [142]. Within the transgene, a lox-
STOP-lox (LSL) is upstream of HA-tagged human SMAD7, followed by an IRES driving expression of 
eGFP.  EcoRI restriction sites are designated by an “X”.  (B) The left (5’; 526bp product) and right (3’; 
490bp product) panels are PCR analysis detecting for incorporation of different ends of the transgene 
in ES cell clones after two rounds of selection. There was high integration of the transgene, as 
evidenced by a positive PCR signal in >90% of the clones screened. Tx: purified transgene, wt: wild-type 
ES cell genomic DNA.  (C) MGB PCR analysis detecting the correct insertion of the LSL-SMAD7 transgene 
into the Rosa26 locus.  The primers were designed in that the forward primer hybridized to the 
endogenous Rosa26 sequence and the reverse primer hybridized close to the LSL, after the 5’ arm.  The 
target amplification was 1.3Kb and was detected in ~85% of the positive ES cell clones. (D) Southern 
blot analysis using the rosa-5’ probe to screen the 5’ integration event (left) or the eGFP probe to 
screen the 3’ integration event (right).  With an EcoRI digest and rosa-5’ probe (left), the correct 
integration should yield a 4.3Kb band while wild-type should be 15.7Kb.  The blot was stripped and re-
probed with eGFP probe (right), which with an EcoRI digest should yield a 13Kb band only if integrated.   
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2.4 Mouse Maintenance and Genotyping 
Blastocyst injections and chimeric breeding were carried out using the C57bl6/J strain by 
the Dartmouth Transgenic Mouse Facility.  The mice were humanely handled, and 
experiments were approved by the Institutional Animal Care and Use Committee at 
Dartmouth and by Laboratory Animal Resource Centre (LARC) at Indiana School of 
Medicine. Genotyping of the F1 progeny was achieved using an established screening 
protocol for the eGFP sequence by Jackson Labs (refer Table 2.1, Primer 3 and 4). The 
successful F1 progeny was used to maintain heterozygous breeding of Rosa-LSL-
SMAD7 mice. Sections 2.1, 2.2, 2.3 and 2.4 were designed and performed by Dr. 
Alixanna Norris when she was a post-doctoral fellow in Dr. Korc’s laboratory at 
Dartmouth. 
2.5 Generation of KS7C, KtetS7C and KR+/-S7C mouse models 
Genetically Engineered Mice Conditional Rb-/-, Pdx1-Cre mice, and LSL-KrasG12D mice 
were obtained from the Mouse Models of Human Cancer Consortium at National Cancer 
Institute (NCI) (strain numbers 01XC1, 01XL5,and 01XJ6, respectively). The tetO-
Smad7and Rosa26rtTA-EGFP (R26rtTA-EGFP) mice were previously described [143] 
and were a generous gift from Dr. Simon Conway at Indiana University School of 
Medicine.  
KS7C mice: The triple mutant LSL-SMAD7; Pdx1-Cre; LSL-KrasG12D mice (KS7C), and 
various littermate controls (KC or S7C) were on a mixed FVB; 129; C57Bl/6J genetic 
background. These mice were also backcrossed six generations into C57Bl/6Jand KC 
and KS7C mice were assessed at 3 months and 6 months of age. 
KR+/-S7C mice: The quadruple mutant Rb-/-,LSL-SMAD7; Pdx1-Cre; LSL-KrasG12D mice 
(KR+/-S7C), and various littermate controls (KR+/-C or KC) were on a mixed FVB; 129; 
C57Bl/6 genetic background.  
 
KtetS7C: The quadruple mutant tetO-Smad7and Rosa26rtTA-EGFP; Pdx1-Cre; LSL-
KrasG12D mice (KtetS7C) were maintained on a mixed genetic background. Pregnant 
mice were administered green dyed doxycycline food pellets at concentration of 
200mg/kg (BioServ) for induction of Smad7 in utero, or mice were administered green 
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dyed doxycycline food pellets at ages of 1, 2 and 3 months of age, up to 6 months. The 
control mice were provided with regular diet (Figure 2.2).  
 
 
 
Figure 2.2 Schematic for regime of doxycycline food for KtetS7 mice 
KtetS7 mice were fed with Doxycycline food at 1 month, 2 month and 3 month of age to induce 
expression of Smad7 at different time points. Mice fed with regular food (no overexpression of Smad7) 
were used as controls. 
 
2.6 DNA extraction from tail  
Tail snips were collected from 2 week old mice and digested with 150 µL tail lysis buffer 
at 95ºC for 50 minutes in thermocycler. The tails were cooled and neutralized with 1M 
Tris HCl, pH 8.2. 
 
2.7 Genotyping 
LSL-KrasG12D 
The protocol provided on NCI mouse repository was used to amplify mutant LSL-
KrasG12D allele. 
 
Pdx1-Cre, LSL-SMAD7,tetO-Smad7 
Refer to Table 2.2 for PCR set up and Table 2.3 for cycling conditions. 
 
LSL-Rb-/- 
The protocol provided on NCI mouse repository was used to amplify LSL-Rb-/-allele with 
slight modifications. There was no DMSO used and the final concentration of MgCl2 used 
was 1.25mM compared to 2mM in final reaction. For the PCR conditions, the annealing 
time was reduced to 1 minute instead of 2 minutes. 
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Rosa26rtTA-EGFP 
Protocol as described under JaxLab stock#005670. 
2.8 RNA isolation from murine pancreatic tissues and cell lysates and conversion 
to cDNA 
RNA was isolated from frozen pancreatic tissue of mice using the low-temperature 
guanidine isothiocyanate method as described previously [144, 145]. RNA was isolated 
from cell lysates using Trizol – Chloroform method [146]. The RNA was then analyzed 
for quantity and contamination on Nano drop (Thermo Scientific). Equal amount of RNA 
(50ng-2000ng) for each sample was diluted with water to make up the volume of 9 µL. It 
was then converted to cDNA using a high capacity RNA to cDNA kit from Applied 
Biosystems (Carlsbard, CA). 
2.9 DNA extraction from cells 
DNA was isolated from human pancreatic cancer cells (hPCCs) using the spin column 
protocol with DNeasy kit from Qiagen. 
2.10 Gene expression analysis 
Expression of Hs_SMAD7, Rn_SMAD7, Hs_p21, Hs_AGR-2 and Mm_AGR-2 (Hs- 
human, Rn – Rat and Mm- mouse) was determined using pre-validated primer and 
probe sets (Assays on Demand, Applied Biosystems,Carlsbard, CA). Expression of 
MUC1, MUC13 was analyzed using SYBR green method. 2X power SYBR Green 
enzyme mix (Applied Biosystems) 2X Fast Taqman PCR mix (Applied Biosystems, 
Carlsbard, CA) were used to prepare a 20 µL reaction with primer and an equal amount 
of cDNA. qPCR was performed with an ABI ViiATM 7 sequence detection system (Applied 
Biosystems, Carlsbard, CA). Each sample was assayed in triplicates and Rps6, β-actin 
or 18S were used as endogenous controls for normalization in tissues, mPCCs and 
hPCCs respectively. Gene expression was calculated relative to control using the 2-
ΔΔCt method. Data are plotted as means +/- SEM.  
2.11 Protein isolation and quantification 
Protein was isolated from cells by using complete lysis buffer (RIPA buffer with 1X 
protease inhibitor cocktail (tablets from Roche, Mannheim, Germany), 10mM Sodium 
orthovandate, 10mM β-Glycerophosphate and phenylmethylsulfonyl flouride (PMSF)). 
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The protein in each sample was quantified by Bicinchoninic Acid Assay (BCA) using the 
Pierce BCA Protein Assay Kit from Thermo Fisher Scientific (Rockford, IL).  
2.12 Immunoblotting and quantification of bands 
Equal amounts of protein (20μg), as measured by BCA, were run on 10, 12 or 15% 
Sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE), transferred 
to 0.45 or 0.22 µM PVDF membrane, blocked with 5% BSA or 5% skimmed milk 
(according to antibody data sheet) in TBS-0.05%/Tween-20 and immunoblotted with the 
indicated primary antibodies overnight at 4°C. After three washes in TBS-0.05%/Tween-
20, Horse Radish Peroxidase (HRP) conjugated secondary antibodies (1:5000) were 
applied for one hour at room temperature. This was followed by three washes, and 
protein bands were detected using enhanced chemiluminescence (ECL) western blot 
detection reagent (Thermo Fisher Scientific) on X-Ray or Bio-Rad gel documentation 
system using Image lab software. Antibodies against β-actin or α-tubulin were used to 
assess loading of lanes. Quantification of band areas in each immunoblot was 
performed with ImageJ software (http://imagej.nih.gov/ij/), using blots from three 
independent experiments for each set of data. Quantification was presented as mean ± 
SEM. Target protein band intensity was normalized to indicated housekeeping protein. 
For phosphoprotein analysis, normalized signal of each phosphoprotein was expressed 
relative to the normalized total amount of that protein.  
 
2.13 Histology, Immunohistochemistry (IHC), and Immunofluorescence (IF) 
Mice were sacrificed at various time points – 1.5, 3, 6, 9 or 12 months for the KS7C 
mice, 3 months and 6 months for the KtetS7C mice and at 3 months or at morbidity for 
the KR+/-S7C mice. The tissues from each mouse were collected and fixed in 10% 
formalin overnight, processed using an automated tissue processor (STP 420, Thermo 
Scientific, Waltham, MA) and embedded in paraffin. Sections (5µm thick) were prepared 
using the HM355s microtome (Thermo Scientific, Waldorff, Germany). H&E staining was 
performed for one section for each mouse using a standard protocol [147]. For IHC or IF, 
the tissues were deparaffinized, rehydrated and then subjected to antigen retrieval with 
antigen unmasking solution (Vector Labs, Burlingame, CA) or Tris EDTA (pH9).Tissues 
were incubated overnight with primary antibody as per data sheet (refer Table 2.4). For 
IHC detection, biotinylated secondary antibodies and a NOVA RED detection kit (Vector 
Labs) were used. For IF, fluorescent secondary antibodies were used. Nuclei were 
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visualized with 4, 6-Diamidino-2-phenylindole (DAPI).Masson’s Trichrome (American 
MasterTech, Lodi, CA) was performed according to manufacturer’s recommendations. 
Alcian blue staining was performed according to a standard protocol from IHC world 
[147]. 
2.14 IF quantification 
Images were acquired using an Olympus BX60 microscope and a QImaging EXi Blue 
camera. For quantification, images were acquired from 5 different fields at 20X 
magnification and overall intensity was determined using Cell Profiler software and mean 
values were plotted with +/- SEM from 6 mice in each group[39]. 
2.15 Statistics 
One-way ANOVA with Dunnett’s post hoc tests and studentttests were used where 
applicable to test the significance of differences using Sigma Plot 12.0 Software (Systat 
Software, Inc, Chicago, IL). Survival curves and Kaplan-Meyer survival analyses were 
also generated and analyzed using Sigma Plot. A p-value < 0.05 was considered 
statistically significant in all tests.  
2.16 Cell culture 
The human PCC lines (COLO-357 and IUSCPCC-1) were grown in Dulbecco’s Modified 
Eagle Medium(DMEM) (Lonza, Allendale, NJ) supplemented with 7% fetal bovine serum 
(FBS) (Tissue Culture Biologicals, Los Alamitos, CA), 100U/ml penicillin and 100mg/ml 
streptomycin (Hyclone, GE Lifesciences, Logan, Utah). BPXPC-3 and ASPC-1 were 
grown in Rosewell park memorial institute medium(RPMI) media (Hyclone) 
supplemented with 5% FBS, 100U/ml penicillin and 100mg/ml streptomycin. For the 
tetracycline inducible Smad7 cell lines similar media was used, but regular FBS was 
replaced with tetracycline free (TF) FBS (Clontech, Mountain View, CA). The mouse cell 
lines (KC, KR+/-S7C and KS7C) were grown in RPMI supplemented with 5% FBS and 
antibiotics. The KtetS7C cell line was grown in RPMI supplemented with 5% TF FBS and 
antibiotics. The serum free (SF) media used in the experiments was DMEM or RPMI 
containing 0.5% FBS, 5 mg/ml Apo-transferrin, 5 ng/ml sodium selenite and antibiotics. 
For induction of Smad7 in hPCCs and KtetS7C cells, the cells were treated with TF 
media supplemented with 2µg/mL Doxycycline (Sigma Aldrich, St. Louis, MO). Human 
COLO-357 overexpressing SMAD7 PCCs were as described previously [123]. The 
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IUSCC-PC-1 cell line was established from a patient-derived orthotopic xenograft in an 
athymic mouse [148]. IUSCC-PC-1 cells were authenticated, and confirmed to be human 
and free of pathogens and other cell types by IDEXX Bioresearch (St. Louis, MO). PCCs 
were cultured in DMEM with 1% antibiotic (100 units/ml penicillin; 100 mg/ml 
streptomycin) and 7% FBS.0.5nM TGF-β1 was used for all cell culture experiments.  
2.17 Tetracycline inducible SMAD7 overexpressing hPCCs 
Adding c-Myc tag to SMAD7 cDNA: Primers FP_S7a and RP_S7myc (Refer primer table 
for sequence) and clone S7XL6 from Origene (Rockville, MD) was used as a template to 
amplify c-Myc tagged SMAD7 cDNA. Gateway cloning of SMAD7-cMyc cDNA: Next, the 
att B1 and attB2 sites were added to the SMAD7-c-Myc cDNA using primers FP_attB1 
and RP_attB2. This product was gel purified and used as template for cloning into the 
donor vector (pDONRTM221, Invirogen) using BP Clonase enzyme (Invitrogen) to 
prepare the S7-c-Myc P221 entry vector. The plasmid was transformed into NEB® 5-
alpha Competent E. coli (High Efficiency) competent cells (New England BioLabs, 
Ipswich, MA). Miniprep for plasmid isolation was carried out using Qiagen kit for 8 of 
these colonies and the plasmids were screened for presence of SMAD7 by PCR using 
the primers FP_S7a and RP_S7myc. LR Clonase enzyme was then used to catalyze in 
vitro homologous recombination between the entry S7-c-Myc P221 entry plasmid and 
the gateway destination lentiviral vector, PLIX-402 (a gift from David Root, Addgene 
plasmid # 413394). The reaction was then transformed into NEB competent cells and 
once again 8 colonies were picked and their plasmids were screened for SMAD7-c-Myc 
insertion by sequencing using LNCX-FP and PLIX_seqRP. The plasmids were 
sequenced for the transactivator rtTA (reverse tetracycline-controlled transactivator) and 
the Tet Responsive Element (TRE) with PLIX_SQ_FP1 & RP1 and PLIX_SQ_FP2 and 
RP2 respectively. The sequence for SMAD7-c-Myc, rtTA and TRE match 100% when 
blasted against the known sequence plasmid from colony #7. A maxi – prep using 
Qaigen kit was performed for colony # 7 and this was further used for transfecting 
hPCCs.  
The SMAD7-c-Myc PLIX-402 lentiviral plasmid was then transfected into 293T cells, 
along with packaging plasmids PAX-2 and pMD2.G, using lipofectamine to generate viral 
particles. The media from the transfected 293T was collected 48, 72 and 96 hours post 
transfection and used to transduce hPCCs. A similar transfection was carried out using 
the PLIX-402 without the SMAD7-c-Myc gene to generate Sham hPCCs as controls. 4-6 
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µg of puromycin was used to select the hPCCs with the SMAD7-c-Myc gene. The 
hPCCs used for transduction were ASPC-1, BXPC-3, COLO-357 and IUSCC-PC1. 
Validation of SMAD7 mRNA and protein was carried out for ASPC-1, BXPC-3 and 
COLO-357 cell lines.  
2.18 Constitutive overexpression of SMAD7 in hPCCs  
c-Myc tagged SMAD7 in pLNCX vector has been previously described[123].  Phoenix 
cells were transfected with the retroviral c-Myc SMAD7 construct using lipofectamine. 
The media from the transfected Phoenix cells was collected 48, 72 and 96 hours post 
transfection and used to transduce IUSCC-PC1cell line. COLO-357 cells transduced 
with this plasmid have been previously described [123]. Validation of SMAD7 mRNA by 
q-PCR and proteins by western blotting was carried out for both the cell lines.  
2.19 Knockdown of SMAD3 in COLO-357 
pGIPZ lentiviral vector containing SMAD3 targeting shRNA  was transfected into 293T 
cells along with packaging plasmids PAX-2 and pMD2.G using lipofectamine to generate 
virus particles. The viral supernatant from the transfected cells was used to transduce 
COLO-357 cells. Simultaneously Sham COLO-357 (control) were generated using only 
the pGIPZ backbone. The cells were selected with 4 µg of puromycin and then sorted by 
flow cytometery for green fluorescent protein (GFP). Knockdown of Smad3 was 
validated by analyzing mRNA and protein levels. 
2.20 SMAD3 CRISPR of hPCCs 
Guide Oligo sequences targeting Exon 6 of SMAD3 were designed using Blenching 
software. The sequences of which are:  
G1-FP: P-5’CACCGTACGAGCTGAACCAGCGCGT3’; 
G2-FP: P-5’ CACCGCCGGCTCGCAGTAGGTAAC3’. Each guide sequence was then 
annealed with a reverse compliment sequence, G1-RP: P- 5’ 
aaacACGCGCTGGTTCAGCTCGTAC3’ and G2-RP: P-
5’aaacGTTACCTACTGCGAGCCGGC 3’. The annealed guide1 and guide2 were then 
cloned into plasmids pSpCas9n (BB)-2A-Puro (PX462) V2.0 (a gift from Feng Zhang 
[Addgene plasmid # 62987]) and pSpCas9n (BB)-2A-GFP (PX461) V2.0 (a gift from 
Feng Zhang [Addgene plasmid # 48140]) respectively using standard protocol [149]. The 
plasmids containing the guides were then co-transfected into COLO-357 and IUSCC-
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PC-1 cells. Simultaneously plasmids with scrambled guide sequences from Santa Cruz 
Biotechnology (SC-43728) were also transfected into COLO-357 and IUSCC-PC-1 to 
create sham cells. 48 hours post transfection, the cells were sorted for GFP and then 
plated in 7% DMEM with 4µg/mL puromycin. The cells were then allowed to recover, and 
plated as single cells by serial dilution method into 96-well plates. Single cell clones for 
each cell lines were then isolated and validated for Smad3 knockout by protein and 
mRNA expression. The portion flanking Exon6 was amplified by PCR using the primers 
S3-Exon FP and S3- Exon RP and sent for sequencing to analyze the mutations. 
2.21 Isolation of mouse cells from tumor 
A small piece of the tumor was washed with Hank’s Balanced Salt Solution (HBSS) from 
Lonza containing 1% antibiotic-antimycotic (Gibco, Carlsbad, CA) two times. The tissues 
were then cut into small pieces using sterile scalpels. These pieces were then 
transferred into a conical tube with 5mL of collagenase IV, (Worthington, Lakewood, NJ) 
2mg/mL in HBSS and incubated for 1 hour at 37C. After 1 hour, 5mL of HBSS was 
added to the collagenase and it was filtered through a 70 µM sieve. The cells were then 
centrifuged at 1000rpm for 4 minutes, re-suspended in RPMI media with 20% FBS and 
1% antibiotics. The cells were plated in a 60mm dish and PCCs were cultured. They 
were then slowly weaned to media with 5% RPMI[113]. The cells were routinely checked 
for Mycoplasma and then were authenticated, and confirmed to be murine and free of 
pathogens and other cell types by IDEXX Bioresearch (St. Louis, MO). 
2.22 Immunocytochemistry (ICC) 
5000 cells per well were seeded onto chamber glass slides coated with chemically 
modified CC2 growth surface (Lab-Tek, Thermo Scientific) and incubated at 37°C and 
5% CO2 in growth media until ~80 % confluence was achieved. Then the cells were fixed 
in 10% formalin for 15 minutes at room temperature followed by three quick washes in 
Phosphate buffered saline pH 7.4 (PBS). The cells were permeabilized and blocked by 
incubating with 0.15% Triton X-100, 1% BSA in 5% normal goat serum (blocking 
solution) for 30 minutes. The cells were then incubated with cytokeratin 19 (CK19) 
(1:200 dilution) or/and Alpha smooth muscle actin (α-SMA) (1:100) in blocking buffer for 
an hour. Dylight 488 conjugated goat anti-rat secondary antibody (1:400) was used to 
probe for CK19 and Dylight 555 conjugated goat anti-mouse secondary antibody (1:400) 
was used to probe for α-SMA. The coverslips were mounted using Prolong Gold 
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Antifade mounting medium containing DAPI (Thermo Fisher Scientific) for nuclear 
staining. The cells were imaged using an Olympus BX60 microscope and a QImaging 
EXi Blue camera or Leica DMI3000 inverted microscope outfitted with a DFC300 FX 
camera. 
2.23 Cell proliferation assays 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium (MTT) from Sigma Aldrich was 
used to determine cell proliferation [150]. Each of the mouse cell lines - KC, KR+/-S7C, 
KtetS7C, and KS7C were seeded (5000/well) in 6 wells of a 96-well plates. Proliferation 
was assessed at 48 hours after incubating them with 12.5µL of MTT solution (1mg/mL) 
for 3-4 hours. Viable cells convert MTT to an insoluble formazan product. This was 
solubilized by adding acidified isopropanol to cells which resulted in a purple solution. 
The absorbance of the solution was measure by U.V spectrophotometer at 560nm. The 
value of absorbance is directly proportional to number of viable cells. The mean value for 
absorbance of control-treated cells was normalized to 100%, and changes in 
proliferation were calculated as percent control in three independent experiments. Data 
are shown as means +/- SEM. 
2.24 3-Dimentionsional (3D) tissue culture 
Mouse cells were grown in 3D culture as previously described [151]. Briefly, each well of 
a 96-well plate was coated with 1% soft agar with media, followed by seeding2000 
mouse cells per well with 3% Matrigel (BD Biosciences). Four days post-plating and 
every three days thereafter the Matrigel was replenished with fresh media with or without 
500 pM TGF-β1. Images were acquired with a Leica DMI3000 inverted microscope 
outfitted with a DFC300 FX camera before each treatment. On the 14th day, colony 
growth was quantified using the MTT. Cells were stained with 20µL MTT and then 
scanned. Colony density and area were determined using ImageProPlus, version 7.0. 
The total density and area of KC cells (control) was normalized to 100%, and changes in 
growth for KS7C, KR+/-S7C and KtetS7C were calculated as a percentage of control.  
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2.25 Orthotopic injections 
KS7C and KR+/-S7C (200,000 cells) were suspended in 30μL of PBS and injected 
directly into the mouse pancreas of 8 weeks old, male NOD scid gamma (NSG) mice by 
the Indiana University Simon Cancer Center In vivo Therapeutics Core. The mice were 
monitored for tumor formation each week for 3-6 weeks. Animals were sacrificed when 
moribund. Tumor, spleen, liver, kidney and lungs were collected for parfin embedding. 
Cell lines were isolated from the tumors and metastatic lesions.  
2.26 Induction of Acute Pancreatitis 
The mice to be injected were fasted overnight. KC and KS7C mice were injected every 
hour with caerulein or with vehicle (0.05M NH4OH) alone for upto 7 hours [112, 134]. 
The procedure was repeated 48 hours later. Caerulein (Sigma, St. Louis MO) was 
diluted in 6% dextran 70, 0.9% NaCl and injected at a dose of 50μg/kg of body weight. 
Six KS7C mice were injected with caerulein in parallel with six KC mice. A second group 
of KC and KS7C mice received injections of carrier buffer only. All animals were fasted 
for 12 hours before the experiment. 
2.27 Chromatin Immunoprecicpitation (ChIP) Assays 
Sham or Smad7 overexpressing COLO-357 and IUSCC-PC1 cells were plated in 15-cm 
dishes, cross-linked with formaldehyde and glycine and then collected. ChIP assays 
were performed with c-Myc, Smad3 and 4 or control IgG antibodies using the Simple 
ChIP Enzymatic Chromatin IP kit (Cell Signaling, Danvers, MA) as per manufacturer’s 
instructions. The AGR2promoter (See Table 2.1 for sequence) was amplified by q-PCR 
and the percent input was calculated based on CT values. 
2.28 Gene Set Enrichment Analysis (GSEA) 
A Smad3 gene signature was generated using public microarray expression data of 
A549 cells treated with TGF-β or SiS3 (specific inhibitor of p-Smad3) and TGF-β for 24 
hours[152].  GSE-26858 expression files were downloaded from GEO-database, and 
differential gene expression analysis was performed using R (version 3.2) and the limma 
package (version 3.4, Bioconductor)[153, 154]. Genes that were significantly 
differentially expressed between TGF-β versus TGF-β plus SIS3 (FC =>2 or <=2, p < 
31 
0.05) (Supplementary Table 6.1) were then used to generated a Smad3 signature. To 
determine whether the generated Smad3 signature was enriched in pancreatic cancer 
patients, Gene Set Enrichment Analysis (GSEA) was performed comparing expression 
of adjacent normal human pancreas tissue and corresponding tumors. GSE-62452 
expression data of adjacent normal and pancreatic cancer human samples were 
downloaded from the GEO-Database [155, 156]. Data were prepared from the 
downloaded microarray expressionset, and a GSEA was performed against the 
generated Smad3 signature using the GSEA desktop application (Gsea2-2.2.3, Broad 
Institute) according to GSEA guidelines [157]. 
2.29 Composition of buffers used 
A. RIPA buffer for cell lysis for protein extraction:  
50mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% Na-Deoxycholate; 150mM NaCl; 1mM EDTA; 
1mM NaF 
B. 5X Running Buffer 
0.96M Glycine; 125mM Tris 
C. 10X TBS 
1.36M NaCl; 200mM Tris, pH 7.6 
D. Stripping Buffer 
2% SDS; 62.5mM Tris, pH 6.8. 350µL β-Mercaptoethanol (BME) was added to 50mL 
just before use.  
E. Transfer Buffer 
25mM Tris; 192nM Glycine; 20% Methanol 
F. Upper Buffer for SDS-PAGE Gel 
0.5M Tris; 0.4% SDS, pH 6.8 
G. Lower Buffer for SDS-PAGE Gel 
1.5M Tris; 0.4% SDS, pH 8.8 
H. 6X Protein loading dye 
32 
1g SDS, 7mL upper buffer, 3mL Glycerol, 600µL BME, 0.6% bromophenol blue 
H. DNA lysis buffer for genotyping 
50mM NaOH, 2mM EDTA  
2.30 Primers used (Table 2.1) 
 
Name Experiment Direction Sequence 
 
LSL-SMAD7 
integration in ES 
Forward 5’ GGCGGACTGGCGGGACTA 3’ 
 
LSL-SMAD7 
integration in ES 
Reverse 
5’ 
GGGACAGGATAAGTATGACATCATCAAGG 
3’ 
EGFP mut _FP 
LSL-
SMAD7genotyping 
Forward 5’ AAGTTCATCTGCACCACCG 3’ 
EGFP mut _RP 
LSL-
SMAD7genotyping 
Reverse 5' TCCTTGAAGAAGATGGTGCG 3' 
K005 
LSL-KrasG12D  
genotyping 
Forward 
5' AGCTAGCCACCATGGCTTGAGTAAGTCT 
3' 
K006 
LSL-KrasG12D  
genotyping 
Reverse 5' CCTTTACAAGCGCACGCAGACTGTAGA 3' 
Cre1 
Pdx1-Cre 
genotyping 
Forward 5' TGATGAGGTTCGCAAGAACC 3' 
Cre2 
Pdx1-Cre 
genotyping 
Reverse 5' CCATGAGTGAACGAACCTGG 3' 
R007 Rb-1 genotyping Forward 5' GGCGTGTGCCATGAATG 3' 
R008 Rb-1 genotyping Reverse 5' AACTCAAGGGACCTG 3' 
Tet_S7FP 
tetO-
Smad7genotyping 
Forward 5’ ATCCACGCTGTTTTGACCTC 3’  
Tet_S7RP tetO- Reverse 5’ GAGCGCAGATCGTTTGGT 3’ 
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Smad7genotyping 
GrtA P1 
Rosa26rtTA-EGFP 
WT genotyping 
Forward 5'CTGGCTTCTGAGGACCG3' 
GrtA P2 
Rosa26rtTA-EGFP 
WT genotyping 
Reverse 5'CAGGACAACGCCCACACA3' 
GrtA P3 
Rosa26rtTA-EGFP 
mut genotyping 
Forward 5'AGGGCGAGGAGCTGTTCA3' 
GrtA P4 
Rosa26rtTA-EGFP 
mut genotyping 
Reverse 5'TGAAGTCGATGCCCTTCAG3' 
Mm_Muc1 FP 
Mm_Muc1 
expression 
Forward 5’ ACATCTTTCCAACCCAGGAC 3’ 
Mm_Muc1 RP 
Mm_Muc1 
expression 
Reverse 5’ GAGACTGCTACTGCCATTACC 3’ 
Mm_βAct FP 
Mm_βAct 
expression 
Forward 5' GGCTGTATTCCCCTCCATCG 3' 
Mm_βAct RP 
Mm_βAct 
expression 
Reverse 5'CCAGTTGGTAACAATGCCATGT 3' 
Hs_MUC1 FP 
Hs_MUC1 
expression 
Forward 5’ AGTACCCCACCTACCACAC 3’ 
Hs_MUC1 RP 
Hs_MUC1 
expression 
Reverse 5’ CCCTACAAGTTGGCAGAAGTG 3’ 
Hs_MUC13 FP 
Hs_MUC13 
expression 
Forward 5’ CAGTATCAGAAACATTTGACCCAG 3’ 
Hs_MUC13 RP 
Hs_MUC13 
expression 
Reverse 5’ GGTGACAGAGATGTGCTTACAG 3’ 
Hs_GPX2 FP 
Hs_GPX2 
expression 
Forward 5’ GCTTCCCTTGCAACCAATTTG 3’ 
Hs_GPX2 RP 
Hs_GPX2 
expression 
Reverse 5’ TTCTGCCCATTCACCTCAC 3’ 
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Hs_18S FP Hs_18S expression Forward 5' GTAACCCGTTGAACCCCATTC 3' 
Hs_18S RP Hs_18S expression Reverse 5' CCATCCAATCGGTAGTAGCG 3' 
FP_S7a 
Adding c-Myc Tag 
to Smad7 
Forward 5' CATGTTCAGGACCAAACGATCT 3' 
RP_S7Myc 
Adding c-Myc Tag 
to Smad7 
Reverse 
5' 
CAGATCCTCTTCTGAGATGAGTTTTTGTTCG
TACCGGCTGTTGAAGATGAC 3' 
FP_attB1 
Adding att sites to 
c-Myc-SMAD7  
Forward 
5' 
GGGGACAAGTTTGTACAAAAAAGCAGGCTG
CATGTTCAGGACCAAACGATCTG 3' 
RP_attB1 
Adding att sites to 
c-Myc-SMAD7  
Reverse 
5' 
GGGGACCACTTTGTACAAGAAAGCTGGGT
CCTACAGATCCTCTTCTGAGATGAGTTTTTG 
3' 
LNCX-FP  
sequencing for GOI 
in PLIX402 plasmid 
Forward 5' AGCTCGTTTAGTGAACCGTCAGATC 3' 
PLIX_seq RP 
sequencing for GOI 
in PLIX402 plasmid 
Reverse 5' CCGGATCCTTAGTGGTGGTG 3' 
PLIX_SQ_FP1 
sequencing the 
rtTA sequence in 
PLIX402  
Forward 5’ GTGGTGATGTTGAAGAAAACCCTGG 3’ 
PLIX_SQ_RP1 
sequencing the 
rtTA sequence in 
PLIX402  
Reverse 5’ AAGCAGCGTATCCACATAGCG 3’ 
PLIX_SQ_FP2 
sequencing the 
TRE sequence in 
PLIX402  
Forward 5’ AGGCAAAGAGAAGAGTGGTGCA 3’ 
PLIX_SQ_RP2 
sequencing the 
TRE sequence in 
PLIX402  
Reverse 5’ CGTGTGATTCCAAATCTGTTCC 3’ 
AGR2_chip FP4 AGR2 promoter for Forward  5’ GTCCCAACTCTGCCCTAAAC 3’ 
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ChIP 
AGR2_chip 
RP4 
AGR2 promoter for 
ChIP 
Reverse 5’ AACTAGCAGGCCCTTAGATAGA 3’ 
S3-Exon 6 FP 
sequencing Exon 6 
of Smad3 in 
CRISPR cells 
Forward 5' CTCCAGACACCTGAGCATCTTG 3' 
S3-Exon 6 RP 
sequencing Exon 6 
of Smad3 in 
CRISPR cells 
Reverse 5' CCTTCAGAGGCTGTGTGTTCAG 3' 
2.31 PCR reactions (Table 2.2) 
Sr. 
No. Substance 
Final conc 
LSL-SMAD7 
Final conc 
Pdx-1 Cre 
Finalconc 
tetO-Smad7 
Cloning of 
Smad7 
1 Buffer 1X 1X 1X 1X 
2 dNTPs 0.375mM 0.25mM 0.25mM 0.25mM 
3 MgCl2 1.5mM 1.5mM 1.5mM 1.5mM 
4 FP 0.6μM 0.5μM 0.5μM 0.5μM 
5 RP 0.6μM 0.5μM 0.5μM 0.5μM 
6 Taq 0.025U/μL 0.025U/μL 0.025U/μL 0.025U/μL 
2.32 PCR cycling conditions (Table 2.3) 
Step # Step 
Final conc 
LSL-SMAD7 
Final conc 
Pdx-1 Cre 
Finalconc 
tetO-Smad7 
Cloning of 
Smad7 
1 Hot start 
95 ºC    
15 minutes 
95 ºC  
 15 minutes 
95 ºC   
 15 minutes 
95 ºC   
 15 minutes 
2 Denaturing 95 ºC   95 ºC    95 ºC   95 ºC   
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 30 seconds 30 seconds  30 seconds  30 seconds 
3 Annealing 
55 ºC   
45 seconds 
58 ºC   
30 seconds 
60 ºC   
 1 minute 
55/56 ºC   
45 seconds 
4 Extension 
72 ºC   
1 minute 
72 ºC   
30 seconds 
72 ºC   
 1 minute 
72 ºC   
 1 minute 
5 
# of cycles 
steps 2-4 34 35 34 35 
6 Extension 
72 ºC   
 10 minutes 
72 ºC   
 2 minutes 
72 ºC   
2 minutes 
72 ºC   
 10 minutes 
7 Hold/End 10 ºC  -  ∞ 10 ºC  -  ∞ 10 ºC  -  ∞ 10 ºC  -  ∞ 
2.33 List of antibodies used (Table 2.4) 
Antibody Vendor Dilution Application 
CK19 DSHB 1:10/1:200 IHC/ICC 
α - SMA Sigma 1:100 ICC 
p-Histone H3 (S10) Cell Signaling 1:200 IHC 
Phospho RB(S807/S811) Cell Signaling 1:400 /1:1000 IF/ IB 
Ki67 Novocastra 1:200 IF 
Phospho Smad2 Millipore 1:200 IF 
Phospho Smad3 Abcam 1:200 IF 
Insulin Abcam 1:800 IF 
Amylase Abcam 1:400 IHC 
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Glucagon Abcam 1:400 IF 
c-Myc Millipore 1:1000/1 μg IB/IP/ChIP 
Smad7 Abcam 1:1000 IB 
PP-1c Santacruz 1:500 IB/IP 
β-actin Cell Signaling 1:50,000 IB 
γ-tubulin Sigma 1:1200 IB 
Total Smad3 Cell Signaling 1:1000 IB 
Total Smad2 Cell Signaling 1:1000 IB 
Total Smad3 Cell Signaling 1:50 ChIP 
Total Smad4 Cell Signaling 1:100 ChIP 
Total pRB Pharminogen 1:1000 IB 
AGR-2 Abcam 1:1000/1:1000 IHC/IB 
p21 Santacruz (F-5) 1:50/1:200 IF/IB 
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3. Results 
Transforming growth factor beta (TGF-β) signaling is awry in PDAC and all of its three 
mammalian isoforms are overexpressed [27, 118]. The canonical signaling pathway 
involves phosphorylation of Smad2 and Smad3 which then bind with Smad4. These 
Smad complexes then translocate from the cytoplasm of the cells to the nucleus to 
modulate gene transcription that in turn regulate cellular processes such as proliferation, 
differentiation, migration, deposition of extra cellular matrix, and apoptosis. Inhibitory 
Smad6 and Smad7proteins serve as negative feedback regulators for the TGF-β 
pathways and are over-expressed in patients with PDAC [120, 121, 158].  
The Korc lab has previously shown that overexpression of Smad7 (Smad7 OE) in 
COLO-357 cells inactivates pRb or keeps it hyper-phosphorylated by blocking TGF-β-
mediated de-phosphorylation of pRb[123]. Consequently, there is a loss of TGF-β-
mediated growth inhibition in spite of the ability of TGF-β to phosphorylate Smad2 and to 
up-regulate p21, an important inhibitor of cell cycle progression. PAI-1 expression 
increases with Smad7 overexpression in COLO-357 cells and TGF-β and confers an 
ability to the PCCs to form large tumors in nude mice[121, 122]. However, another study 
has reported that in PDAC patients, low levels of Smad7 correlate with poor prognosis 
and lymph node metastasis [129]. These findings appear to contradict each other and 
suggest a dual role for Smad7 in PDAC. Therefore we generated a transgenic mouse 
model to unravel the role of Smad7 and its effects on the canonical TGF-β pathway in 
pancreatic cancer. We first examined the effects of Smad7 overexpression in the context 
of Kras mutation in PDAC. A tetracycline inducible Smad7 mouse model was used to 
induce Smad7 expression at different ages to determine if it played a role in initiation or 
progression of PDAC or both. Mouse tissue, human PCCs, and primary cell lines from 
mouse tumors were used to confirm previous findings and address the impact of Smad7 
on pRb phosphorylation and p21 levels. Effects on phosphorylation of Smad2 and 
Smad3 were analyzed by IF of mouse tissues and by western blotting using lysates 
prepared from cells treated with TGF-β. In addition, ChIP assays were performed to see 
if Smad7 bound directly to DNA that regulate expression of TGF-β-mediated genes that 
were altered by overexpression of Smad7.  
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3.1 Validation of SMAD7 overexpression in mice genetically modified with Rosa-
LSL-SMAD7and Pdx1-Cre (S7C) transgene 
To overexpress SMAD7, the mice harboring the LSL-SMAD7 transgene on the Rosa26 
locus were crossed with those encoding the Pdx1-Cre gene (S7C). The Cre 
recombinase is expressed from the Pdx-1 promoter, which is transcriptionally active in 
the ES cells of the foregut endoderm around 8.5 days [159, 160] and contributes to 
formation of the early pancreatic bud cells. At 9.5 days, along with P48 transcription 
factor, Pdx-1 then gives rise to pancreatic progenitor cells.  Thus, the Cre recombinase 
is expressed in all pancreatic progenitor cells and removes the lox stop lox cassette from 
the Rosa-LSL-SMAD7 transgene, which allows for expression of the SMAD7 specifically 
in the pancreas (Figure 3.1-A). 
 
 
Figure 3.1 Validation of SMAD7 overexpression in mice with Rosa-LSL-SMAD7 and Pdx1-
Cre transgene 
 
(A) Schematic figure showing LSL-SMAD7 (S7) transgenic mouse, when crossed with mice harboring 
Pdx1-Cre (C). The Cre (blue) is expressed in the pancreatic progenitor cells (blue) which results in 
removal of the stop cassette preceding the SMAD7 transgene, thus resulting in expression ofSMAD7 in 
the pancreas of the mice (S7C mice). (B) SMAD7 mRNA levels measured by q-PCR are significantly 
elevated in the S7C (test) mice compared to the ones with S7 (control) alone. Data are the means ± SEM 
from 4 individual mice done in triplicates for each group. *p value <0.05 was considered significant. 
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Levels of SMAD7 mRNA were determined by qPCR in the pancreata of four S7C mice 
and 4 mice with only the SMAD7 transgene (WT). Compared to WT mice, the S7C mice 
had a 9-fold increase in SMAD7 expression (Figure 3.1-B). To determine if 
SMAD7overexpression affected pancreas development or its function, tissues from two 
3 month, two 6 month, and two 12 month old S7C mice were stained with H&E and IF or 
IHC for expression of insulin, glucagon and amylase. The pancreata of all the mice 
showed normal histology and normal expression and distribution of insulin and glucagon 
in the islets, and amylase in the acinar cells (Figure 3.2). Taken together, these results 
suggest that pancreas development, morphology and physiology are not compromised 
by Smad7 overexpression.  
 
 
Figure 3.2 Overexpression of SMAD7 alone does not affect pancreas development or physiology 
Representative IF images (from 6 different mice) of 5 µm sections from a 12 month-old S7C mouse 
revealed co-expression of Insulin (red) and glucagon (green) in islets. Amylase expression in acinar cells 
was demonstrated by IHC.  
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3.2 SMAD7 overexpression accelerates PanIN progression when combined with 
oncogenic Kras mutation 
Approximately 92-95% of pancreatic cancers harbor Kras mutations, which is the main  
oncogenic driver gene for PDAC[161].The Kras mutation leads to the formation of PanIN 
lesions by 8 weeks of age in mice that progress to PDAC by 9-11 months[160]. Since 
expression of oncogenes or deletion of tumor suppressors cooperates with the Kras 
mutation, we next introduced KrasG12D into the mice in combination with SMAD7 and 
thePdx1-Cre gene (KS7C) (Figure 3.3 A). Mice encoding the KrasG12D and Pdx1-Cre 
(KC) transgenes were used as controls. 12-14 mice per group were used for survival 
analysis and 3-6 mice per group were sacrificed at 3, 6, 9 and 12 months of age to 
assess PDAC progression. All the mice with KS7C genotype displayed acinar to ductal 
metaplasia (ADMs) at 8 weeks of age, and 3 of 6 mice developed PDAC by 3 months of 
age. These mice exhibited significantly lower survival compared to KC mice (Figure 3.3 
B).  
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Figure 3.3 The KS7C mouse model that express oncogenic Kras in presence of Smad7 OE 
(A) Schematic representation of generation of the KS7C mouse model. (B) Mice harboring both the 
oncogenic KrasG12D and SMAD7 transgene (KS7C) exhibit significantly lower survival (p value < 0.001) 
compared to KC mice (N=12 for KC, N=14 for KS7C). 
 
Histopathological analysis and IHC staining with CK19 revealed that KS7C mice had an 
increased number of abnormal lesions compared to age matched KC mice. Figure 3.4 is 
a representative section of pancreas from KC and KS7C mice, which shows mostly 
normal acinar cells with foci of ADMs and PanIN1 (top panel) for a KC mouse. Age 
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matched KS7C mouse section (bottom panel) showed cystic lesions with PanIN3 insitu 
carcinoma.  
 
 
Figure 3.4 Smad7 overexpression combined with oncogenic Kras accelerates progression of 
PanIN 
Representative images from 6 month old KC and KS7C mice showing that KC mice have some normal 
tissue and a foci of ADMs and low-grade PanIN. By contrast, KS7C mouse pancreata revealed high-
grade PanIN and invasion of epithelial cells into the surrounding stroma as seen marked by CK19 
positive cells. Scale bars represent 100µM. Magnified inset shown in the right column.   
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Next, images of 5 random fields for 6 KC and 6 KS7C mice were taken and the number 
of ADMS, PanINs and PDAC lesions per field were counted. The KS7C mice displayed 
higher number of ADMs, PanIN1A, B and 2 compared to the KC mice at 3 and 6 months 
of age. (Figure 3.5 A). The incidence of PDAC was also significantly increased in KS7C 
mice when compared to the KC mice (Figure 3.5 B). These results indicate that Smad7 
OE increases ADM formation and accelerates PanIN to PDAC progression. 
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Figure 3.5 Smad7 overexpression increases PanIN formation and incidence of PDAC 
(A) Bar graph represents the number of ADM and PanIN lesions observed per field for 3-6 month old KC 
mice (black) and KS7C mice (white). (B) Bar graph represents the percent of KC mice that develop PDAC 
at 12 months of age with (white) or without (black) Smad7 overexpression. * p value < 0.05 was 
considered significant. 
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3.3 Tetracycline inducible Smad7 mouse model 
To further test the findings of the autochthonous SMAD7 mouse model and to address 
the question of whether Kras mutation in combination withSMAD7 overexpression at 
different stages after Kras mutation accelerates PDAC, tetracycline inducible SMAD7 
mice [143] were crossed with the KC mice, generating KtetS7C animals. Smad7 
expression was measured in the pancreas by q-PCR and was 14-fold higher in the 
pancreata of mice that received doxycycline in their food when compared to those that 
were fed regular diet (Figure 3.6 A). To confirm that the Tet-on promoter was not leaky 
and doxycycline alone did not change the expression Smad7, we compared levels of 
Smad7 in mice with the tet-Smad7 transgene in presence (test) or absence of the Pdx-1 
Cre transgene. Both groups of mice received doxycycline in their food. The mice with the 
Pdx-1 Cre transgene displayed an 18-fold increase in Smad7 mRNA levels compared to 
mice without the gene (Figure 3.6 B).  
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Figure 3.6 Validation of Smad7 expression in Tet inducible Smad7 mouse model 
 
 (A) Smad7 mRNA levels were measured by q-PCR and showed significant increases in the KtetS7C 
(test) mice fed with doxycycline compared to those without doxycycline (control).  (B) Smad7 mRNA 
levels measured by q-PCR are significantly elevated in the KtetS7C (test) mice fed with doxycycline 
compared to those without Pdx-1 Cre (control). Data are represented as mean ± SEM from 6 individual 
mice (A) and 4 individual mice (B), done in triplicates for each group. * p value < 0.05 was considered 
significant. 
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The KtetS7C mice were provided with doxycycline in their food at various time points (1 
month, 2 months and 3 months of age to induce Smad7 expression. All mice were 
sacrificed at 6 months of age. The KtetS7C mice on doxycycline displayed accelerated 
progression of ADMs to PanIN lesions (Figure 3.7 A) and had higher incidence of PDAC 
(Figure 3.7 B) when compared to mice that did not receive doxycycline. The mice 
induced with doxycycline at 1, 2 and 3 month of age all had more aggressive disease 
compared to mice with no doxycycline. However, no overall significant differences were 
observed between the various times of induction.  
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Figure 3.7 Smad7 overexpression accelerates PDAC progression 
(A) Bar graph represents the percentage of mice exhibiting ADM and PanIN lesions for 6 month old 
KtetS7C mice provided with doxycycline feed at 1 month (patterned bar) to induce Smad7 and KtetS7C 
mice provided with regular feed, without doxycycline (black bars). (B) Bar graph represents the percent 
of KtetS7C mice that developed PDAC at 6 months of age fed doxycycline (patterned) or with regular 
feed (black). 
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3.4 KS7C and KtetS7C cell lines 
To further address the molecular mechanism underlying Smad7 overexpression in 
PDAC development, primary cancer cell lines were established from the tumors derived 
from the KS7C and the KtetS7C mice as described in Chapter 2. Cells were stained with 
CK19, a marker for epithelial cells and α-SMA, a marker for mesenchymal cells. Both 
cell lines stained positive for CK-19 and α-SMA (Figure 3.8 A). These findings indicate 
that the cell lines are of epithelial origin, but the positive α-SMA staining suggests that 
they may have undergone EMT. Next, the levels of Smad7 expression were validated by 
qPCR in both the cell lines compared to the cell line derived from a KC mouse. The cell 
line derived from the KtetS7C mouse model was grown and maintained in TF media. To 
induce Smad7 expression, the cells were treated with 2 µg/mL of doxycycline in TF 
media. Levels of Smad7 were compared among the KC cell line, the KtetS7C cell line in 
TF media, and KtetS7C treated with doxycycline (Figure 3.8 B).  By comparison, there 
was no difference in the levels ofSmad7between the KC and the KtetS7C cells grown in 
TF media, indicating that the tetracycline promoter is tightly regulated for expression of 
Smad7 in these cells.  There was a 110-fold increase in Smad7mRNA levels upon 
doxycycline treatment of the KtetS7C cells. The KS7C cell line exhibited a 30-fold 
increase in SMAD7 levels as judged by qPCR when compared to the cell line derived 
from a KC mouse (Figure 3.8 C). 
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Figure 3.8 Validation of KS7C and KtetS7C cell lines 
(A) Cells derived from tumors stain positive for CK19 and α-SMA, indicating that they are epithelial in 
origin; however there are suggestions of the cells transitioning into a mesenchymal type. (B-C) Bar 
graph showing significantly higher levels of SMAD7mRNA in KS7C or KtetS7C cells compared to KC cells 
by qPCR. Data are represented as mean ± SEM for three individual experiments for each cell line.*p 
value < 0.05 considered significant. 
 
Next, all three cell lines were grown in 3D tissue culture to analyze the differences in 
proliferation and colony formation. Although viable, KC cell lines failed to grow large 
colonies in 3D. The KS7C cell lines in contrast form large, spherical colonies and 
covered over 3 times the area when compared to the KC cell line (Figure 3.9 A and B). 
The KtetS7C cells were plated in TF media with 2 µg/mL of doxycycline. These cells 
were viable and they formed large spherical colonies. Colony sizes were not as large as 
the KS7C cell lines, however still significantly larger than the KC cell line. The colonies 
formed by the KtetSC cell line covered 2.5 times the area of that of the colonies formed 
by KC cell line. Thus Smad7 overexpression increased proliferation in 3D tissue culture. 
These results are consistent with previously published results on COLO-357 cells 
overexpressing Smad7 that formed large colonies in soft agar [121]. 
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Figure 3.9 Smad7 overexpression increases proliferation 
(A) Representative images from 3 independent experiments in 3D demonstrating that KS7C and 
KtetS7C proliferate at higher rates compared to KC and form large colonies in vitro. (B)  Bar graph 
quantifying area occupied by colonies formed by the three cell lines. Results are the average of 3 
independent experiments ± SEM. Scale bar represents 100 µM.*p value < 0.05 considered significant. 
 
 
3.5 Orthotopic mouse model with KS7C cell line  
To test the tumorigenic potential of the KS7C cell line, the cells were orthotopically 
injected into the pancreas of 8 weeks old, male NSG mice. These mice developed 
palpable tumors within 2 weeks from the day of injection. The median survival time of the 
injected mice was 34 days (Figure 3.10 A) and 7 of the 9 mice had ascites in their 
abdomen. Tumors formed from the KS7C cells were small and not densely fibrotic for 
each of the 9 mice (Figure 3.10 B). All mice had complete infiltration of cancer cells in 
their liver (Figure 3.10 B). One of the mice had intestinal seeding, and 3 of the 9 mice 
had metastatic nodules on their spleen. Thus the KS7C cell line is highly tumorigenic 
and metastatic.   
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Figure 3.10 Orthotopic mouse model with KS7C cell line 
(A) Kaplan-Meier curve for KS7C cell line orthotopic mice (N=9). (B) Represenative images from 4 different 
miceinjected with KS7C cell line, showing extensive metastatic seeding to the liver (M1, M2, M3, M4)  and 
small non fibrotic tumors attached to spleen (M5, M6, M7, M8). 
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3.6 Smad7 promotes PDAC progression by disrupting TGF-β-mediated cell growth 
inhibition and inactivating functional pRb 
Previously, it has been shown that in the presence of inactivated pRb or 
hyperphosphorylated pRb, TGF-β can exert mitogenic effects in PCCs [39]. Studies from 
our lab have also demonstrated that in hPDAC and in mPDAC tumors from GEMMs of 
PDAC with oncogenic Kras and deletion of p16Ink4a (KIC) and p53 (KPC), there is 
evidence for activated TGF-β signaling and inactivated pRb in actively proliferating cells 
[39]. Thus the levels of Smad7 in the pancreas of KIC and KPC mice were examined by 
qPCR. The KC mice had Smad7 levels similar to wild type (WT) mice, or mice with no 
transgene. However, the pancreata from the KIC and KPC mice exhibited significantly 
elevatedSmad7 levels compared to lesion-matched KC mice (Figure 3.11). These 
results suggest that enhanced expression of Smad7 in mouse tumors was not sufficient 
to attenuate p-Smad2 levels, however pRb remained inactivated. 
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Figure 3.11 Expression of Smad7 is enhanced in PDAC mouse models 
Levels of Smad7 mRNA in KIC and KPC mice models were significantly elevated compared to lesion-
matched KC mice by q-PCR. Data are represented as mean ± SEM from 3 independent experiments.* p 
value < 0.05 considered significant. 
 
Overexpression of Smad7 in COLO-357 PCCs impedes the ability of TGF-β to maintain 
pRb in an active, hypo-phosphorylated state even in the presence of activated p-Smad2 
[122]. Therefore we next analyzed p-pRb and p-Smad2 in KS7C mice pancreatic lesions 
at various ages and exhibiting different grades of PanIN lesions. Serial sections from 
mouse tissues were co-stained with antibodies recognizing p-Smad2 and Ki67 followed 
by staining of serial section with those recognizing p-pRb and Ki67. Figure 3.12 and 3.13 
are representative images from 3 mice (M1, M2, and M3). Co-expression of p-pRb and 
p-Smad2 was observed in proliferating cells of PanIN and cystic lesions of KS7C mice. 
KC mice tissues (control) were also stained for pRB and p-Smad2. KC mice pancreata 
exhibited abundant p-Smad2, however their PanIN lesions showed low positivity for p-
pRb (Figure 3.14). Previously the Korc lab has published similar observations which 
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showed that PanIN lesions in KC mice pancreata exhibited abundant p-Smad2 with very 
few Ki67 and p-pRb positive cells [39]. 
 
 
Figure 3.12 Co-localization of p-pRb and Ki67 in pancreatic tissue of KS7C mice 
Double IF of 5µm serial sections from 3 different KS7C mouse tissues using antibodies that recognize Ki-
67 (green) and p-pRb (red). Results show that p-pRb co-express with Ki-67 (yellow) in lesions of these 
mice. Scale bars  represent 100µM. 
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Figure 3.13 Co-localization of p-Smad2 and Ki67 in pancreatic tissue of KS7C mice 
Double IF on 5µm serial sections from 3 different KS7C mouse tissues using antibodies that recognize Ki-
67 (green) and p-Smad2 (red). Results show that p-Smad2 co-express with Ki-67 (yellow) in lesions of 
these mice. Scale bars represent 100µM. 
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Figure 3.14 Co-localization of p-pRb and p-Smad2 in KC mice 
IF on 5µm serial sections from 3 different KC mouse tissues using antibodies that recognize p-pRb (red) 
and p-Smad2 (green). Results showed that p-Smad2 is abundant in KC mice pancreata with very few 
positive p-pRb in lesions of these mice. Scale bars represent 100µM. 
 
The cells that stained positive for p-pRb and p-Smad2 were then quantified based on 
total Ki67 positive cells for individual mice (Figure 3.15 A and B). The ratios of p-pRb to 
Ki67 and p-Smad2 to Ki67 were found to be similar to those previously published in 
hPDAC tissues (~62% and 65% respectively). Thus Smad7 overexpression in vivo also 
results in pRb inactivation in the presence of activated p-Smad2 signaling. 
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Figure 3.15 p-pRb and p-Smad2 levels are elevated in proliferating cells of KS7C PanIN lesions 
Quantification of various grades of lesions in 6 different KS7C mice showed that the average percent of 
Ki67 positive PCCs expressing p-pRb (A) and p-Smad2 (B) is 62% and 65%, respectively. For each mouse, 
data are represented as mean percent ± SEM. 
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We next measured the levels of p21 protein in the KS7C mice. The KS7C mice tissues 
did not show any positivity for p21 in highly proliferative cysts (Figure 3.16 A-M1). The 
low grade PanIN lesions (M2) showed weak positivity in some of the cell nuclei (circled). 
KC mice were used as controls. The lesions of KC mice showed positivity for p21 
(Figure 3.16 B), which was consistent with previously published findings [39]. 
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Figure 3.16 p21 levels are attenuated in KS7C mice tissues 
IF on 5 µm serial sections from 3 different KS7C mouse tissues (A) for p21 (red) showed no positivity in 
most cells and weak positivity in some (dotted circle). Cells in PanIN lesions of KC mice (B) mice stained 
positive for p21. Nuclei are stained blue with DAPI. Scale bars represent 100µM. 
 
To address whether there were differences in canonical signaling of TGF-β pathways 
between the KC and KS7C cell lines described in section 3.4, these cells were cultured 
in SF conditions and then treated with TGF-β1. The cell lines established from the KS7C 
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mouse model exhibited increased p-pRb when grown in SF condition compared to those 
derived from the KC mice (Figure 3.17 A). When these cells were treated with TGF-β1, 
the p-pRb levels decreased in both cell lines, however the levels of p-pRb in KS7 cells 
treated with TGF-β were still higher compared to KC cells in SF conditions.  
The pRB antibody detects both phosphorylated and unphosphorylated pRb. To confirm 
that there is enhanced dephosphorylation of pRb in KC cell line and not degradation, the 
KC and KS7C cell lines were grown in 5% FBS and their pRb levels were measured 
(Figure 3.17 B). Both cell lines express equal levels of pRb. When grown in SF 
condition, the KC cell line underwent rapid dephosphorylation of pRb and growth arrest. 
However, the KS7C cell line continued to proliferate in SF conditions, and showed 
increased levels of p-pRb, indicating that it is a Smad7 dependent effect. We next 
measured p-Smad2 levels in these cells. The amount of p-Smad2increased in KC cells 
when they were treated with TGF-β1for 24 hours. In KS7C cells treated with TGF-β1, 
TGF-β1 mediated phosphorylation of Smad2 was attenuated, but not fully blocked 
(Figure 3.17 C). There were similar levels of total Smad2/3 proteins in both of these cell 
lines. These results indicate that overexpression of Smad7does not block Smad2 
activation in vivo or in vitro, however elevated levels of Smad7 do lead to inactivation of 
pRb (Figure 3.18). 
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Figure 3.17 p-pRb and p-Smad2 levels in KS7C cell line 
(A)  The KS7C cell line grown in SF condition has more p-pRb than the KC cell line grown in SF 
conditions (0.5% FBS). Levels of p-pRb were reduced upon addition of 0.5nM TGF-β1 in either of these 
cell lines. (B) There were similar levels of p-Rb between these cell lines when grown in media with 5% 
FBS.  (C) TGF-β1 enhanced the levels of p-Smad2 in the KC cell line. This upregulation was attenuated in 
the KS7C cell line. β-actin was used as loading control.  Shown are representative blots from three 
independent experiments. The total Smad2/3 and β-actin are the same as those for Figure 3.27 as data 
was collected from same blot. 
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Figure 3.18 Smad7 OE allows activation of p-Smad2 by TGF-β, however it decreases p21 and 
keeps pRb inactivated 
Smad7 OE does not block TGF-β mediated p-Smad2 (depicted by green arrows); however Smad7 OE results in 
downregulation of p21 levels, resulting in accumulation of p-pRb (inactive pRb) and increased thus increased cell 
proliferation.  
 
3.7 PDAC progression in KR+/-S7C mice and KR-/-C mice 
As described in section 3.6, Smad7 keeps pRb in a hyper-phosphorylated state in vivo. 
Therefore I next determined whether heterozygous deletion of Rb1 combined with 
overexpression of Smad7 and oncogenic Kras (KR+/-S7C) would recapitulate features 
seen in mice with oncogenic Kras and homologous deletion of Rb1 (KRC). The KR+/-C 
mice were used as controls compared with the KR+/-S7C. The median survival for KR+/-
S7C mice was 24 weeks which is longer than that for previously published KRC mice 
(~10 weeks) [114]. However, the KC and KR+/-C (median survival 36 weeks) mice 
survived for a significantly longer period when compared to the KR+/-S7C mice (Figure 
3.19).  
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Figure 3.19 Survival of KR+/-S7C mice 
The KR+/-S7C mice survive for significantly shorter time than the KR+/-C (p-value 0.0385) or the KC mice 
(p-value <0.001). (N=12 for KC, N=15 KR+/-S7C, and N=7 for KR+/-C). 
 
Gross examination of the pancreata from some of these mice showed cystic nodules 
and 2 of the mice (one 2 months and one 6 months old) had visible tumors.Next, we 
compared the grades of PanIN and presence of cysts in KR+/-S7C mice with previously 
published reports of KRC mice between 2-3 months of age. The percent of mice 
exhibiting each of the grades of PanINs between the two mouse models was not 
significantly different. (Figure 3.20).The KR+/-S7C mPDAC also displayed high levels of 
p-Smad2 and p-pRb (Figure 3.21) as seen in other mouse models of PDAC and in the 
KS7C mice. The presence of p-pRb in these mice also indicated that there was no loss 
of heterozygosity of Rb1in these lesions. Altogether, heterozygous loss of Rb1 with 
Smad7 overexpression has the same effects as loss of homozygous Rb1. These 
findings suggest that Smad7 exerts its effect on PanIN initiation and progression via 
inactivation of pRb. 
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Figure 3.20 PDAC progression in KR+/-S7C mice and KR-/-C mice 
The bar graph depict the percent of mice in KR+/-S7C (blue bars) and KR-/-C groups (white bar with 
pattern, data adapted from Carriere et al, 2011, Gastroenterology) with ADMs, PanIN lesions, and 
PDAC progression. 
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Figure 3.21 Co-localization of p-pRb and p-Smad2 in pancreatic tissue of KR+/-S7C mice 
IF of 5 µm serial sections from 3 different mice. The KR+/-S7C mPDAC tissue showing expression of p-
pRb (red), and p-Smad2 (green). Scale bars represent 100µM. 
 
3.8 KR+/-S7C cell lines 
A primary cancer cell line from a 5.5 month KR+/-S7C mouse tumor was established as 
described above. The tumor derived cells stained positive for CK19 and α-SMA (Figure 
3.22 A), indicating that these cells have an epithelial origin and may be undergoing EMT. 
These cells exhibited a 4-fold increase in Smad7 compared to the KC cell line (Figure 
3.22 B).The KR+/-S7C cells when grown in 3D tissue culture formed spherical colonies 
and showed increased colony growth formation (Figure 3.23 A) compared with the KC 
cells. The area covered by colonies formed by the KR+/-S7C cells was 2.5 times more 
area than similarly cultured KC cells (Figure 3.23 B).  
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Figure 3.22 Validation of the KR+/-S7C cell line 
 
(A) Cells derived from tumors of  KR+/-S7C mice stain positive for CK19 and α-SMA indicating that they 
are epithelial in origin, however they maybe transitioning into mesenchymal type. (B) Bar graph 
showing significantly higher levels of SMAD7 in KR+/-S7C cells compared to KC cells by qPCR. Data are 
represented as mean ± SEM for three individual experiments for each cell line.* p value < 0.05  
considered significant. 
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Figure 3.23 Smad7 overexpression and Rb1 deletion increased colony growth 
(A) Representative images from 3 independent experiments in 3D demonstrating that KR+/-S7C cells 
proliferate at a higher rate compared to KC and form large colonies in vitro. (B)  Bar graph quantifying 
area occupied by colonies formed by the two cell lines. The area is plotted as the average of 3 
independent experiments ± SEM. Scale bars represent 100µM.*p value < 0.05 considered significant. 
 
 
3.9 Orthotopic mouse model with KR+/-S7C cell line  
To test the tumorigenic potential of the KR+/-S7C cell line, the cells were orthotopically 
injected into the mouse pancreas of 8 weeks old, male NSG mice. The mice developed 
palpable tumors following 1 week from the day of injection and the median survival time 
was 31 days for these mice (Figure 3.24 A). Tumors formed from the KR+/-S7C xenograft 
were large and very fibrotic for each of the 9 mice (Figure 3.24 B). Furthermore all mice 
had tumors that were locally invasive (Figure 3.24 B). No visible metastatic nodules were 
seen in any of the mice tissues, including spleen, liver or lungs. Thus heterozygous loss 
of Rb1 and overexpression of Smad7 increased tumorigenicity of cells in vitro and in 
vivo. 
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Figure 3.24 Orthotopic mouse model with KR+/-S7C cell line 
 
(A) Kaplan-Meier curve for KR+/-S7C cell lines orthotopic mice (N=9). (B) Representative images from 
4 mice (M1, M2, M3, M4) injected with KR+/-S7C cell line, showing large protruding fibrotic tumor, 
attached to spleen and  images from two mice (M5, M6) showing no visible metastatic lesions to 
the liver. 
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3.10 Smad7 decreases p-Smad3 in vivo 
Previous studies by our lab and others [39, 123, 130, 162] have used p-Smad2 as an 
indicator for activated TGF-β. The KS7C mice exhibited increased p-Smad2 levels in the 
Ki67 positive cells of their lesions (Figure 3.14) as shown by IF. However, Smad2 and 
Smad3 are both downstream signaling molecules for canonical TGF-β signaling. 
Therefore the KS7C mice were then stained for p-Smad3 and there was an absence of 
p-Smad3 in the KS7C mice (Figure 3.25). The figure shows p-Smad3 levels in different 
stages of lesions from three different mice (M1, M2 and M3).  
 
 
 
Figure 3.25 p-Smad3 levels are decreased in KS7C mice tissues 
IF of 5 µm serial sections from KS7C mouse tissues for Ki-67 (green) and p-Smad3 (red). Minimal p-
Smad3 was detected in the lesions of these mice. 
 
The lesions of KC mice on the other hand stained positive for p-Smad3 as seen in figure 
3.26. M1 and M2 represent sections from a 3 month and 6 month KC mouse 
respectively.  
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Figure 3.26 p-Smad3 staining in KC mice tissues 
IF of 5 µm serial sections from two KC mouse tissues for p-Smad3 (red) showed that there was p-
Smad3 positivity in the nuclei (stained blue with DAPI) in lesions of these mice. Scale bars represent 
100µM. 
 
When the KC cell line was treated with TGF-β1 for 24 hours, it showed abundant p-
Smad3 levels compared to SF conditions (Figure 3.26). However phosphorylation of 
Smad3 was largely blocked in the KS7C cell line upon treatment with TGF-β1 (Figure 
3.27). These results indicate that Smad7 allows for phosphorylation of Smad2 upon 
exposure to TGF-β both in vitro and vivo. However, overexpression of Smad7results in a 
complete attenuation of p-Smad3 levels in vivo and a marked attenuation of p-Smad3 
levels in vitro. 
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Figure 3.27 Overexpression of Smad7 attenuates induction of p-Smad3 in KS7C cells when 
treated with TGF-β1 
p-Smad3 levels were upregulated in KC cell line when exposed to 0.5nM TGF-β1 24 hours. This 
induction was markedly attenuated in the KS7C cell line. β-actin was used as loading control.  Shown 
are representative blots from three independent experiments. The total Smad2/3 and β-actin are the 
same as those for Figure 3.17 as data was collected from same blot. 
 
3.11 Tetracycline inducible Smad7 overexpression in hPCCs  
To delineate the mechanism of pRb hyper phosphorylation by overexpression of Smad7 
and to verify if the findings from the mouse model are comparable to the human disease 
model, we established tetracycline inducible Smad7 (Tet-Smad7 OE) hPCCS (ASPC-1, 
BXPC-3 and COLO-357) as described in Chapter 2. Primarily, the COLO-357 cell lines 
were validated for induction of Smad7 mRNA and protein with doxycycline. The sham 
and Tet Smad7 OE cells were plated in duplicates in TF media. Twelve hours after 
plating, the media on 1 set of sham and 1 set of Tet-Smad7 OE cells was replaced with 
TF media containing 2µg/mL final concentration of doxycycline. RNA and protein were 
collected from each set and analyzed. The Sham cells when treated with doxycycline 
had no effect on Smad7 expression, indicating that doxycycline by itself does not affect 
Smad7 expression (Figure 3.28 A and B). There was no difference in Smad7 mRNA or 
protein expression between Sham cells in TF or treated with doxycycline and in Tet-
Smad7 OE cells grown in TF media. This indicates that the promoter for Tet-Smad7 is 
not leaky. Tet-Smad7 OE COLO-357 cells grown in doxycycline showed ~4.4 fold 
increase in Smad7 levels compared to the cells in TF alone or Sham cells grown in TF or 
doxycycline. When blotted with the Smad7 antibody, there were multiple non-specific 
74 
bands in all groups, however a prominent band at ~50 kDa (expected size for Smad7 
which is 46kDa) appeared only in the doxycycline treated Tet-Smad7 OE cells. To 
confirm that the band was Smad7 and to test the efficiency of the Tet promoter, an 
experiment was performed, where the Tet-Smad7 OE cells were treated with 
doxycycline for 24 hours, then washed and kept in TF media for 24 hours. 
Simultaneously, similar experiments were carried out where cells were treated with 
doxycycline for 24 hours, then washed and grown in TF media for 48 hours (Figure 3.28 
C and D). Smad7 mRNA and protein were induced with doxycycline and this was 
followed by reduction in the mRNA and protein levels when the doxycycline was 
removed. Thus, stable tetracycline Smad7 inducible COLO-357 were successfully 
generated and validated.  
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Figure 3.28 Tet-inducible Smad7 OE in COLO-357 
(A) Bar graph shows that high expression of SMAD7 mRNA levels in doxycycline treated COLO-357 cells 
transduced with Tet-Smad7. Data are represented as mean ± SEM for three individual experiments for 
each cell line. (B) Western blot with anti Smad7 indicating significantly different expression of Smad7 in 
Tet-Smad7 cells treated with doxycycline compared to TF media or sham cells in TF media or 
doxycycline. γ-tubulin was used as loading control. Shown is representative blot from 3 independent 
experiments. (C) Bar graph showing expression of SMAD7 mRNA levels in doxycycline treated COLO-
357 cells transduced with Tet-Smad7 which were reduced when doxycycline was removed as early as 
24 hours. (D) Western blot with anti Smad7 indicating upregulation of Smad7 with doxycycline 
treatment at 24 and 48 hours and reduction in Smad7 levels when doxycycline was removed from the 
media for 24 or 48 hours. γ-tubulin was used as loading control. 
 
Similar to COLO-357 cells, ASPC-1 (Figure 3.29 A& C) and BXPC-3 (Figure 3.29 B & D) 
cells were stably transduced with the Tet-Smad7 OE plasmid and validated for 
expression of Smad7 mRNA and protein levels. Next, the p-pRb in Tet-Smad7 hPCCs, 
with or without doxycycline and with or without TGF-β1 were analyzed. The data 
generated for p-pRb status with Smad7 OE and treatment with TGF-β1 was not 
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conclusive, hence all further experiments were performed with previously generated 
COLO-357 overexpressing c-Myc tagged Smad7 cells (CS7)[123]. 
 
  
 
Figure 3.29 Tet- inducible Smad7 OE in ASPC-1 and BXPC-3 
 
(A & B) Bar graph showed high expression of SMAD7 mRNA levels in doxycycline treated ASPC-1 cells 
(A) and BXPC-3 cells (B) transduced with Tet-Smad7. Data are represented as mean ± SEM for three 
individual experiments for each cell line. *p value < 0.05 considered significant. (C & D) Western blot 
with anti Smad7 indicating significantly different expression of Smad7 in ASPC-1 (C) and BXPC-3 (D) 
cells transduced with Tet-Smad7 cells treated with doxycycline compared to TF media or sham cells in 
TF media or doxycycline. γ-tubulin was used as loading control. Shown are representative blots from 3 
independent experiments. 
 
3.12 Overexpression of Smad7 in hPCCs  
The c-terminal Myc tagged SMAD7 was overexpressed in a recently derived PDX-cell 
line, IUSCC-PC1 (IUS7). COLO-357 (CSham) and IUSCC-PC1 (IUSham) transduced 
with the empty vector were used as controls. The expression of Smad7 was validated in 
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the cell lines by q-PCR and western blotting. The CS7 cell lines exhibited a 30-fold 
increase in SMAD7 mRNA levels compared to CSham cells (Figure 3.30 A). For the 
protein expression, the lysates were run in duplicates. One set was blotted for Smad7 
antibody and the other for c-Myc tag. The bands by western blotting ran at the same 
molecular weight and showed overexpressed protein at around 50kDa molecular size 
band which is around the expected size for Smad7 (46KDa is the precise molecular 
weight). β-actin and Erk-2 were used as loading controls for Smad7 and c-Myc 
respectively (Figure 3.30 B). The IUS7 cells displayed a 57-fold increase in Smad7 
mRNA compared to the Sham cells (Figure 3.30 C). For the IUS7 cells, only the Smad7 
antibody was used to confirm overexpression (Figure 3.30 D).  
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Figure 3.30 Smad7 OE in hPCCs 
(A) Bar graph showed high expression of SMAD7 mRNA levels in CS7 cells (pink) compared to sham 
cells (purple)  (p<0.0001). Data are represented as mean ± SEM for three individual experiments for 
each cell line. (B) Western blot with anti-Smad7 and anti-c-Myc indicated significantly different 
expression of Smad7 or c-Myc in CS7 cells compared to sham. β-actin and Erk-2 were used as loading 
controls. Shown are representative blots from 3 independent experiments. (C) Bar graph showed high 
expression of SMAD7 mRNA levels in IUS7 cells (pink)  compared to sham cells (purple) (p<0.0001). 
Data are represented as mean ± SEM for three individual experiments for each cell line. (D) Western 
blot with anti-Smad7 indicated significantly different expression of Smad7 in IUS7 cells compared to 
sham. β-actin was used as loading control. Shown are representative blots from 3 independent 
experiments. 
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3.13 Effects of Smad7 overexpression and TGF-β1 on p-pRb, p-Smad2 and p-
Smad3 
Previously, our lab published that when CS7 cells were treated with 500 pM of TGF-β1 
for 24 hours, TGF-β1 mediated phosphorylation of Smad2 and de-phosphorylation of 
pRb was not attenuated by Smad7 overexpression[123]. To determine if there were 
changes in p-Smad3 with Smad7 overexpression and TGF-β, we next treated the 
CSham and CS7 OE cells with 500 pM of TGF-β1 for 24 hours and blotted for phospho- 
and total Smad2 and Smad3. Total Smad2 and Smad3 levels did not change with 
Smad7 overexpression or with TGF-β1 treatment. (Figure 3.31). TGF-β1 markedly 
increased p-Smad2 and p-Smad3 levels in CSham cells.Smad7 overexpression 
decreased basal levels of p-Smad2 and p-Smad3 levels when compared to Sham cells. 
Smad7 overexpression did not attenuate p-Smad2 levels with TGF-β1 treatment, 
however p-Smad3 levels were lowered when compared to sham cells treated with TGF-
β1.  
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Figure 3.31 Effects of Smad7 overexpression and TGF-β1 on p-Smad2 and p-Smad3 
p-Smad2 and p-Smad3 levels were upregulated when Csham cells were treated with 0.5nM TGF-β1 for 
24 hours. Smad7 overexpression did not affect p-Smad2 upregulation by TGF-β1, however it decreased 
p-Smad3 upregulated by TGF-β1. Total Smad2 and Smad3 levels did not change with Smad7 
overexpression or TGF-β1 treatment. β-actin was used as loading control. Shown are representative 
blots from 3 independent experiments. 
 
To quantify phosphorylated Smad2 and 3 levels between the Sham and Smad7 cells 
treated with TGF-β, we quantified the intensities of the protein bands and normalized the 
p-Smad2 levels to the total Smad2 levels. The ratio of phosphorylated Smad2 to total 
Smad2 between the groups was similar, however we found a significant difference in the 
ratio of the phosphorylated to the total Smad3 proteins (Figure 3.32). 
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Figure 3.32 p-Smad3 levels decrease significantly with Smad7 overexpression and TGF-β1 
The ratio for Smad2 (blue) was significantly different with TGF-β1 treatment in Sham (p=0.005) and 
Smad7 OE (p=0.0001) compared to SF conditions. There was no significant difference in the ratio 
between Sham and Smad7 cells in SF condition or those treated with TGF-β1. The ratio for Smad3 
(green) was significantly different with TGF-β1 treatement in Sham (p=0.021) and Smad7 OE (p=0.028) 
compared to SF conditions. There was no significant difference in the ratio between Sham and Smad7 
cells in SF condition, however there was a significant difference in the ones treated with TGF-β 
(p=0.0368). Data are represented as mean ± SEM for three individual experiments for each cell line.(* 
p<0.05, compared to Sham SF; † p<0.05, compared to Sham + TGF-β, # p<0.05, compared to Smad7 OE 
SF by 2 tailed student t test). 
 
These results corroborate with the in vivo findings, where p-Smad2 and p-Smad3 get 
attenuated differently with Smad7 overexpression. To see if these findings were similar 
in another hPCC, the IUS7 cells were treated with 500 pM of TGF-β1 for 24 hours and 
analyzed the phosphorylated and total levels of pRb, Smad2 and Smad3 in these cells. 
The Sham cells were used as controls. The IUSham cells when treated with TGF-β1 
show a marked decrease in p-pRb levels (Figure 3.33 A). There was no difference 
between the p-pRb levels between the Sham and Smad7 overexpressing cells grown in 
SF media. The Smad7 OE cells treated with TGF-β1 did not show a decrease in p-pRb 
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levels when compared to Smad7 OE cells grown in SF media. This data follows a similar 
trend to the COLO-357 cells. Next we analyzed canonical TGF-β signaling activity by 
probing for p-Smad2 and p-Smad3. IUSham cells when treated with TGF-β1, showed a 
marked increase in p-Smad2 (Figure 3.33 B) and pSmad3 (Figure 3.33 C) levels 
compared to Sham cells grown in SF media. Smad7 OE resulted in a decrease in basal 
p-Smad2 and p-Smad3 levels when compared to Sham cells. When Smad7 OE cells are 
treated with TGF-β1, Smad7 attenuated the levels of phosphorylated Smad2 and Smad3 
when compared to Sham cells treated with TGF-β1.  
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Figure 3.33 Effects of Smad7 overexpression and TGF-β1 on p-pRb, p-Smad2 and p-Smad3 in 
IUSCC-PC1 cells 
 
IUsham cells treated with 0.5nM TGF-β for 24 hours exhibit a decrease in p-pRb, (A) p-Smad2 (B) and p-
Smad3 (C) levels. Smad7 overexpression results in attenuation of TGF-β1 mediated decrease in p-Rb 
and increase in p-Smad2 and p-Smad3. Total pRb, Smad2 and Smad3 levels did not change with Smad7 
overexpression or TGF-β1 treatment. β-actin was used as loading control. Shown are representative 
blots from 3 independent experiments. 
 
The protein band intensities on the western blots were then quantified for the ratio of 
levels of the p-Smad2 and p-Smad3 to their respective total proteins. There was a 
significant difference in the ratios of phosphorylated to total protein for Smad2 and 
Smad3 in the TGF-β1 treated groups compared to SF for Sham and Smad7 OE (Figure 
3.34). There was a decrease in the ratio between Sham and Smad7 OE cells grown in 
SF conditions or those treated with TGF-β1, however it was not significant. Overall, in 
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IUSCC-PC1 cells, Smad7 OE attenuated TGF-β signaling and kept pRb hyper 
phosphorylated.  
 
 
 
Figure 3.34 p-Smad2 and p-Smad3 levels decreased in IUSCC-PC1 cells overexpressing Smad7 
and treated with TGF-β1 
Quantification of ratio of p-Smad2 to total Smad2 (blue) and p-Smad3 to total Smad3 protein (green) in 
IUSCC-PC1 cells overexpressing Smad7 and/or treated with TGF-β. The ratio for Smad2 (blue) was 
significantly different with TGF-β1 treatment in Sham (p=0.0001) and Smad7 OE (p=0.005) compared to 
SF conditions. There was no significant difference in the ratio between Sham and Smad7 cells in SF 
condition or those treated with TGF-β1. The ratio for Smad3 (green) was significantly different with 
TGF-β1 treatement in Sham (p=0.0058) and Smad7 OE (p=0.0076) compared to SF conditions. There 
was no significant difference in the ratio between Sham and Smad7 cells in SF condition or those 
treated with TGF-β1. Data are represented as mean ± SEM for three individual experiments for each 
cell line. 
 
 
3.14 Smad7 overexpression and p21 
The KS7C mouse model displayed loss of p21 in high grade PanIN lesions. Previous 
studies from our lab have shown that levels of p21, a TGF-β induced cell cycle inhibitory 
protein are decreased in hPDAC samples even in the presence of high p-Smad2 or 
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activated TGF-β signaling [39]. It was also reported that TGF-β stimulates CDKN1A 
(gene encoding p21) promoter, using luciferase reporter assay in COLO-357 cells [121]. 
In the same study, Smad7 OE attenuated TGF-β mediated activation of 
CDKN1Apromoter. Thus the CDKN1A mRNA levels in Smad7 overexpressing cells were 
analyzed next. In COLO-357 (Figure 3.35 A) and IUSCC-PC1 (Figure 3.35 B) Sham 
cells, TGF-β1 increased expression of CDKN1A. When Smad7 was overexpressed in 
these cells, the CDKN1A levels were significantly reduced by 2-folds. When Smad7 over 
expressing cells are treated with TGF-β1, CDKN1A levels were increased when 
compared to SF conditions, however they were significantly lower than the TGF-β 
treated Sham cells.  
 
 
Figure 3.35 Smad7 overexpression and CDKN1A 
 
(A and B) TGF-β1  treatment (pattern bar) resulted in significant upregulation of CDKN1AmRNA levels 
in COLO-357 (A) and IUSCC-PC1 (B) Sham cells (purple bars) (p=0.01 for both). Smad7 overexpression 
(pink bars) resulted in significant decrease of CDKN1A mRNA in both cell lines (p=0.04 for both). There 
was a significant decrease in CDKN1A mRNA levels between the Sham and Smad7 OE, TGF-β treated 
groups for IUSCC-PC1 (p=0.02) (* p<0.05, compared to Sham SF; † p<0.05, compared to Sham + TGF-β, # 
p<0.05, compared to Smad7 OE SF by 2 tailed student t test). 
 
Next, the levels of p21 were analyzed in the CS7 (Figure 3.36A) and IUS7 (Figure 
3.36B) cells. The basal levels of p21 were very low in the Sham cells for both the cell 
types. Upon TGF-β1 treatment, p21 levels increased in the Sham cells. Smad7 
overexpressing cells had almost no or lowered p21 compared to Sham cells grown in SF 
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conditions. When TGF-β1 was added to Smad7 overexpressing cells, in COLO-357 
cells, p21 levels were upregulated to the same level as that of Sham, while in the 
IUSCC-PC1, the upregulation of p21 by TGF-β1 was attenuated. 
 
 
Figure 3.36 Smad7 overexpression and p21 
 
(A and B) Smad7 overexpression decreased p21 levels in COLO-357 (A) and IUS7 (B) cells.TGF-β1 
treatment upregulated p21 levels in Sham cells, and this effect was attenuated with Smad7 
overexpression in IUS7 cells, but not in CS7 cells. β-actin was used as loading control. Shown are 
representative blots from 2 independent experiments for A and 3 independent experiments for B. 
 
 Since p21 levels regulate p-pRb status, Smad7 maybe attenuating p21 levels, resulting 
in prevention of dephosphorylation of pRb. These results, along with thein vivo data 
indicate that Smad7 regulates p-Smad2 and p-Smad3 differently in pancreatic cells and 
in mouse tissues, resulting in attenuation of TGF-β mediated cell growth inhibition 
(Figure 3.37). 
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Figure 3.37 Smad7 OE allows activation of p-Smad2 by TGF-β1, however it attenuates p-Smad3 
levels, thus decreasing p21 and keeping pRb inactivated 
 
Smad7 OE does not block TGF-β mediated p-Smad2 (depicted by green arrows); however Smad7 OE 
attenuates p-Smad3 levels, such that it results in downregulation of p21 levels, resulting in 
accumulation of p-pRb (inactive pRb). The signaling path results in transactivation of E2F, increasing 
transcription of cyclins and increased cell proliferation.  
 
3.15 Gene Set Enrichment Analysis and validation of Smad3 dependent, TGF-β 
regulated genes  
The tissues from Smad7 overexpressing mouse (KS7C) stained negative for p–Smad3 
levels and in the KS7C cell line, upregulation of p-Smad3 levels with TGF-β was 
attenuated. Therefore, I hypothesized that Smad7 overexpression preferentially 
attenuates p-Smad3 levels over p-Smad2 levels, resulting in differential regulation of 
TGF-β regulated genes. Next, to determine the genes that are regulated by TGF-β and 
are Smad3 dependent. A Smad3 dependent TGF-β gene signature was generated by 
using the microarray expression data from a previous study conducted in A549 lung 
epithelial cells [152]. The gene signature was generated by comparing gene expression 
in A549 cells treated with TGF-β versus SiS3 (specific inhibitor of p-Smad3) combined 
with TGF-β, with each treatment being for 24 hours. Next, GSEA was carried out for 
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Smad3 dependent TGF-β gene signature on a ranked list of genes that were 
differentially regulated in human PDAC tissues and their adjacent normal [156]. The 
genes that were differentially regulated in PDAC versus control tissues, correlated 
strongly with the Smad3 dependent, TGF-β gene signature. (Figure 3.38). This work was 
done by another graduate student in the laboratory at IUSM. 
 
 
Figure 3.38 Gene Set Enrichment Analysis and validation of Smad3 dependent, TGF-β 
regulated genes 
 
Gene array from inhibition of Smad3 in lung cancer cells, followed by TGF-β treatment leads to 
deregulation of TGF-β-mediated genes which are enriched in hPDAC tumors when compared to 
normal. 
 
Next, the significantly upregulated genes from the Smad3 dependent TGF-β gene 
signature that were significantly up regulated in PDAC and have been previously shown 
to play a role in increasing PDAC aggressiveness were chosen for validation. The genes 
were GPX2, MUC1, MUC13 and AGR2. Their expression was tested in the CS7 and 
IUS7 cells with or without TGF-β1. In COLO-357 Sham cells, and treated with TGF-β the 
MUC1, MUC13 and AGR2 expression was significantly decreased (Figure 3.39). Smad7 
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overexpression in the COLO-357 cells in SF conditions increased the levels of MUC1, 
MUC13 and AGR2 significantly. GPX2 levels were increased with Smad7 
overexpression, however the change in mRNA levels were not significant. Next the 
Sham and Smad7 TGF-β1 treated groups were compared.  TGF-β1 lowered the 
expression of all four genes. GPX2 was not significantly different in the Sham and 
Smad7 overexpressing groups, however MUC1, MUC13 and AGR2 were significantly 
elevated in the Smad7 overexpressing cells treated with TGF-β.  
 
 
Figure 3.39 Smad7 OE enhances expression of MUC1, MUC13 and AGR2 in CS7 OE cells 
TGF-β1 (pattern) significantly lowered and Smad7 OE (pink) significantly increased AGR2, MUC1 
and MUC13 levels compared to Sham (purple bars). MUC13 and AGR2 levels were significantly 
different in the TGF-β1 treated Sham and Smad7 OE groups. (* p<0.05, compared to Sham SF; † 
p<0.05, compared to Sham + TGF-β1, # p<0.05, compared to Smad7 OE SF by 2 tailed student t 
test). 
 
In the IUSCC-PC1 cells all four genes were significantly decreased with TGF-β 
treatment when compared to SF in Sham cells (Figure 3.40) and significantly elevated 
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with Smad7 overexpression when comparing the SF conditions alone. When IUS7 cells 
were treated with TGF-β1, all four genes were lowered when compared to SF conditions, 
however their levels were significantly different from TGF-β1treated IUSham cells. These 
results indicate that Smad7 OE in hPCCs lowers the induction of Smad3 dependent 
genes in response to treatment with TGF-β1.  
 
 
Figure 3.40 Smad7 OE enhances expression ofGPX2, MUC1, MUC13 and AGR2in IUS7 OE cells 
 
TGF-β1 (pattern) significantly lowers and Smad7 OE (pink) significantly increasedGPX2, AGR2, MUC1 
and MUC13 levels compared to Sham (purple bars). GPX2, AGR2, MUC1 and MUC13were 
significantly different in the TGF-β1 treated Sham and Smad7 OE groups. (* p<0.05, compared to 
Sham SF;†p<0.05, compared to Sham + TGF-β1, # p<0.05, compared to Smad7 OE SF by 2 tailed 
student t test). 
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3.16 Knockdown of SMAD3 in COLO-357 
Based on the results of the GSEA analysis and validation of Smad3 dependent genes in 
Smad7 overexpressing cells, Smad3 was stably knocked down in COLO-357 (CS3KD) 
cells to determine if CDKN1A and p-pRb levels were regulated directly by Smad3. 
COLO-357 cells were stably transduced with shRNA against SMAD3. These cells were 
validated for SMAD3 knockdown by qPCR and western blotting. The SMAD3 levels were 
reduced by 50% in the SMAD3 knockdown cells (Figure 3.41 A) and there was a 
reduction in the protein levels (Figure 3.41B).  
 
Knockdown of Smad3 in COLO-357 cells resulted in decreased CDKN1Alevels (Figure 
3.41 C) and increased p-pRb when compared to Sham cells (Figure 3.41 D). TGF-β1 
mediated upregulation of CDKN1A and dephosphorylation of pRb were attenuated when 
there was loss of Smad3.  
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Figure 3.41 Knockdown of Smad3 in COLO-357 
  
(A) There was a 50% reduction in SMAD3 mRNA levels in CS3 KD cells compared to sham cells 
(p=0.00045). Data are represented as mean ± SEM for three individual experiments for each cell line. 
(B) Western blot with anti Smad3 indicate decreasedSmad3 levels in the Knockdown cells compared 
to sham. β-actin was used as loading control. Shown are representative blots from 3 independent 
experiments. (C)TGF-β1  treatment (pattern bar) resulted in significant upregulation of CDKN1A 
mRNA levels in COLO-357 Sham (purple bars) and Smad3 KD (pink bars) cells. Smad3 Knockdown 
resulted in a significant decrease in basal CDKN1AmRNA levels and between the sham and Smad3 
KD, TGF-β1 treated groups. Data are represented as mean ± SEM for three individual experiments 
for each cell line.(* p<0.05, compared to Sham SF; † p<0.05, compared to Sham + TGF-β1, # p<0.05, 
compared to Smad3 KD SF by 2 tailed student t test). (D) When CS3KD cells were treated with 
500nM TGF-β1, p-pRb levels were increased, and p-Smad3 levels were decreased. Total Smad2 
levels did not change with Smad3 KD or TGF-β1 treatment. β-actin was used as loading control. 
Shown are representative blots from 3 independent experiments. 
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3.17 SMAD3 CRISPR of hPCCS 
To confirm the effects observed by SMAD3 knockdown, CRIPSR of SMAD3 in COLO-
357 and IUSCC-PC1 cells was carried out. The CRIPSR was performed as described in 
Chapter 2. The cell clones were validated for loss of Smad3 by western blotting (Figure 
3.42). When blotted for total Smad3, the mixed pool of COLO-357 Sham cells and the 2 
single clones (D5 and E5) showed presence of Smad3 protein. This band disappeared 
completely in the Smad3 CRIPSR mixed pool of COLO-357 cells and the 4 single clones 
D7, E7, F6 and F7. Since there was a faint upper band seen in the SMAD3 CRISPR 
cells with the Total Smad3 antibody, I stripped the blot and re-probed with Total 
Smad2/3 antibody. The COLO-357 Sham mixed pool cells and single clones D5 and E5 
showed presence of Smad2 and Smad3. The mixed pool from Smad3 CRISPR cells 
showed no presence of Smad3 and neither did the clones D7, E7, F6 or F7, however 
they did show presence of Smad2. Sequencing of PCR amplified region around Exon 6 
confirmed partial deletion of Exon 6 in the CRIPSR clone F7. Thus the Smad3 CRIPSR 
was successful in the F7 derived clone of COLO-357 cells.  
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Figure 3.42 Smad3 CRISPR in COLO-357 
Western blot with anti-Smad3 indicated complete loss of Smad3 levels in the CRISPR mixed pool, and 
the 4 clones, D7, E7, F6 and F7 cells compared to sham mixed pool cells and the two clones, D5 and 
E5 for COLO-357 cells. Blotting with Total Smad2/3 antibody showed intact Smad2 band (upper) for 
all the cells, however the lower band (Smad3) was absent in the mixed CRISPR cells as well as the 4 
clones. β- actin was used as loading control. Shown are representative blots from 2 independent 
experiments. 
 
Similarly western blotting for IUSCC-PC1s (Figure 3.43) was carried out, for mixed 
population of cells and a single clone for Sham and Smad3 CRISPR cell. The Smad3 
protein was successfully CRISPR in IUSCC-PC1s. 
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Figure 3.43 Smad3 CRISPR in IUSCC-PC1 cells 
 
Western blot with anti-total Smad2/3 antibody showed intact Smad2 band (upper) for all the 
samples, however the lower band (Smad3) was absent in the mixed CRISPR cell pool as well as the 
single cell clone D5. β- actin was used as loading control. This was an initial experiment (n=1). 
 
3.18 AGR2 is upregulated by knockdown of Smad3 and overexpression of Smad7 
AGR2 is an ER stress marker that belongs to the protein disulfide isomerases 
family[163, 164]. AGR2 is upregulated in PDAC and correlates with poor survival [165-
168]. AGR2 is suppressed by TGF-β via Smad4 and co-localizes with MUC1 in PanIN 
lesions [169]. AGR2 was amongst the top 5 genes in the array of TGF-β regulated 
genes, dependent on Smad3. Thus, we confirmed the upregulation of AGR2 levels with 
Smad3 knockdown (Figure 3.44 A). AGR2 upregulation with Smad7 overexpression in 
hPCCS was validated by qPCR (Figure 3.39 and 3.40). Next the effects on AGR2 
protein with TGF-β and Smad7 overexpression were analyzed. AGR2 protein levels 
follows similar patterns as the AGR2 mRNA with TGF-β1 and Smad7, where TGF-β1 
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lowered AGR2 levels and Smad7 OE increased basal AGR2 levels when compared to 
Sham in COLO-357 (Figure 3.44 B)  and IUSCC-PC1 (Figure 3.44 C)  cells. Smad7 
overexpressing cells attenuated TGF-β1 mediated suppression of AGR2 in COLO-357 
cells. In IUSCC-PC1, the attenuation of AGR2 level was not as prominent as the Sham 
cells. Taken together, these results indicate that expression of AGR2 levels are 
suppressed by TGF-β1 as shown previously. Smad3 knockdown increases AGR2 levels 
and Smad7 overexpression increases AGR2 mRNA and protein levels.  
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Figure 3.44 AGR2 is upregulated by knockdown of Smad3 and Smad7 OE in hPCCs 
 
(A) Smad3 knockdown in hPCCs increasedAGR2 mRNA levels p<0.001. TGF-β1 (pattern) significantly 
lowers and Smad3 KD (pink) significantly increasedAGR2 levels compared to Sham (purple bars). AGR2 
levels are significantly different in the TGF-β1 treated Sham and Smad3 KD groups. (* p<0.05, 
compared to Sham SF; † p<0.05, compared to Sham + TGF-β1, # p<0.05, compared to Smad7 OE SF by 2 
tailed student t test). (B-C) TGF-β1 lowered AGR2 protein levels in COLO-357 (B) and IUSCC-PC1 (C) 
cells. Smad7 OE significantly increased AGR2 protein levels in both cell lines. Smad7 attenuated TGF-β1 
mediated AGR2 suppression. β-actin was used as loading control. Shown are representative blots from 
3 independent experiments. 
 
3.19 AGR2 is upregulated in KS7C mice tissues and cell lines  
Since Smad7 OE and deletion of Smad3 led to increased AGR2 expression in hPCCs, I 
next analyzed AGR2 expression in the KS7C and KTetS7C cell lines that were derived 
from the mouse tumors. The KS7C cell line showed a marked increase in AGR2 levels 
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when compared to KC (Figure 3.45 A). In the KtetS7C cell lines, doxycycline was added 
to induce Smad7 overexpression. The KtetS7C cells in TF media were used as controls. 
Smad7 induction resulted in increased AGR2 levels in these cells (Figure 3.45 B).  
 
 
Figure 3.45 AGR2 is upregulated in KS7C and KtetS7C cell lines 
 
(A) AGR2 levels were significantly higher in KS7C cell lines compared to KC (p<0.0001). (B)AGR2 levels 
were significantly higher with induction of Smad7 in the KtetS7C cell line when treated with 
doxycycline (p<0.001). Data are represented as mean ± SEM for three individual experiments for all 
qPCR data. 
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AGR2 was abundant in KS7C mice pancreas when compared to KC mice by IHC 
(Figure 3.46).  
 
 
 
Figure 3.46 AGR2 is upregulated in KS7C mouse tissues 
Representative images for AGR2 staining from 3 KC and 3 KS7C mice (M1, M2 and M3) tissues             
(4X magnification) which showed increased expression of AGR2 in KS7C mice when compared to KC 
mice. Lower most panel are 20X magnified images of KS7C tissue areas marked in dotted rectangle. 
Scale bars represent 100µM. 
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This finding was consistent in the tetracycline inducible Smad7 mouse model (Figure 
3.47). Thus Smad7 overexpression in vitro increases AGR2 levels in murine cells and in 
tissues.  
 
 
Figure 3.47 AGR2 levels are upregulated in KtetS7C mice pancreatic tissue fed with doxycycline 
Representative images for AGR2 staining from 3 KtetS7C with or without Doxycycline (4X 
magnification). Lower most panel are 20X magnified images of KtetS7C tissue areas marked in dotted 
rectangle. Scale bars represent 100µM. 
 
3.20 Smad3 and Smad4 suppress AGR2 by directly binding to its promoter and 
this binding is abolished in presence of Smad7 
Smad7 overexpression increased AGR2 mRNA and protein levels in hPCCs and mouse 
tissues. To determine if Smad7 directly bound to the AGR2 promoter to regulate its 
levels, a ChIP assay with c-Myc tag in hPCCs overexpressing c-Myc tagged Smad7 was 
carried out. Smad7 did not bind directly to the AGR2 promoter (Figure 3.48 A). Since 
knockdown of Smad3 resulted in increased AGR2 levels, we hypothesized that Smad3 
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binds to the AGR2 promoter to repress its activity. ChIP assays with Smad3 and Smad4 
demonstrated that the two bound directly to theAGR2 promoter, and this binding was 
abolished in the presence of Smad7 overexpression (Figure 3.48 B). Therefore, these 
results support the hypothesis that AGR2levels are directly repressed by Smad3 and 
Smad4. When Smad7 is overexpressed, the binding of Smads 3 and 4 to the AGR2 
promoter was inhibited or decreased, resulting in increased expression of AGR2. ChIP 
assay analysis with Smad3 and Smad4 binding to AGR2 promoter were consistent in the 
IUSCC-PC1 cells (Figure 3.48 C).  
 
 
Figure 3.48 Smad3 and Smad4 suppressed AGR2 by directly binding to its promoter and this 
binding was abolished in presence of Smad7 
 (A) ChIP - qPCR assays revealed that Smad7 did not bind directly to the AGR2 promoter.  (B) ChIP 
assay in CSham cells revealed that Smad3 and 4 bound to AGR2 promoter (p=0.023). This binding 
was abolished with Smad7 overexpression in COLO-357 cells. (C) ChIP assay in IUSham cells revealed 
that Smad3 and 4 bound to AGR2 promoter (p=0.029). This binding was abolished with Smad7 
overexpression in IUSCC-PC1 cells. Data are represented as mean ± SEM for three individual 
experiments for all qPCR data.  
 
102 
3.21 Smad7 and Pancreatitis 
Pancreatitis is an important risk factor associated with pancreatic cancer. TGF-β is an 
important regulator of inflammation and fibrosis and Smad7 has been shown to inhibit 
this effect. Furthermore, previous studies have shown that Smad7 overexpression is 
protective against caerulein-induced chronic pancreatitis [138, 139]. Previous studies 
have shown that induction of acute pancreatitis in rats administered with caerulein 
results in upregulation of TGF-βI, II and III [134]. Studies by Wilde et al [135] have 
shown that an intact TGF-β signaling pathway in required for induction of inflammation 
by caerulein. Another group [131, 132, 137] showed using transgenic mouse models of 
dominant negative mutant TβRII, that when subjected to caerulein injections, the mice 
pancreata displayed amelioration of fibrosis. The Korc lab has previously shown that 
inducing acute pancreatitis in Kras mutant mice results in rapid PDAC progression[112]. 
Together these prior reports support the hypothesis that in the presence of Smad7, the 
progression to PDAC will regress in mice with Kras mutation after induction of acute 
pancreatitis. To test this hypothesis, the KS7C mice were injected with Caerulein as 
described in Chapter 2. KC mice were used as controls. Simultaneously KC and KS7C 
mice injected with vehicle alone were used as controls for caerulein effects. The mice 
were injected at 2.5 months of age and then sacrificed 2 months later. The histology of 
the KC mice exhibited marked acinar cell loss. Instead these tissues were replaced with 
low and high grade PanIN lesions and stroma. The KS7C mice on the other hand had 
less tissue remodeling in their pancreas and exhibited only ADMs and low grade PanINs 
(Figure 3.49 A).  The number of KC mice that exhibited PanIN 2, 3 and developed 
PDACs were significantly more than KS7C mice (Figure 3.49 B). Next, Masson’s 
trichrome staining was performed on the mice tissues to analyze collagen deposition, an 
indicator of fibrosis. Three mouse pancreata were stained from the vehicle injected 
group and 4 from the caerulein injected group (Figure 3.49 C). The KS7C control mice 
displayed lesser collagen deposition than the KC mice in the pancreas, however this 
difference was not statistically significant (Figure 3.49 D). The KC mice subjected to 
caerulein exhibited significant increase in collagen deposition when compared to vehicle 
injected mice. There was no difference in the collagen deposition between the KS7C 
caerulein injected or control mice. There was a significant decrease in collagen 
deposition between KC and KS7C mice that had been injected with caerulein. These 
results indicate that overexpression of Smad7 reduces overall collagen deposition and 
thus fibrosis when mice are subjected to acute pancreatitis.  
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Figure 3.49 Smad7 and Pancreatitis 
(A) Representative images from KC and KS7C mice showing that KC mice have complete tissue 
remodeling with cancer. Section from KS7C mouse shows normal tissue, surrounding lowgrade PanINs. 
Scale bars 100µM. (B) Bar graph represents the percent of total  KC mice (black) and KS7C mice (gray) 
injected with caerulein, exhibiting different grades of PanIN. (* p<0.05). (C) Representative images 
from KC and KS7C mice showing that KC mice have increased collagen deposition (blue) compared to 
KS7C mice. Scale bars represent 100µM. (D) Quantification of collagen deposited for each group shows 
that caerulein increased collagen deposition significantly in KC mice. There was a significant decrease in 
collagen deposition between KC and KS7C mice injected with caerulein. For each group N=3 for KC and 
N=4 for KS7C were used. From each mice 5 random field were imaged and quantified. Data are 
represented as mean percent ± SEM of area covered by collagen. 
 
Altogether, the above observations indicate that in case of inflammation or acute 
pancreatitis, Smad7 may play a protective role by attenuating inflammatory responses 
and fibrosis deposition, thus resulting in slowing down the PanIN to PDAC progression.   
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4. Discussion  
TGF-β and its isoforms are overexpressed in PDAC and correlate with poor survival [27]. 
It is surprising that Smad7, which is an inhibitor of TGF-β is also overexpressed in PDAC 
[120, 121]. Clinical studies in PDAC patients demonstrate that low levels of Smad7 
correlate with poor prognosis and increased lymph node metastasis[129]. However, the 
effects of Smad7 overexpression (Smad7 OE) in vitro and in vivo, results in abrogation 
of TGF-β mediated cell growth inhibition and increased tumorigenesis [121-123]. Thus, 
to delineate the role of Smad7 overexpression in PDAC we created a mouse model 
specifically overexpressing Smad7 in the pancreas.  
4.1 Overexpression of Smad7 functions with oncogenic Kras to accelerate PDAC 
progression in a transgenic mouse model  
We determined that overexpression of Smad7 (Smad7 OE) alone did not affect the 
histology of the pancreas or induce acinar to ductal metaplasia in either of the mouse 
models of Smad7 OE (KS7C and KtetS7C). These observations differ from the findings 
by Kuang et al [130] who indicated that Smad7 OE lead to induction of PanIN-2 in the 
pancreas of 6 months old mice even in the absence of oncogenic Kras. The differences 
between this earlier Smad7 findings and our findings may be due to differences in the 
model system, which features Pdx-1 driven Cre recombinase to target Smad7 
expression in the pancreas. By comparison Kuang et al [130] utilized the Elastase 
promoter to drive Smad7 expression in acinar cells. ThePdx-1 promoter drives 
expression of Cre in all the three cell types, the ductal, acinar and pre-endocrinal of the 
pancreas versus the elastase which is specific to the acinar cells [160, 170]. Additionally, 
the amount of overexpression of Smad7 in the two models described in this thesis when 
compared to, may be different than that of Kuang et al, resulting in different outcomes. 
Another study by Smart et al [171] which featured Smad7 OE by Pdx-1, revealed 
abnormalities in the pancreas and foregut development. The physiological function of 
islets was also disrupted in these mice, with low insulin and high glucagon levels. The 
KS7C and KtetS7C mouse models described in this thesisexhibited similar levels of 
Smad7 expression and showed normal pancreatic histology and expression of glucagon, 
insulin, and amylase up toat least6 months of age. Therefore we hypothesize that the 
levels of Smad7 overexpression may differ due to differences in transgene copy number, 
promoter efficiency or different mouse strains. 
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When a Kras mutation was introduced into the Smad7 overexpressing mice, there was 
enhanced progression of PanIN lesions to PDAC and a significant decrease in survival. 
Of importance, these results were reproducedin thetetracycline-induced Smad7 model 
where induction of Smad7 combined with oncogenic Kras at 1 month, 2 months or 3 
months of age, enhanced progression to PDAC. In the earlier study by Kuang et al.[130], 
effects of Smad7 OE were assessed without combination with another transgene. As 
described earlier, Kras is an important driver oncogene in PDAC. This study for the first 
time unravels the role of Smad7 in the presence of oncogenic Kras using GEMMs of 
PDAC. The study by Xin Lui et al [172] describes how Smad7 OE in keratinocytes 
requires oncogenic ras (v-ras) to form squamous cell carcinoma, whereas Smad7 OE 
alone resulted in hyperplasia in this cell type. These findings are in agreement with the 
findings of Kuang et al and the data for KS7C and KtetS7C mice, where oncogenic Kras 
is important and required for acceleration to the cancerous stage.  
The KS7C mice exhibited heterogeneity in the progression of the disease pathology, 
with a few mice exhibiting accelerated progression to PDAC as early as 7 weeks of age 
to some exhibiting advanced lesions, but no PDAC. This finding may be due to the 
differences in efficiency of the promoters driving any of the transgenes. Previous studies 
[173]have also used fluorescent tracing and determined that when there are multiple 
transgenes present in a mouse model, the efficiency of recombination for the different 
transgenes by cre-recombinase in the same cells is different[174, 175]. This may explain 
why mice from the same litter exhibited differences in the number and aggressiveness of 
the PanIN lesions. Unfortunately IHC staining with anti-HA or anti-Smad7 was not 
successful probably due to low expression levels of Smad7 and lack of specific 
antibodies. These reasons made it difficult to confirm the recombination status and 
expression of Smad7 transgene in the mouse tissues. Quantification of Smad7 mRNA in 
KS7C mice of the same age, exhibiting differences in pathology was done for a total of 3 
mice (Supplementary figure 6.2), which suggests that there may be a correlation 
between the levels of Smad7 and number and aggressiveness of the lesions exhibited 
by mice. In follow up studies, the number and ages of mice would be expanded to 
confirm this hypothesis.  
Another potential reason for the heterogeneity in the number of lesions observed in the 
mice may be due to the differences in cellular signaling events that occur downstream of 
Kras and Smad7 resulting in initiation of ADM and progression to PDAC. In the 
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transgenic mouse models of PDAC, to the best of my knowledge, no studies have been 
done by sequencing multiple pancreata or tumors to examine the differences among 
mice with same genotype. Anecdotally researchers agree that there is considerable 
variations in KPC mice in terms of onset of disease[159]. As PanINs progress to PDAC, 
the different cells from the same mouse could accumulate different mutations that could 
then lead to enhanced progression of disease in a subset of cells, while the rest of the 
pancreas exhibits normal cellular architecture.  
4.2 Smad7 promotes PDAC progression by disrupting TGF-β-directed inhibition of 
cell growth by a signaling pathway involving inactivation of pRb 
Inactivation of pRb in combination with induced TGF-β signaling, are important hallmarks 
in mPDAC and hPDAC [39, 114]. I now demonstrate that pRb is inactivated in a patient 
derived hPCC with an oncogenic KRAS mutation and in the GEMMthat features Smad7 
OE and oncogenic Kras. Cells isolated from pancreata of KC mice exhibited cell cycle 
arrest, as illustrated by decreased p-pRb levels in SF conditions. By comparison, tumor 
cells derived from the KS7C mice exhibited increased levels of p-pRb in SF conditions 
which further suggests that Smad7 OE confers a growth advantage to the cells. 
Treatment of KC cells with TGF-β, lead to a decrease in p-pRb, not readily detectable. 
Furthermore, when the KS7C cells were treated with TGF-β, the levels of p-pRb 
decreased when compared with the SF condition; however p-pRb levels were still higher 
than the KC cell line. These results indicate that Smad7 inactivates pRb, resulting in 
increased proliferation, in agreement with previously reported findings from the Korc lab. 
Thus it was shown that Smad7 overexpression in COLO-357 cells results in pRb 
inactivation [123] and that pRb inactivation allowed TGF-β to be a mitogen as a 
consequence of the activation of non-canonical signaling pathways, including those 
featuring ERK, Src, and Smad4-dependent upregulation of Wnt7b, which acts to further 
increase mitogenesis[39]. Overexpression of Smad7 in COLO-357 cells, did not block 
TGF-β mediated activation of MAPK, JNK1/2, p38 and AKT2 [123] which are known to 
increase EMT, migration and invasion of cancer cells. Activation of these proteins by 
TGF-β in the presence of inactivated pRb leads to increased mitogenesis [39]. 
Therefore, it will be important to analyze the activation of MAPK, JNK1/2, p38 and AKT2 
in the KS7C mouse model to determine if Smad7 allows activation of these pathways by 
TGF-β in vivo. Furthermore, if one or more of these key regulators are activated, it would 
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be important to determine if inhibition of the non-canonical signaling in combination with 
Smad7 could decrease PDAC progression in a transgenic mouse model. 
To confirm that tumorigenic outcomes by Smad7 OE involve inactivation of pRb, anRb1 
heterozygous deletion was introduced in KS7C mice (KR+/-S7C) and compared to mice 
that had a Kras mutation and homozygous deletionRb1 (KRC) in the pancreas. The 
KR+/-S7C mice developed PanINs and PDAC at a similar rate compared to the KRC 
mice and exhibited increased pRb phosphorylation in their lesions. These observations 
were also consistent with the KS7C mice. The KR+/-S7C mice pancreata also presented 
with other similarities to the KRC mice pancreata, such as inflammation associated with 
disease and cystic lesions (seen in N=3) which also suggest that Smad7 OE and 
heterozygous loss of Rb1 may have similar downstream implications compared to the 
homozygous loss of Rb1. The presence of p-pRb in the KR+/-S7C mice tissues also 
confirmed that the effects seen in the mice were not because of loss of heterozygosity of 
Rb1, but due to effects of Smad7 OE. These results suggest that Smad7 may exert its 
effect in PDAC via inactivation of pRb. To further demarcate the events downstream of 
pRb, it would be interesting to generate additional cell lines from the KR+/-S7C mice 
tumors and investigate the effects ofTGF-β1on proliferation and colony growth in 3D 
tissue culture.  
4.3 Overexpression of Smad7 and effects of TGF-β on Smad2 and Smad3 
Smad7 OE did not decrease p-Smad2 levels in the KS7C mice tissues;however, 
elevated levels of Smad7 did result in decreased levels of p-Smad3. Smad7 OE in 
hPCCs, it blocked the phosphorylation of both Smad2 and Smad3. with an enhanced 
effect on levels of p-Smad3 as compared to p-Smad2. However this effect was cell type 
dependent. For example, Smad7 OE did not attenuate TGF-β1 mediated 
phosphorylation of Smad2 in COLO-357 cells; however elevated levels of Smad7 did 
attenuate p-Smad2 levels in IUSCC-PC1 cells, while they lowered levels of p-Smad3 in 
both cell lines. In both cell lines, enhanced expression of p21 and attenuation of AGR2 
by TGF-β1 in presence of elevated Smad7 had different outcomes. The results obtained 
from the in vitro and in vivo analysis of Smad7 OE and treatment with TGF-β suggests 
that Smad7 regulates the function of TGF-β1ina context-dependent manner and some of 
the possibilities for the differences observed in the results are discussed below.  
108 
Previously it was observed that when COS-7 cells (kidney fibroblasts) overexpressing 
Smad7, were treated with TGF-β1 it led to the localization of Smad7 to the cytoplasm 
[123]. Smad7 OE also attenuated or blocked translocation of Smad2 and Smad3 from 
the cytoplasm to the nucleus which is as expected of the canonical TGF-β signaling 
pathway [64]. However, when Smad7 was overexpressed in COLO-357 cells (PDAC 
cells), Smad7 failed to translocate to the cytoplasm upon TGF-β signaling activation. 
Smad2 and Smad3 remained nuclear even when Smad7 was overexpressed and the 
cells were treated with TGF-β1[123]. The differences observed with Smad7 OE on the 
canonical TGF-β signaling pathways between the cell lines may be due to factors, such 
as expression of SMURFS which regulate the shuttling of Smad7 between the nucleus 
and cytoplasm [77, 78, 176]. In IUSCC-PC1, we did not verify the distribution of Smad7 
and its effects on p-Smad2 or p-Smad3 localization to confirm whether it exhibited 
similar results as COLO-357. These effects of differences in localization are likely due to 
differences in the levels of p-Smad2 and p-Smad3, thus affecting the actions of TGF-β 
on gene expression. 
Another potential explanation for the differences observed in the results between the two 
hPCCs may be due to the genetic alterations between each of the cell lines. For 
example COLO-357 cells do not have a Kras mutation, whereas IUSCC-PC1 has a Kras 
mutation. Perhaps oncogenic Kras is driving differential signaling which maybe the 
primary reason for differences in levels ofp-Smad2, AGR2 and p21 with Smad7 OE and 
TGF-β treated cells. Thus, it would be interesting to see the outcomes with Smad7 OE 
and TGF-β treatment when oncogenic Kras is introduced into COLO-357 cells to 
specifically determine the effects of overexpression of Smad7 and Kras in this signaling 
context and PDAC.  
A third explanation for the differences in p-Smad2, AGR2 and p21 levels with Smad7 OE 
and TGF-β in the hPCCs may involve other transcription factors that regulate their 
expression [163, 177]. The Smad3 complex maybe an important factor, but it may not be 
the only transcription factor responsible for regulation on these genes. To confirm that 
effects observed with Smad7 OE are modulated by Smad3, we next knocked down 
Smad3 in hPCCs and examined the effects on CDKN1A, AGR2 and p-pRb.   
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4.4 Overexpression of Smad7 decreased p-Smad3 levels, modulating expression 
of CDKN1A and AGR2: two potentially important targets that regulate cell cycle 
and migration 
The effects of Smad7 overexpression and knockdown of Smad3 were similar on 
CDKN1A levels and inactivation of pRb in vitro. TGF-β increased CDKN1A levels in 
hPCCs, and Smad7 OE resulted in reduced basal transcript levels of CDKN1A. 
Knockdown of Smad3 in COLO-357 also resulted in downregulation of CDKN1A, 
indicating that Smad3 regulates CDKN1Alevels in hPCCs.We hypothesize that 
increased cell proliferation seen in vivo with elevated levels of Smad7 could be a 
consequence of decreased levels of p-Smad3. GSEA of genes that change with 
inhibition of Smad3 using SiS3 and TGF-β[152] indicated that these genes are 
significantly enriched in hPDAC, implying that deregulation of Smad3 may be vital for 
progression of hPDAC. Overall, our findings suggest that Smad7 significantly decreases 
the levels of p-Smad3 and low levels of phosphorylated Smad3, result in PDAC 
aggressiveness mediated by TGF-β signaling. 
Based on our studies and several published reports, the effects of Smad3 on p21 seem 
to be specific to Smad3. Similar to our findings, studies by Anny et al.[178] in HaCaT 
cells (immortalized keratinocyte cells)demonstrate that individual knock down of Smad3, 
led to decreased p21 levels and coincident with enhanced phosphorylation of pRb, were 
independent of Smad2 and Smad4 knockdown. Furthermore, depletion of Smad3 
resulted in increased levels of plasminogen activator inhibitor (PAI-1) as was observed 
previously in Smad7 overexpressing COLO-357 cells [121]. In another study, 
keratinocytes from Smad3 knockout mice, transduced with V-ras, resulted in a by-pass 
of senescence via downregulation of p15 and c-Myc, which culminated in malignancy 
[179]. Furthermore, this signaling pathway was shown to be Smad3 specific and could 
not be rescued by overexpression of Smad2 or Smad4. Studies comparing knockdown 
of Smad3 and Smad2 independently in PANC-1 cell (PDAC cell) indicated that depletion 
of Smad3, but not of Smad2 resulted in decreased cell growth inhibition by TGF-β [180]. 
Together these earlier observations and ours indicate that Smad3 is indispensable for 
regulation of p21 levels in hPCCs and TGF-β1 mediated cell growth inhibition. 
In pancreatic cancer cells and tissues inactivation of Smad3 by Smad7OE resulted in 
decreased expression of CDKN1A, increased p-pRb and abrogation of TGF-β mediated 
cell growth inhibition. Levels of p21 are also lowered by Smad7 OE in KS7C mice. 
110 
Decreased p21 levels have been shown to correlate with lower survival in PDAC 
patients [39, 181].  The PDAC mouse model harboring a heterozygous deletion of p21 
and a Kras mutation exhibit increased PanIN lesions compared to the KC mice and 
havea mean survival of 75 days [181]. Together these earlier observations and our 
results suggest that downregulation of p21 in PDAC plays a role in disease progression 
and one of the mechanisms that leads to downregulation of p21 in GEMMs and patients 
may be through Smad7 OE and subsequent inactivation of p-Smad3. 
In hPCCs, the CDKN1A and p21 levels were regulated differently at the transcript level 
versus the protein levels. Smad7 overexpression was associated with low basal 
CDKN1A levels and an attenuated increase in the presence of TGF-β1. At the protein 
level, p21 levels were enhanced by TGF-β1 to the same extent in both, the Smad7 
overexpressing cells and control. This finding suggests that there might be other factors 
that may play a role in stabilization of CDKN1AmRNA transcripts when cells are treated 
with TGF-β1, thus resulting in upregulated p21 protein levels by TGF-β1 even in the 
presence of Smad7 OE.In the KS7C transgenic mouse model however, there was loss 
of p21. Taken together these results indicate that the regulation of p21 protein levels 
may involve a different mechanism in hPCCs versus in the tissue. It would be important 
to see if p21 is regulated at transcript levels in KS7C tissues to confirm the effects of 
Smad7 seen mechanistically in hPCCs. 
In contrast to p21 expression with Smad7 OE, AGR2 expression is markedly increased 
in our GSEA analysis and has been shown to play a role in PDAC aggressiveness [163, 
166, 167, 169, 182]. KC mice with AGR2 deletion show delayed progression of PanIN 
[163] indicating its importance in PDAC progression. Our results showed that AGR2 
mRNA and protein increased with Smad7 OE and knockdown of Smad3 in hPCCs. This 
increase in AGR2 expression was also observed in KS7C and KtetS7C mice as 
compared to KC mice, indicating that another mechanism by which Smad7 OE results in 
PDAC progression might be via upregulation of AGR2. Previously we have shown that 
AGR2 levels are suppressed by Smad4 [169]. ChIP results demonstrated that Smad3 
and Smad4 bind to the AGR2 promoter in hPCC and that Smad7 OE inhibits their 
binding to the AGR2 promoter. These findings imply that together Smad3 and Smad4 
bind to the AGR2 promoter and repress its transcription. When overexpressed, Smad7 
inhibits the binding of Smad3 and Smad4 to the AGR2 promoter, resulting in 
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upregulation of AGR2 mRNA and protein (Figure 4.1). Upregulation of AGR2 in mice 
that overexpress Smad7 may be explained by the decrease in p-Smad3 levels. 
 
 
Figure 4.1 Schematic representation of TGF-β mediated AGR2 expression 
TGF-β1 suppresses AGR2 expression via Smad3 and Smad4. When Smad7 is overexpressed Smad3 
and Smad4 do not bind to the AGR2 promoter, resulting in its upregulation of AGR2 transcription.  
 
TGF-β1 decreased expression of AGR2 mRNA and protein levels in COLO-357, while 
Smad7 OE increased the levels of AGR2 mRNA and protein. When Smad7 
overexpressing COLO-357 cells were treated with TGF-β1, Smad7 attenuated the TGF-
β mediated decrease of AGR2 mRNA and protein. In IUSCC-PC1 cells, Smad7OE 
attenuated TGF-β1 mediated downregulation of AGR2, however the AGR2 protein in 
IUS7 under SF conditions and following treatment with TGF-β1 were similar. This 
indicates that other factors likely stabilize the AGR2 protein, thus resulting in blocking 
the TGF-β1 mediated downregulation of AGR2 when Smad7 is overexpressed in 
IUSCC-PC1 cell line.  
 
 
112 
4.5 Smad7 and pancreatitis 
Chronic Pancreatitis (CP) is an important risk factor for PDAC [41, 42, 44]. Previous 
studies have shown that TGF-β signaling is important for induction of inflammation 
(pancreatitis) by caerulein and the fibrosis associated with it [133-135, 137, 140]. 
Induction of acute pancreatitis in KC mice results in enhanced PDAC progression [112]. 
When KS7C mice were injected with caerulein, overexpression of Smad7 resulted in 
decreased fibrosis and attenuation of PDAC progression when compared with KC mice 
injected with caerulein. These results are in agreement with previous studies, where 
attenuation of TGF-β resulted in inhibition of caerulein-induced pancreatitis [135] and 
decreased fibrosis [137]. Studies by Jing He et al [138] and Xuan Li et al [139] using 
Smad7 overexpressing and Smad7 null transgenic mice demonstrated that in a model of 
chronic pancreatitis, Smad7 inhibits the TGF-β mediated inflammatory response and 
fibrosis, thus preventing damage to the pancreas. Oncogenic Kras plays an important 
role in prevention of tissue repair after damage caused by pancreatitis [111, 112, 183] 
(Figure 4.2). 
 
 
Figure 4.2 Smad7 inhibits tissue damage and fibrosis in chemical induction of pancreatitis 
Caerulein induces pancreatitis which results in upregulation of TGF-β followed by increased fibrosis. 
This effect is blocked by Smad7 OE. Induction of Inflammation in the presence of oncogenic Kras results 
in accelerated progression to PDAC. However, in the presence of high levels of Smad7, caerulein-
induced pancreatitis was associated with attenuated tissue remodeling and lowered deposition of 
collagen. 
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In KC mice, PanIN lesions are surrounded by activated stroma[112, 184]. The 
microenvironment for PDAC has a higher ratio of T regulator cells (Tregs) compared to T 
effector (Teff) cells, as well as a higher ratio of M2 to M1 macrophages[185]. High Treg 
ratios suppress the immune system and are associated with lower PDAC patient 
survival. Therefore we hypothesized that in the presence of Kras mutation, when mice 
pancreata are subjected to acute pancreatitis, there is infiltration and development of 
PanIN and stroma that results in an immune suppressive tumor environment. When 
Smad7 is overexpressed, it may modulate TGF-β mediated responses by inhibiting Treg 
formation, resulting in an inverted ratio for Treg and Teff, thus reducing the inflammatory 
response and fibrosis. To test this hypothesis in the future, the pancreata from KC and 
KS7C mice could be analyzed for infiltration of M1 and M2 macrophages and the Teff 
and Treg. This can be done using cell surface markers, such as CD4, CD8, and FoxP3 
for T cells and CD163, CD120 for macrophages [185, 186]. 
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5. Conclusion and future directions 
In conclusion, using mouse models we have now established that Smad7 OE in the 
presence of oncogenic Kras results in increased PDAC aggressiveness as 
demonstrated by increased number of PanIN lesions. TGF-β is overexpressed in 
PDAC[27], however its tumor suppressor activity is lost. The tumor promoting role of 
TGF-β has been well studied, and now we show that Smad7 overexpression in vivo 
blocks TGF-β-mediated cell cycle inhibition. Smad7 levels were increased in mice with 
dominant negativep53mutation and Kras mutation (KPC) (Figure 3.11). Mongersen, an 
oral SMAD7 antisense drug, has now finished phase II clinical trials for Crohn’s 
Disease[187]. Smad7 inhibits TGF-β mediated epithelial cell growth inhibition [121-123], 
thus it would be interesting to test this Mongersen in the well characterized KPC mouse 
model of PDAC and see if it has any effects treating the progression of tumors and 
metastatic disease observed in KPC mice.  
Smad7 exerts effects on p-Smad3, which acts as a switch for effects exerted by TGF-β 
downstream of Smad3. Lowered p-Smad3 levels result in upregulation of tumor 
promoting genes, such as like AGR2 and suppression of tumor suppressors like 
CDKN1A (Figure 5.1), however the total Smad3 levels do not change. The precise 
mechanism by which Smad7 lowers p-Smad3 levels has not been uncovered in this 
thesis work. There are two likely possibilities by which Smad7 could lower p-Smad3 
levels. Firstly, by preventing Smad3 phosphorylation by TGβ receptors and secondly by 
rapidly dephosphorylating p-Smad3, thus preventing its binding with Smad4 and 
translocation of the complex to the nucleus (Figure 5.2). One of the ways to test this 
hypothesis would be to perform cell fractionation experiments and determine the 
distribution of Smad3 in the nucleus and cytoplasm and how the distribution changes 
with overexpression of Smad7 and/or TGFβ1.  
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Figure 5.1 Schematic representation summarizing the effects of overexpression of Smad7 and 
enhanced PDAC progression 
Smad7 OE in the presence of oncogenic Kras does not block TGF-β mediated p-Smad2 (depicted by 
green arrows); however Smad7 OE attenuates p-Smad3 levels, such that it results in downregulation of 
p21 levels, resulting in accumulation of p-pRb (inactive pRb). The signaling path results in 
transactivation of E2F, increasing transcription of cyclins and increased cell proliferation. 
Simultaneously, decreased p-Smad3 causes attenuation of Smad3 mediated repression of AGR2, thus 
resulting in increased AGR2 levels. Red color indicates pro-tumorigenic effects. Together, these actions 
lead to enhanced PDAC progression. 
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Figure 5.2 Schematic representation of possible ways that Smad7 may lower p-Smad3 levels 
Smad7 lowers p-Smad3 levels by either inhibiting phosphorylation of Smad3 by TβRI or by 
dephosphorylating Smad3 preventing it from binding to Smad4 and translocating to the nucleus.  
 
It would be helpful to confirm that Smad7 mediates its signaling effects via Smad3 and 
not by Smad2. To test this idea, genetic manipulation of Smad2 via CRISPR or 
knockdown could be performed in hPCCs and the effects on expression of AGR2 and 
p21 mRNA and protein analyzed. If the effects are predominantly through Smad3 and 
not Smad2, then we would expect to observe no changes in levels of p21 or AGR2 with 
loss of Smad2 in presence of TGF-β. Lastly, high levels of p-Smad2 levels in hPDAC 
samples have been shown previously as an indicator for activated TGF-β signaling in 
cancer cells [39]. Thus, it would be important to measure p-Smad3 levels in hPDAC 
tissues and determine if there is a negative co-relation with elevated Smad7 levels. The 
effects of overexpressed Smad7 on preferential inhibition of p-Smad3, suggest a switch 
between the oncogenic and tumor suppressor roles of TGF-β.  
Overall, our studies with the transgenic mouse model have provided a deeper 
understanding into the effects of Smad7 on the TGF-β canonical signaling pathway, 
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bringing us closer to target Smad7 as therapeutic for PDAC and promote anti-
tumorigenic effects of TGF-β.  
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6. Supplementary information 
6.1 KrasG12D recombination in mouse tissues 
Some of the mice which genotyped positive for KrasG12D and Pdx1-Cre or KrasG12D, 
SMAD7 and Pdx1-Credisplayed normal histology with intact architecture of the 
pancreas. To understand the reasons why this may have happened, the KrasG12D 
recombination was examined in these mice. The mice with pathology were used as 
control. To confirm recombination of KrasG12D, primers and protocol were used according 
to Jackson lab protocol for KrasG12D Conditional PCR (Figure 6.1A). T2407, T2491 and 
T2226 were 12 month KS7C mice which showed no pathology but were positive for all 
three genes by genotyping. NT, T2146, T2205, T2284, T2331 mice were positive for all 
3 transgenes and showed pathology. RNA was isolated from pancreas of these mice 
and a known positive control (mice with KrasG12D and Pdx1-Cre transgene) was used. 
The 500bp product confirmed presence of LSL-KrasG12Dtransgene. The 622 bp product 
indicated the presence of wildtype (WT) Kras allele. The 650bp product confirmed the 
presence of recombined LSL-KrasG12Dtransgene. The mice T2409 and T2491 showed 
presence of the LSL-KrasG12Dtransgene however it did not undergo recombination. The 
LSL-KrasG12Dtransgene in T2226 underwent recombination, but showed very little 
pathology (Figure 6.1B).  
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Figure 6.1 PCR detected recombination of LSL- KrasG12D transgene 
(A) PCR amplification of LSL- KrasG12D transgene yields a 500bp product with primers #3 and 2. The 
recombined LSL- KrasG12D transgene yields a 650bp product and the WT Kras a 622bp with primers #1 and 
2. (B) PCR amplification of cDNA from mice pancreas showed that the positive control had presence of all 
three products indicating successful recombination of LSL- KrasG12D transgene, which was absent in the 
negative control as expected. Two of the three mice (T2226, T2407 and T2491) showed absence of 
recombined LSL- KrasG12D transgene. 
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We next analyzed the levels of SMAD7 in these mice and confirmed that T2409, T2491 
and T2226 had no overexpression of SMAD7. This could explain the less diseased 
pathology of the mouse. The Kras G12D Conditional PCR was carried out for all mice 
without pathology and these were then excluded from the analysis (Figure 6.2).  
 
 
Figure 6.2 Expression of SMAD7 in KS7C mice with negative and positive pathology 
SMAD7 mRNA levels measured by q-PCR were significantly lower in KS7C mice which were negative 
for pathology (green) when compared to KS7C that exhibited pathology (red)  in the pancreas. 
 
6.2 Rb1 recombination in cell line from KR+/-S7C mice and pRb expression. 
To confirm that the Rb1 single allele in the KR+/-S7C mice was intact and functioned as 
expected we first did Rb1 recombination analysis by PCR. The Rb1 allele deletion 
involves deletion of Exon 19 in the Rb1 gene which results in loss of pRb. One set of 
PCR primers flank the regions around Exon 19. Therefore when the exon is intact a 
larger product is formed, as seen in the KC and KS7C cell line, however when there is a 
deletion the product is smaller in size as seen by the smaller product in KR+/-C and KR+/-
S7C cell lines. Where upper band indicates presence of intact exon 19 and lower one 
represents deleted exon 19. The other set of primers are designed to amplify the region 
flanking the lox p sites around exon 19. In a mouse with homozygous deletion, no 
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product will be formed, and in a mouse with heterozygous deletion there will be a 235bp 
product formed as seen in Figure 6.3. Thus by PCR method the KR+/-S7C cell line were 
confirmed to be heterozygous for Rb1 without loss of heterozygosity.  
 
 
Figure 6.3 PCR detection for Rb1 deletion 
PCR amplification of genomic DNA from cell lines for genotyping of Rb1. (B) PCR amplification of cDNA 
from mice pancreas showed that the positive control for Rb1 deletion (KR-/-C) had presence of the 
260bp product indicating loss of exon 19 and absence of 283bp product indicated lack of intact exon 
19.  The KC and KS7C cell lines were positive only for wild type exon 19, while the KRS7C cell line shows 
presence of both bands, confirming heterozygosity for Rb1 transgene.  
 
Next, to confirm expression of pRb in these cell lines the protein from the cells was 
isolated, separated by gel electrophoresis and blotted with anti-pRb antibody. The Figure 
6.4 shows expression of pRb in the KC, KS7C, KR+/-C and KR+/-S7C cell lines, 
confirming expression of pRb in all the cell lines.  
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Figure 6.4 pRb expression in tumor derived murine cell lines 
Western blot with anti-pRb indicated presence of pRb in KC and KS7C cell lines. In KR+/-C and KR+/-
S7C cell lines the pRb levels are present, however reduced when compared to KC and KS7C cell 
lines. β-actin was used as loading control. Shown are representative blots from 3 independent 
experiments 
 
6.3 Immunoprecipitation (IP) of Smad7 and PP-1 
We hypothesize that Smad7 binds with PP-1, resulting in decreased p-Smad3 levels or 
increased p-pRb. To test this hypothesis, we carried out an IP with c-Myc tag as 
described earlier in chapter 2 and probed for PP-1 catalytic subunit. Figure 6.5A shows 
that c-Myc IP was successful as the IP with Smad7 overexpressing COLO-357 cells 
shows distinct band with Smad7. Blotting the c-Myc-IP with PP-1 (Figure 6.5B) showed 
that Smad7 and PP-1 form a complex. The soup after antigen- antibody was also run, 
which shows that PP-1 remains unbound in the lysate in Sham cells, however in Smad7 
overexpressing cells, most of the PP-1 is bound to Smad7 and is removed from soup. 
This experiment was performed once with Tet-Smad7 COLO-357 and once with COLO-
357 constitutively expressing Smad7. The amount of pull down in the tet-Smad7 v/s the 
constitutive Smad7 cells was different, owing to the differences in amounts of Smad7 
levels overexpressed in the two cell lines.  
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Figure 6.5 Immunoprecipitation of Smad7 and PP-1 
(A) Western blot with anti-c-Myc and anti-Smad7 confirm successful pull down of Smad7 in CSmad7 
cells when compared to Csham cells. (B) Western blot with anti-PP1 after IP with anti-c-Myc antibody 
showed that PP-1 bound to Smad7 in CSmad7 cells. The soup after antibody-antigen pull down during 
IP shows removal of PP-1 from soup, thus confirming that Smad7 binds with PP-1. 
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Supplementary tables 
Table 6.1 Expression of TGF-β mediated Smad3 dependent genes. 
GENE_SYMBOL logFC adj.P.Val 
KANK4 -5.54017602666667 2.84849087890363e-14 
COL1A1 -5.32464619466667 5.04719187373406e-14 
C20orf160 -5.160246489 6.74271845993217e-13 
INHBB 5.121086058 6.79969557151773e-13 
MARCH4 -5.114444256 9.14565576711578e-13 
COL22A1 -4.980302075 9.14565576711578e-13 
RGMA -4.878878008 1.87203254522402e-12 
LEFTY2 -4.65730220166667 2.29386822029635e-12 
SLN -4.622404638 2.29386822029635e-12 
MAF -4.518065675 2.6009757215957e-12 
AGR2 4.51724214666667 4.55585303438102e-12 
KIF26B -4.512902306 5.09178504704738e-12 
BCAS1 4.50237311066667 5.67978803547205e-12 
TNFAIP6 -4.39067652066667 6.1101373922509e-12 
GSTA5 4.24202532266667 6.5561793754626e-12 
CRLF1 -4.22358469133333 7.27660710424072e-12 
C15orf48 -4.19772507133333 8.35085946379151e-12 
SERPINE1 -4.17044398166667 9.85447674523448e-12 
ZBED2 -4.100225975 9.85447674523448e-12 
TF 4.097648297 9.85447674523448e-12 
SPON2 4.092811869 1.0108347762857e-11 
DOCK2 -4.011560016 1.08210995860228e-11 
RET -3.986156827 1.15102574908618e-11 
PACSIN1 3.96808003133333 1.37500591525221e-11 
SLC26A9 3.96409701533333 1.37500591525221e-11 
DACT1 -3.961207129 1.37500591525221e-11 
MFAP4 -3.86278868566667 1.38575173564305e-11 
OSTBETA 3.85782712966667 1.38575173564305e-11 
FRMD6 -3.834923246 1.48703296969347e-11 
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RASGRP1 -3.77935782033333 1.54534268551438e-11 
LOX -3.764458134 1.54534268551438e-11 
LPAR5 -3.752690725 1.54534268551438e-11 
RNF43 3.73569102733333 1.55738735339639e-11 
RHOV 3.73444811266667 1.96478685590584e-11 
KCNJ15 -3.654122303 2.25900563163813e-11 
TSPAN2 -3.64085642766667 2.32450694487283e-11 
PVRL4 -3.62812431633333 2.39369645196538e-11 
PIK3AP1 -3.625712684 3.39734682486697e-11 
IGFBP5 -3.61955629733333 3.39734682486697e-11 
TMEM88 -3.61029387366667 3.65418115448111e-11 
MMP2 -3.57630364866667 3.97941312680258e-11 
CGB -3.55660603533333 4.00328054457391e-11 
ACOX2 3.540256309 4.18651844984236e-11 
PPP1R14C -3.509664476 4.18651844984236e-11 
MMP10 -3.503883926 4.57221449197131e-11 
CACNA1I -3.49842832833333 4.67058733014329e-11 
FGA 3.49056601266667 4.67058733014329e-11 
CP 3.473055741 5.7276217485458e-11 
GPR68 -3.47182135566667 5.7276217485458e-11 
ADAM19 -3.38905993 5.7276217485458e-11 
ZNF365 -3.38550174366667 5.7276217485458e-11 
COL4A1 -3.37682253433333 5.90260227372096e-11 
RABGAP1 -3.33262988133333 6.25856361726711e-11 
CYP4F3 3.32903214733333 6.34833514160545e-11 
PDGFRA -3.32548621 6.46892531929595e-11 
FGA 3.319606301 6.46892531929595e-11 
MGAM 3.319155001 6.46892531929595e-11 
PLEK2 -3.30346004033333 6.46892531929595e-11 
SPDEF 3.286049889 6.49774223855637e-11 
CDH22 -3.28348109333333 6.49774223855637e-11 
ANXA13 3.28281844166667 6.49774223855637e-11 
TIMP3 -3.27389385666667 7.01577423281714e-11 
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R3HDML -3.26170046166667 7.24397423681478e-11 
PLXNA4 -3.25648175733333 7.39871165375772e-11 
CCKBR 3.24464545233333 7.39871165375772e-11 
OCA2 -3.24218035533333 8.98816660795501e-11 
HOXD10 -3.23613188066667 8.98816660795501e-11 
GPX2 3.23416095266667 9.00302723120275e-11 
MUC13 3.22815786433333 9.00302723120275e-11 
DDC 3.22488391166667 9.02862112653262e-11 
WNT5B -3.21112774333333 9.27235274006547e-11 
FAM176A -3.20008471466667 9.27235274006547e-11 
MAF -3.17050612066667 9.27235274006547e-11 
CEACAM6 3.12224817266667 9.69189069507968e-11 
GPR115 -3.11744449233333 9.69189069507968e-11 
RAB37 3.10318040866667 9.95278360393052e-11 
CEACAM6 3.09271240066667 9.95278360393052e-11 
CPN1 3.08449553166667 1.03328929837096e-10 
TAGLN -3.08311384333333 1.05754762372201e-10 
EHF 3.08263033233333 1.07668918967227e-10 
PLA2G12B 3.08201110233333 1.09161305486453e-10 
DOK7 3.06362447433333 1.11497244788063e-10 
ESAM -3.06022688266667 1.11497244788063e-10 
HNF4A -3.05383223133333 1.19425139171075e-10 
SLC2A12 -3.04513697166667 1.20038256157082e-10 
DDIT4L 3.04132713733333 1.20038256157082e-10 
MUC5AC 3.036409741 1.22699269164007e-10 
C1orf61 3.033280365 1.22952399750947e-10 
MEG3 -3.01421503633333 1.24221289510468e-10 
LEFTY1 -2.99423803666667 1.35580405523954e-10 
XYLT1 -2.98553106066667 1.37378202010544e-10 
FGFBP1 2.98401749066667 1.51733645571491e-10 
DIO3OS 2.98180119366667 1.51733645571491e-10 
SPARC -2.980808223 1.5221527501096e-10 
HAPLN3 -2.98003480566667 1.52642731975161e-10 
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SRD5A2 -2.967626532 1.57142844302332e-10 
PITPNC1 -2.96087354566667 1.57466318335744e-10 
SPOCK1 -2.958050313 1.60240232275399e-10 
TSPAN7 2.94515172 1.70308113450606e-10 
ITGB6 -2.936949738 1.7508092223996e-10 
ARRB1 2.93515087733333 1.7508092223996e-10 
GPR115 -2.928546625 1.76671793605682e-10 
PEAR1 -2.91052854333333 1.76671793605682e-10 
GNG4 -2.90922872966667 1.77028927798015e-10 
CXCR5 -2.90590559966667 1.8484060847793e-10 
LHX4 2.90095814266667 1.90548924223183e-10 
HSD17B6 -2.89935440333333 1.91583205100115e-10 
NECAB2 2.89539171633333 1.91883597450794e-10 
GDA 2.885120996 1.94534659441361e-10 
 -2.88271998833333 1.96204109064969e-10 
FRMD6 -2.87794971633333 1.98542683060521e-10 
TAGLN -2.87574675366667 2.03895566832801e-10 
GDF15 2.864557706 2.03895566832801e-10 
BEAN1 -2.86237500933333 2.03895566832801e-10 
TAS2R1 -2.84620907 2.03895566832801e-10 
GRID1 -2.84450980766667 2.07265112074973e-10 
VSTM4 -2.812245632 2.39557102833663e-10 
ABLIM3 -2.81109145966667 2.4579045713269e-10 
ITGA11 -2.809999498 2.49073867766127e-10 
KIF5A -2.808656112 2.61900870779965e-10 
LOC100422737 2.80541499733333 2.92006189390244e-10 
SLC6A15 -2.80398127133333 3.04083385343789e-10 
FGFR1 -2.803937723 3.060041055099e-10 
PLA2G10 -2.78928590433333 3.060041055099e-10 
FAM49A -2.78786549433333 3.07689026930101e-10 
UNC13A 2.78196384866667 3.17390459803398e-10 
CILP -2.78182885666667 3.41281767981122e-10 
FLRT3 2.77912489866667 3.53576672802847e-10 
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KCNJ2 2.77591658733333 3.67090861688633e-10 
COL5A1 -2.77439309333333 3.67090861688633e-10 
PCDHAC2 2.766785395 3.67090861688633e-10 
LAMC2 -2.75384008266667 3.91823287340614e-10 
RNF144B 2.747229973 3.91823287340614e-10 
SLPI 2.743233727 3.98331608120242e-10 
APOH 2.74160214966667 4.00542848211979e-10 
DUSP26 -2.74086166166667 4.10136331068445e-10 
ANKDD1A -2.73643878033333 4.10707097053326e-10 
C4BPB -2.715511658 4.1167197878266e-10 
CYP4F12 2.71427385066667 4.15752577542488e-10 
GREM1 -2.71254406066667 4.1617991229746e-10 
STK32A -2.712324188 4.23065618643514e-10 
 2.71201713966667 4.44305004819245e-10 
RUNX1 -2.694185281 4.44305004819245e-10 
INPP4B -2.69265385133333 4.50067982499643e-10 
IL11 -2.682447109 4.65876158500592e-10 
CXCR7 -2.68202600366667 4.84680270139213e-10 
FGB 2.67462698633333 5.02818988307645e-10 
PRRX2 -2.662409606 5.27349517094414e-10 
SPRY1 2.66045673733333 5.27349517094414e-10 
PER2 2.658663345 5.33927066200457e-10 
FGG 2.65805852466667 5.47787351876291e-10 
CSF2RA 2.65603348233333 5.6950766321074e-10 
CHRNA9 -2.65436665633333 5.72149449240583e-10 
RDH10 2.64646641166667 5.76448317428785e-10 
TNFRSF19 -2.64525239633333 5.80630686540941e-10 
H19 2.644763341 5.80630686540941e-10 
C18orf1 -2.63401407766667 5.80630686540941e-10 
PDGFB -2.633731095 5.80630686540941e-10 
ERBB3 2.627118391 5.80630686540941e-10 
B3GALT5 2.622160357 5.835999112642e-10 
FA2H 2.62198626766667 5.835999112642e-10 
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SLC6A15 -2.617161204 6.06952567808473e-10 
ST6GALNAC1 2.60886208733333 6.29673536290518e-10 
OSGIN1 2.60211627133333 6.41298162511837e-10 
WSCD1 2.59980512633333 6.47461593240722e-10 
C2orf82 -2.59940285666667 6.47461593240722e-10 
RASSF5 2.597926025 6.47461593240722e-10 
VSTM4 -2.592232725 6.72301118157131e-10 
 -2.58801225133333 6.75133182307934e-10 
VDR -2.58174733166667 6.75133182307934e-10 
C12orf39 2.576985283 7.11153658860745e-10 
METTL7A 2.575040609 7.29701832305406e-10 
C4orf26 -2.56708607466667 7.3534972971618e-10 
TMC8 2.556858214 7.99979856835872e-10 
SLC6A15 -2.55486451566667 8.30351620445139e-10 
RNF182 -2.55285095533333 8.56587291700358e-10 
C11orf41 -2.55035290733333 8.57100027597445e-10 
FGA 2.53976565033333 8.78024346697206e-10 
EREG 2.53520150133333 8.98498995305366e-10 
MEGF6 -2.52527755866667 8.98498995305366e-10 
IFITM1 2.52521053466667 8.98498995305366e-10 
CXCL5 2.523821575 9.1116463944049e-10 
HEATR7B1 2.51997174033333 9.1116463944049e-10 
PODXL -2.50928030733333 9.25148517229183e-10 
LOC728392 -2.501001619 9.35064984984945e-10 
CDH19 -2.49870996733333 9.58853346963158e-10 
MZB1 2.49718849833333 9.59122769238512e-10 
CXCL3 2.489638381 9.63473244197662e-10 
AREG 2.48765763333333 9.63473244197662e-10 
CYP4F11 2.481679489 9.87254780111171e-10 
TRIM2 -2.47522834666667 1.00634246088075e-09 
C12orf39 2.47517887133333 1.02347996943516e-09 
 -2.46869957033333 1.03305577189801e-09 
MDGA1 -2.468556277 1.05502393461600e-09 
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LOC554207 -2.46349204933333 1.05849446365034e-09 
PSG8 -2.46130091466667 1.05849446365034e-09 
CUX2 -2.461151047 1.09962174057891e-09 
COL4A2 -2.458863404 1.11858806077993e-09 
S1PR5 -2.456754384 1.15403159375645e-09 
SLPI 2.455525307 1.18693354205281e-09 
SDK2 2.45122640566667 1.25685420839799e-09 
FAM43A -2.43990188466667 1.25685420839799e-09 
MIA2 2.436696881 1.26766890351534e-09 
PCDHB6 -2.42670018333333 1.29038605026081e-09 
RBMS3 -2.42607446266667 1.31098575901071e-09 
CSDC2 -2.424594503 1.33317185228165e-09 
MALL 2.41698248633333 1.33540765926928e-09 
SLC23A1 2.40760684833333 1.34842471502303e-09 
CDH16 2.40459485966667 1.34842471502303e-09 
TPM1 -2.40398745 1.34842471502303e-09 
 -2.40318250433333 1.42572043625414e-09 
SORCS2 -2.401847606 1.44808456328894e-09 
SLC6A13 -2.40097560266667 1.50946882193322e-09 
ANGPTL4 -2.398306043 1.55681239677897e-09 
COL20A1 -2.396326441 1.58958229583319e-09 
CYP4F11 2.39469257466667 1.58958229583319e-09 
 -2.38744504966667 1.591342259105e-09 
AQP3 2.382515593 1.60101821948855e-09 
KITLG 2.37836208066667 1.60101821948855e-09 
AQP3 2.37757241666667 1.60308145570487e-09 
ABLIM3 -2.37177302733333 1.60308145570487e-09 
JUNB -2.36980492866667 1.62164980206999e-09 
KRTAP3-3 -2.36843836666667 1.69091228683358e-09 
AKR1C4 2.36366565 1.71038050284611e-09 
ST3GAL5 -2.35326817466667 1.74930161263952e-09 
LZTS1 -2.35048050866667 1.78276946389002e-09 
LOC284344 -2.34806778266667 1.80930182846115e-09 
131 
KLHDC8A -2.34460612933333 1.82274532463624e-09 
 -2.343064724 1.82274532463624e-09 
CDH4 -2.33877697366667 1.90134199220749e-09 
NTF4 -2.33606454166667 1.90134199220749e-09 
PLEKHH2 2.33254693533333 1.90134199220749e-09 
LCE3D -2.33223902333333 1.9240750509088e-09 
SERPINE2 -2.32504849133333 1.9240750509088e-09 
CX3CL1 2.321417867 1.9240750509088e-09 
CYP4F8 2.320823902 1.99792851321477e-09 
ALDH3A1 2.31988413066667 2.00523583933037e-09 
CTGF -2.31786527866667 2.01032968146957e-09 
SDPR 2.315158227 2.01032968146957e-09 
SCEL 2.31285539666667 2.03427787595626e-09 
 -2.30862598466667 2.05606397189318e-09 
FOSB -2.30822992166667 2.06807879837604e-09 
PDGFRB -2.30630004166667 2.06896280174073e-09 
CLDN4 -2.29499024833333 2.13717526685588e-09 
C11orf41 -2.29357576 2.19691242479674e-09 
CCBE1 -2.28650780233333 2.24537602358374e-09 
BAIAP2L2 2.278437052 2.30601901743816e-09 
ST3GAL5 -2.27050396033333 2.34343625000227e-09 
TIMP2 -2.27023562666667 2.35595149994655e-09 
PHLDB1 -2.26940242066667 2.35621050275426e-09 
RGS9 -2.26831059233333 2.35621050275426e-09 
FGF1 -2.26829292466667 2.37524793719708e-09 
C11orf86 -2.26443459866667 2.44283746306066e-09 
DMBX1 -2.26393490233333 2.56829918094462e-09 
 -2.26304683266667 2.58469187430566e-09 
KIAA1644 -2.26095305733333 2.58469187430566e-09 
ALOX5AP -2.25662669233333 2.58744692746726e-09 
STK32B 2.25629003066667 2.58744692746726e-09 
BAIAP2L2 2.25620095133333 2.59799928421846e-09 
ABCA9 2.25521701333333 2.72830993508254e-09 
132 
LOC100268168 -2.246207512 2.72830993508254e-09 
GPR87 -2.245890878 2.72830993508254e-09 
PDE11A -2.24253727733333 2.74241211143386e-09 
CFI 2.2422599 2.78552719224958e-09 
MEG3 -2.23479968166667 2.80812027951822e-09 
SLC6A13 -2.23221732033333 2.84084404055203e-09 
ASGR1 2.23179197966667 2.84084404055203e-09 
AGT 2.22802793133333 2.84084404055203e-09 
KCTD11 -2.22741181933333 2.89115136319385e-09 
ISG20 2.227102416 3.01037353146564e-09 
ZNF608 -2.22331367166667 3.0289982683888e-09 
ULBP2 -2.221129233 3.05035633291483e-09 
GPCPD1 2.21829664266667 3.07247396587874e-09 
DCBLD1 -2.21523510666667 3.07247396587874e-09 
DOCK2 -2.21265734766667 3.10768639910433e-09 
TM4SF5 2.21178327033333 3.12702680775706e-09 
CCDC80 -2.207672054 3.24314507942262e-09 
FBLN2 -2.204188039 3.24314507942262e-09 
P4HA3 -2.202860584 3.29527119141267e-09 
DKFZP434L187 -2.200081073 3.37154059089304e-09 
PPP1R3B -2.18274195 3.44870210376699e-09 
STON1 -2.17826349533333 3.56411116228045e-09 
FOXP1 -2.17381210466667 3.68925732908026e-09 
PPFIBP2 2.173715454 3.73175274978242e-09 
HOXD11 -2.17047847066667 3.74153150782577e-09 
TRIM9 -2.16837250433333 3.8172992061942e-09 
CATSPER1 -2.16184338733333 3.83152147701729e-09 
SPHK1 -2.161304003 3.83152147701729e-09 
COL8A2 -2.15743879866667 3.84211512698188e-09 
FAM84B 2.156639381 3.84211512698188e-09 
TIAM2 -2.156231962 3.90817064947093e-09 
DLC1 -2.150574626 3.97740815527792e-09 
AMBP 2.15056776366667 3.98534743515426e-09 
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IRF6 -2.15024411833333 3.98729433935492e-09 
S1PR5 -2.14932332633333 3.98729433935492e-09 
LOXL4 -2.14728651133333 3.98729433935492e-09 
ARHGEF4 -2.139265882 3.98729433935492e-09 
KLHL24 -2.13754898 4.00028390184216e-09 
PPEF1 2.13393409833333 4.11224201349874e-09 
SYT13 -2.133300233 4.17557015778202e-09 
LINC00442 -2.129674873 4.17557015778202e-09 
NCF2 -2.12860589866667 4.17557015778202e-09 
FAT2 -2.128406925 4.21196926875202e-09 
 -2.128321013 4.25288410306147e-09 
TSPAN12 -2.12737704366667 4.26313744886623e-09 
PER2 2.12672696166667 4.27368121145218e-09 
TMEM47 -2.12591439333333 4.33476301599907e-09 
KDM6B -2.12298744066667 4.33476301599907e-09 
VAV3 2.12214982733333 4.48571952865436e-09 
BMP2 -2.12193545833333 4.50501613328235e-09 
DOCK4 -2.12042111833333 4.56668253279705e-09 
SLC12A2 2.12019589233333 4.58016495635282e-09 
FGF2 -2.11410800833333 4.60385346731381e-09 
CSF1R -2.11262628766667 4.84606548887957e-09 
ZNF185 -2.107670664 4.84606548887957e-09 
ULBP2 -2.107080287 4.878730256918e-09 
GALNT4 2.10294321966667 4.878730256918e-09 
TPM1 -2.10237644566667 4.93966897959591e-09 
CYR61 -2.098457026 5.06634990486752e-09 
DOCK4 -2.09834334566667 5.18876085183078e-09 
CDH19 -2.09560512133333 5.30358803360427e-09 
PBX2 -2.09311102466667 5.69743746118491e-09 
TRIM2 -2.09255436633333 5.81875648862345e-09 
PCDH9 -2.09255199133333 6.02716719340535e-09 
NAP1L3 -2.08298091266667 6.02716719340535e-09 
CLIC3 -2.08087571366667 6.04041609141977e-09 
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LOC284454 -2.07502423466667 6.04041609141977e-09 
SUCNR1 -2.073364187 6.04054201361063e-09 
CRX 2.06999574366667 6.055667858568e-09 
ANGPT1 2.069200057 6.14780232267227e-09 
CSF2RA 2.06669525833333 6.14780232267227e-09 
 -2.065058873 6.22818685774777e-09 
SH3PXD2A -2.06397378366667 6.36302087416479e-09 
CD38 2.063803941 6.44901494288714e-09 
EPHB2 -2.061862565 6.54845730829299e-09 
IGFBP7 -2.061457431 6.59059397645952e-09 
SOCS1 -2.06082129 6.6129531627351e-09 
 -2.05798640833333 6.61650093255221e-09 
ANKS4B 2.05771571233333 6.61650093255221e-09 
MN1 -2.05577793266667 6.66370370022724e-09 
PLCH1 2.0519783 6.72882277583433e-09 
GJB1 2.046861021 6.72882277583433e-09 
NR0B1 2.04576242066667 6.7536118665952e-09 
PGM2L1 -2.04526598266667 6.98242315505514e-09 
FAM125B -2.03545678533333 7.03683646073114e-09 
NAV2 -2.03334443 7.53458491636884e-09 
NUDT10 -2.03169806366667 7.54711237566917e-09 
LTBP2 -2.030301572 7.60757900396455e-09 
RSU1 -2.027196525 7.74913537072674e-09 
LYPD5 -2.02655324 8.02827646401629e-09 
EEPD1 -2.02589919733333 8.02827646401629e-09 
AKAP2 -2.02482754066667 8.03564051892139e-09 
NOG -2.02332642666667 8.14890551414452e-09 
ARL4D -2.02242278433333 8.20911189091644e-09 
DLC1 -2.02120318266667 8.30353493416263e-09 
IRS2 2.018514738 8.30353493416263e-09 
 -2.01390258466667 8.30353493416263e-09 
FOXP1 -2.010898482 8.51899592347641e-09 
PIK3IP1 -2.00985571233333 8.51899592347641e-09 
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SOX2 2.00946746333333 8.51899592347641e-09 
C5 2.00414319633333 8.51978047419849e-09 
PMEPA1 -2.00042088833333 8.63331357626569e-09 
GADD45B -1.99728443766667 8.63718494856543e-09 
P2RY2 -1.99635450466667 8.65014587498943e-09 
FNDC5 -1.99129455566667 8.96337797157933e-09 
DCBLD1 -1.98536186933333 8.98176288430392e-09 
PHEX 1.985137678 9.19174425190031e-09 
LPPR1 1.98410087 9.48195000565818e-09 
DBC1 -1.98390415333333 9.48195000565818e-09 
METRNL -1.98323634033333 9.55285380026107e-09 
CRCT1 -1.983079314 9.68606319409297e-09 
HRASLS2 1.981347329 9.75641927265746e-09 
JUN -1.9808297 9.75641927265746e-09 
COL4A1 -1.98011510033333 9.86032891668978e-09 
TMEM154 -1.979779236 9.86032891668978e-09 
COL4A4 -1.97780010566667 9.86032891668978e-09 
PRDM1 -1.97745555733333 9.93669114332822e-09 
PLCD4 1.97668795166667 1.00254270101291e-08 
FGF1 -1.976273319 1.00489321791097e-08 
TANC2 -1.97610125733333 1.00489321791097e-08 
TBXAS1 1.97515627033333 1.01587712715293e-08 
ECM1 -1.97493128 1.02719090968064e-08 
ARL4D -1.97149577833333 1.03324401211756e-08 
PARM1 1.970816724 1.04291674807022e-08 
SERPINF1 -1.96686500066667 1.05267031281873e-08 
SULF2 -1.96531475 1.06208633626866e-08 
DLX2 -1.965185965 1.06208633626866e-08 
TMEM74 -1.960919259 1.08282459806788e-08 
CYP3A5 1.95856846933333 1.09443416810476e-08 
C11orf82 1.95520000466667 1.12369189690582e-08 
DNER -1.95278671733333 1.12369189690582e-08 
BMP4 1.950526324 1.14233712052579e-08 
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GRHL3 1.94918702233333 1.15988441578905e-08 
CYP3A7 1.948926135 1.17170380702998e-08 
ARHGAP31 -1.945706275 1.177394196216e-08 
MDGA1 -1.94518776733333 1.18112417890312e-08 
 1.94179176833333 1.18112417890312e-08 
GNG4 -1.94145481366667 1.19512015271892e-08 
 -1.94134133933333 1.2039350280311e-08 
ART5 -1.941246469 1.23762956410169e-08 
PARM1 1.94004425 1.24131233244433e-08 
CYP2S1 1.93970422533333 1.24188125117281e-08 
CFH 1.939460217 1.24696411575066e-08 
REPS2 -1.93825275566667 1.25410046075436e-08 
AUTS2 -1.93391505566667 1.25410046075436e-08 
SLCO4A1 1.928310812 1.26263773687695e-08 
PHACTR3 -1.926725331 1.26263773687695e-08 
RPL27A -1.92405867266667 1.27101834168891e-08 
P4HA3 -1.920629197 1.3380197871846e-08 
SCNN1A 1.91909842633333 1.3380197871846e-08 
ULBP2 -1.909348229 1.36189767396195e-08 
DFNB31 -1.907965705 1.3799664542618e-08 
GRTP1 1.90502491566667 1.40681543139269e-08 
HOOK1 1.90408278033333 1.41005526245476e-08 
P2RY1 1.90401910366667 1.41623639484827e-08 
DOK4 1.903931883 1.444163725824e-08 
CHRNA3 -1.90153547033333 1.4737274126139e-08 
 1.89818077966667 1.475693208059e-08 
LCN2 1.89747008 1.48265257770586e-08 
FAM175A -1.89012904033333 1.50547889317623e-08 
DZIP1L -1.886059315 1.51333691332137e-08 
C19orf28 -1.88212480866667 1.52435451720019e-08 
SGCA -1.88064506666667 1.52435451720019e-08 
FAM71F1 -1.88046670133333 1.52877397064632e-08 
FHOD3 -1.88027572133333 1.5315651253694e-08 
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LIMK2 -1.87929828166667 1.54883019646399e-08 
PDZRN4 -1.87795955033333 1.55372890682786e-08 
RAI14 -1.87532656066667 1.59812987118297e-08 
PLAT -1.87463525866667 1.60780605232411e-08 
KCNMA1 -1.87230069433333 1.61578213718312e-08 
AFAP1L2 -1.864118655 1.63020311719093e-08 
NUAK1 -1.859515338 1.64721271521487e-08 
CYR61 -1.85778368966667 1.64812759475383e-08 
QPCT -1.85753683866667 1.64812759475383e-08 
FAM26F -1.85537057033333 1.65559592879683e-08 
HLF 1.85463560966667 1.65584809980791e-08 
NGEF -1.85296104833333 1.65882674737179e-08 
KITLG 1.85242253066667 1.65882674737179e-08 
KCNN1 -1.85157268133333 1.68746270143757e-08 
NRP2 -1.85139867766667 1.69007049656579e-08 
GAL -1.84965868833333 1.69410672259206e-08 
RIIAD1 -1.849597445 1.7031775137804e-08 
TC2N 1.84641133 1.70402903194994e-08 
 -1.83890693633333 1.72618344434678e-08 
TGFBR1 -1.833301297 1.74893648327903e-08 
AHR 1.82853791033333 1.80746695067806e-08 
UNC13A 1.82839606433333 1.80810836468384e-08 
TPM1 -1.82827049933333 1.81798032530666e-08 
RSU1 -1.82819752566667 1.83951717499812e-08 
GPR124 -1.82584426333333 1.86421501509308e-08 
SERPINI1 1.82364100733333 1.86421501509308e-08 
PPP1R3B -1.822534814 1.86838614792398e-08 
TPPP3 1.82240850466667 1.87089505536187e-08 
PRR5L -1.82186309266667 1.88447032051267e-08 
TGFBR3 1.82163617633333 1.88447032051267e-08 
TFEB -1.820695071 1.90909409165011e-08 
ITLN1 -1.82019243166667 1.90909409165011e-08 
HSPB1 -1.817002997 1.92510788741627e-08 
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SLC23A3 -1.81618206866667 1.99332092902725e-08 
TGFB2 -1.815530589 1.99332092902725e-08 
CYR61 -1.81549355933333 1.99332092902725e-08 
DOCK3 -1.813201383 2.04023038197314e-08 
MMP1 -1.81132674833333 2.09425247698406e-08 
CYP1B1 1.81002711533333 2.10427808234417e-08 
CAMKK1 -1.80320690533333 2.10807653927956e-08 
FOXO1 -1.80231788766667 2.10807653927956e-08 
SOX2 1.79797877933333 2.21283953921846e-08 
MYOCD -1.79699795233333 2.21910965926187e-08 
DUSP13 1.79666832266667 2.24839794304184e-08 
PAG1 -1.79586049133333 2.33424617668907e-08 
PTPRR -1.794957862 2.35897597648384e-08 
KCNK5 1.79414714566667 2.36714687443788e-08 
CHST11 -1.793392445 2.37629713518075e-08 
WNT6 1.792515482 2.37629713518075e-08 
HOXB2 1.792163418 2.3990683737266e-08 
DBP 1.79037419866667 2.47649325866954e-08 
SIM2 -1.78811768466667 2.58649445791988e-08 
PMEPA1 -1.78513078033333 2.60233224022183e-08 
KCNF1 1.78492156666667 2.62279216724012e-08 
RNASE4 1.783939846 2.62661908358731e-08 
MICALL2 -1.783721875 2.6512423857241e-08 
TSHZ3 -1.78269672766667 2.66243209962905e-08 
PPFIBP2 1.78258313633333 2.70121549732771e-08 
GPR56 -1.77709104666667 2.77389601678576e-08 
TJP2 1.77690998166667 2.77763119542007e-08 
GPR37 1.775402612 2.86905908701962e-08 
TTLL6 1.77374187166667 2.87828770529278e-08 
ZFP36 -1.77235061 2.96161656979086e-08 
FRMD5 -1.77079392433333 2.98271028741209e-08 
LRP11 -1.76973386066667 3.04901046371787e-08 
LIMD1 1.76910462233333 3.04901046371787e-08 
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 -1.76716951633333 3.05798383183145e-08 
NPC2 -1.76548669066667 3.07901409274839e-08 
EREG 1.76131685766667 3.09066674088366e-08 
 1.7592898 3.14797227416817e-08 
NEXN -1.75711600133333 3.18427825915377e-08 
BIN2 1.75668188933333 3.19285171635484e-08 
DCBLD1 -1.75360932533333 3.21272116938462e-08 
CXCL2 1.75123171533333 3.26645828254085e-08 
LTBP3 -1.74831469566667 3.27425389418319e-08 
FBXO32 -1.745779005 3.36381118560679e-08 
CLN8 -1.743215657 3.44908991990242e-08 
TMEM92 -1.74022250233333 3.45631930596017e-08 
SMOC1 1.73998156966667 3.56922840392838e-08 
TPM1 -1.73763077433333 3.59005543111146e-08 
MXD1 -1.73755417366667 3.64063601430817e-08 
 -1.73718887833333 3.64063601430817e-08 
FGFR1 -1.736068039 3.65824420419311e-08 
MYL10 -1.733926247 3.69892950925847e-08 
VEGFA -1.73329971866667 3.72448066918484e-08 
MFGE8 -1.73166825 3.78393190686829e-08 
CXCL5 1.73087312433333 3.83674074956571e-08 
MRAS -1.73045410833333 3.92386194039128e-08 
FGFR1 -1.72904579133333 3.99074869645553e-08 
CFHR3 1.72722108866667 3.99074869645553e-08 
FAM89B -1.726761759 3.99074869645553e-08 
CEACAM1 1.726052349 4.00706935459578e-08 
ITLN2 -1.72576066333333 4.00811071080798e-08 
SAMD9 -1.721464076 4.05352380584532e-08 
PRKCB 1.719383826 4.07981240708699e-08 
C14orf37 -1.717152925 4.12303910786588e-08 
CA11 1.71579784033333 4.12303910786588e-08 
DCBLD1 -1.715103259 4.17473164009985e-08 
TOB1 1.714897426 4.17473164009985e-08 
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LAMC2 -1.71446800433333 4.34051481749874e-08 
PTHLH -1.71252171733333 4.34976858936906e-08 
 -1.71111782566667 4.38161391551656e-08 
MEI1 -1.71091984333333 4.39254475240426e-08 
GSTT2 -1.70833052566667 4.39687064714498e-08 
DLX2 -1.70825536566667 4.39687064714498e-08 
ARRDC3 -1.70657849066667 4.39908536884725e-08 
PLAU -1.70598289566667 4.42948770320234e-08 
TGFB1I1 -1.70345089233333 4.43954372347099e-08 
ATP2A3 -1.703008128 4.53921170456258e-08 
LHFP -1.70254225966667 4.57413093626722e-08 
HSPB1 -1.70091063533333 4.58539447269548e-08 
COL24A1 1.699309435 4.60205616821375e-08 
PDLIM7 -1.69769205966667 4.62448892116798e-08 
PYGL -1.69740612433333 4.63519364772636e-08 
ALOX5 -1.69678209 4.69889407243582e-08 
PDE8B 1.69540614066667 4.73459791109067e-08 
NOX1 1.69449353166667 4.75704765434664e-08 
LOC154822 1.69379609866667 4.80411287840896e-08 
KRT34 -1.69141750533333 4.81152902613959e-08 
INHBA -1.688136123 4.88143713520117e-08 
LOXL2 -1.687971043 4.93258871382206e-08 
RFTN1 -1.68795722966667 4.9406237753815e-08 
RBP4 1.687650074 4.9406237753815e-08 
TUFT1 -1.685928769 4.96841014405645e-08 
PPL 1.685272733 4.96841014405645e-08 
TNS4 -1.684125925 5.00297642209977e-08 
SIRPA -1.68172303166667 5.00297642209977e-08 
CEACAM7 1.68023655666667 5.12217801896295e-08 
LOC100506686 1.67755093666667 5.12217801896295e-08 
MYL9 -1.67253466066667 5.12217801896295e-08 
S100P 1.672060605 5.20903684606703e-08 
TSPAN13 1.670632026 5.20903684606703e-08 
141 
EPAS1 -1.66930304766667 5.20903684606703e-08 
HIP1 1.667764504 5.39311307505547e-08 
TPCN1 1.666030971 5.43657701732504e-08 
PTK7 -1.66598871066667 5.46055946557815e-08 
CLN8 -1.664478682 5.48405558195469e-08 
VGLL3 -1.66062629066667 5.57537531158815e-08 
TGM2 -1.658069952 5.59052158320934e-08 
TNS1 -1.656009515 5.63808358460917e-08 
RGS22 -1.65402842166667 5.69040332012633e-08 
KIRREL -1.65192638433333 5.69587385275098e-08 
PITX2 -1.65187897666667 5.69587385275098e-08 
GALNT9 -1.649962068 5.79094400837515e-08 
CORO2B -1.64988353933333 5.82278555029251e-08 
MEX3B -1.649183244 5.84230646233395e-08 
ARHGEF18 -1.64810903933333 5.92997815210519e-08 
PDK4 1.64804738 5.93258088895007e-08 
FRG2 -1.64720651766667 5.93258088895007e-08 
COLEC11 1.646325943 6.02535748078826e-08 
ELK3 -1.64497439166667 6.11356507306884e-08 
IL6R 1.641122582 6.14994975253263e-08 
VEGFA -1.640209952 6.24876256943096e-08 
ARSJ 1.639187694 6.26591642905198e-08 
ZNF697 -1.63870695233333 6.36334469031511e-08 
EFHD1 -1.638155378 6.367750756735e-08 
EPAS1 -1.63776255166667 6.38452235664118e-08 
TFAP2C 1.636747486 6.43579222476749e-08 
CAMK2D 1.636270835 6.43579222476749e-08 
CHST11 -1.63550531966667 6.43684812024604e-08 
EPB41L4A 1.635119303 6.43739667848702e-08 
FLVCR2 1.633975526 6.47711129566811e-08 
DACT3 -1.63393665 6.5767005018807e-08 
ROPN1L 1.63327286966667 6.58425098910653e-08 
C6orf105 -1.63300748933333 6.59238672784856e-08 
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VSTM4 -1.63268040466667 6.64925624366874e-08 
ACTC1 -1.63255105466667 6.71325101048475e-08 
CDH1 1.63019116 6.73164971534131e-08 
FAM101B -1.62844234933333 6.74166752262981e-08 
TRIM9 -1.62774090633333 6.79253474824084e-08 
CITED4 -1.62627023766667 6.79253474824084e-08 
GPR162 1.62348108233333 6.98139477213885e-08 
ADAMTS9 -1.62152255033333 7.02053912360362e-08 
ELMO1 1.62063807 7.02406241562333e-08 
GADD45B -1.617126901 7.04861317883651e-08 
ESAM -1.616247307 7.14574100618808e-08 
TCEAL5 -1.61464680033333 7.36701997476997e-08 
HOXC8 -1.613806156 7.39805969111132e-08 
VAMP1 1.61356024266667 7.43934459135052e-08 
TFAP2A 1.61140779366667 7.48648678562606e-08 
TFF3 1.611348443 7.52162495089112e-08 
DIRAS3 1.61056225833333 7.52162495089112e-08 
LIMA1 -1.610009305 7.56629391221337e-08 
SLFNL1 -1.608038597 7.75559652870749e-08 
GPCPD1 1.60295485933333 7.93671684304787e-08 
ELK3 -1.600770511 7.95108590737857e-08 
PLEKHN1 -1.59977799266667 8.01188275311216e-08 
APAF1 -1.59691136733333 8.02483186710238e-08 
SYT11 -1.59613160633333 8.06176335916832e-08 
KCNJ6 -1.594205267 8.1186642637849e-08 
RAB20 1.59310462233333 8.13072863473181e-08 
WDR66 -1.59110949466667 8.14768548977296e-08 
C10orf140 -1.59053513766667 8.20220621234539e-08 
SLC5A10 -1.5903545 8.25733464697975e-08 
HHEX 1.585677926 8.28410654386093e-08 
C3orf80 -1.58503840133333 8.32724138755319e-08 
RAB26 1.58474048733333 8.32958268192073e-08 
ST8SIA4 1.584265721 8.34894711798238e-08 
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 -1.582128011 8.36156572892196e-08 
C20orf196 1.58010445033333 8.36156572892196e-08 
ELF3 1.57922070966667 8.38736928492603e-08 
DOK4 1.57870208 8.45780780808961e-08 
BHLHE40 -1.57509707733333 8.57164806715003e-08 
SAMD14 -1.574983808 8.57164806715003e-08 
SERPINB9 1.57418264766667 8.63693639447176e-08 
QPCT -1.571186091 8.64104407261404e-08 
AUTS2 -1.57063033566667 8.64652210834065e-08 
TM4SF18 1.56974214033333 8.74078025014738e-08 
CAMK2D 1.56892650533333 8.76843453935121e-08 
FMN1 -1.56485516766667 8.79265809062387e-08 
FLRT2 -1.56388159633333 8.87709120063835e-08 
HOXB4 1.56243386566667 8.88860073966031e-08 
BMP1 -1.56205684 8.99056398226098e-08 
ZNF516 -1.55967968433333 8.99056398226098e-08 
 -1.55613149733333 8.9949892870986e-08 
GCLC 1.55554870933333 9.10029451871216e-08 
UACA -1.55482993133333 9.15021120385151e-08 
AHNAK2 -1.55419482133333 9.20509427816119e-08 
PPP1R13L -1.55280512033333 9.24287596190622e-08 
DUSP4 1.55245977966667 9.25527148269484e-08 
NDST1 -1.55226305133333 9.25527148269484e-08 
HIP1 1.54871687533333 9.32589589123038e-08 
KCNN4 -1.54810215133333 9.3411020034236e-08 
NUAK2 -1.54550886433333 9.34538854580698e-08 
BIN1 1.54243934066667 9.3994395598392e-08 
BAAT -1.541295066 9.4645590561058e-08 
RAG1 -1.53797784433333 9.52392894689532e-08 
TRPM6 -1.536396397 9.59006033866002e-08 
TP53I3 -1.53479700166667 9.66955162510512e-08 
OPN3 1.532929163 9.67260563003703e-08 
MIAT -1.53277812933333 9.72004690944417e-08 
144 
BMPR2 -1.529804144 9.73169921539424e-08 
CA2 1.52950755366667 9.76947914550474e-08 
ZFYVE28 1.52907456533333 9.82101151245152e-08 
TPCN1 1.528478257 9.97211062605636e-08 
 -1.52814802366667 1.0020945846639e-07 
BEX4 -1.52780939533333 1.00589086517531e-07 
GPR56 -1.52731063033333 1.00794370616842e-07 
DPEP1 1.526998676 1.01367604529957e-07 
MIAT -1.52611077533333 1.01922402768794e-07 
IRX5 1.52593945 1.01922402768794e-07 
HILPDA 1.52483412733333 1.01974933112542e-07 
COL5A2 -1.52442350533333 1.02517967030522e-07 
NRG4 1.52258819866667 1.03941197584243e-07 
GATS 1.52254719666667 1.0496613059863e-07 
ANG 1.52030746266667 1.06128476134938e-07 
MRAS -1.51717090933333 1.06259411418441e-07 
SYT12 -1.51395916233333 1.06259411418441e-07 
NR1D2 -1.512984615 1.06581166879353e-07 
SDC4 -1.51153262133333 1.06865774268377e-07 
SAMD9 -1.51007159866667 1.07949256356466e-07 
C21orf63 1.50997547666667 1.08099819027445e-07 
TCEAL3 -1.50992212033333 1.09594256396153e-07 
KIAA0182 1.50375718566667 1.10434483144447e-07 
LFNG -1.50355014466667 1.10728477188644e-07 
ARMCX2 -1.50354038233333 1.11403233273328e-07 
PACSIN1 1.50164961166667 1.13118559181904e-07 
TNR -1.50156597366667 1.15276080336234e-07 
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Table 6.2 Expression of TGF-β mediated Smad3 dependent genes in normal versus 
PDAC tumors.  
Symbol logFC_normalvP
DAC 
adj.P.Val_normvalvP
DAC 
logFC_TGFBCtrlvTGFB
SISMAD3 
LAMC2 2.638714758 7.15E-15 -2.753840083 
AHNAK2 1.862427906 8.84E-15 -1.554194821 
FBXO32 1.373784348 3.67E-12 -1.745779005 
S100P 1.177982985 4.61E-11 1.672060605 
CEACAM6 2.676020543 4.84E-11 3.122248173 
KCNN4 0.698837796 5.67E-11 -1.548102151 
TNS4 1.324053897 7.13E-11 -1.684125925 
SCEL 1.620976035 9.09E-11 2.312855397 
ITGA11 1.102795259 1.21E-10 -2.809999498 
PDLIM7 0.792141499 3.33E-10 -1.69769206 
AGR2 2.022349103 3.76E-10 4.517242147 
SLPI 1.687833008 3.76E-10 2.743233727 
PLEK2 1.032971634 4.70E-10 -3.30346004 
PRR5L 0.659273399 7.62E-10 -1.821863093 
PLAU 1.381443313 1.69E-09 -1.705982896 
ECM1 0.756255137 2.87E-09 -1.97493128 
ZNF185 0.554599712 2.87E-09 -2.107670664 
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BCAS1 1.09313189 3.54E-09 4.502373111 
TGM2 1.238534906 4.00E-09 -1.658069952 
BHLHE40 0.834446797 4.83E-09 -1.575097077 
RAI14 0.913454379 6.41E-09 -1.875326561 
SAMD9 1.250711007 6.58E-09 -1.721464076 
PLAT 1.490566633 7.93E-09 -1.874635259 
LOXL2 1.038010973 8.07E-09 -1.687971043 
HSD17B6 0.834635996 1.17E-08 -2.899354403 
CEACAM1 1.140145396 1.47E-08 1.726052349 
PVRL4 0.706840539 1.92E-08 -3.628124316 
INPP4B 1.093206807 2.24E-08 -2.692653851 
SPOCK1 0.721619567 2.24E-08 -2.958050313 
FRMD5 0.529038325 2.57E-08 -1.770793924 
PARM1 -0.796243106 2.57E-08 1.970816724 
FMN1 0.630906131 3.39E-08 -1.564855168 
VDR 0.648569588 4.34E-08 -2.581747332 
PTPRR 0.941607832 4.46E-08 -1.794957862 
C5 -1.17039004 4.55E-08 2.004143196 
GREM1 1.470848774 4.67E-08 -2.712544061 
IGFBP5 1.447138273 4.83E-08 -3.619556297 
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INHBA 1.518812046 5.17E-08 -1.688136123 
NRP2 0.924357604 5.35E-08 -1.851398678 
CHST11 0.7306901 6.08E-08 -1.793392445 
COL5A2 1.418450116 1.04E-07 -1.524423505 
TFAP2A 0.516178302 1.24E-07 1.611407794 
ST6GALN
AC1 
0.790068419 1.37E-07 2.608862087 
ST6GALN
AC1 
0.78999369 1.41E-07 2.608862087 
ADAM19 0.779934481 1.63E-07 -3.38905993 
HHEX -0.69242126 1.88E-07 1.585677926 
COL1A1 1.589983519 2.52E-07 -5.324646195 
CLDN4 0.591929439 3.47E-07 -2.294990248 
SH3PXD2
A 
0.491748085 5.18E-07 -2.063973784 
SERPINI1 -0.859923337 5.63E-07 1.823641007 
SULF2 1.069950422 6.25E-07 -1.96531475 
GPX2 1.451753819 6.50E-07 3.234160953 
FRMD6 0.830707448 9.51E-07 -3.834923246 
ZNF365 0.272449595 9.71E-07 -3.385501744 
COL5A1 0.731632708 1.10E-06 -2.774393093 
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KIF26B 0.571986526 1.15E-06 -4.512902306 
AHR 0.808778435 1.31E-06 1.82853791 
ALOX5AP 0.819059989 1.31E-06 -2.256626692 
DCBLD1 0.726552761 1.41E-06 -2.215235107 
BMP1 0.503229946 1.45E-06 -1.56205684 
PGM2L1 0.752493837 1.88E-06 -2.045265983 
MFGE8 0.717092395 1.89E-06 -1.73166825 
PPEF1 0.50926607 2.18E-06 2.133934098 
DOK4 0.443755012 2.18E-06 1.903931883 
GPR87 1.028485416 2.20E-06 -2.245890878 
PDK4 -1.373371833 2.31E-06 1.64804738 
NRP2 1.077787017 2.79E-06 -1.851398678 
PPP1R3B 0.515937544 3.11E-06 -2.18274195 
DIRAS3 -0.455027691 3.31E-06 1.610562258 
ABLIM3 0.646077395 3.51E-06 -2.81109146 
COL4A2 0.693626262 3.68E-06 -2.458863404 
SLCO4A1 0.508876441 3.86E-06 1.928310812 
TF -0.661957775 3.88E-06 4.097648297 
RAB26 -0.562742927 3.91E-06 1.584740487 
OPN3 0.488284657 4.43E-06 1.532929163 
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TANC2 0.69125832 4.55E-06 -1.976101257 
MXD1 0.806420793 4.70E-06 -1.737554174 
NRG4 -1.56221159 4.88E-06 1.522588199 
B3GALT5 0.787416642 4.92E-06 2.622160357 
CXCL5 1.036652749 5.11E-06 2.523821575 
FGFR1 -0.563290075 5.23E-06 -2.803937723 
C15orf48 0.851246823 5.37E-06 -4.197725071 
GATS -0.536878172 5.77E-06 1.522547197 
TMEM88 -0.673378376 5.88E-06 -3.610293874 
ARRB1 -0.408728596 6.18E-06 2.935150877 
PDGFRB 0.807966905 6.27E-06 -2.306300042 
IGFBP7 0.562700168 6.79E-06 -2.061457431 
SPARC 1.115853155 6.97E-06 -2.980808223 
RNF182 -0.289867302 7.06E-06 -2.552850955 
ACOX2 -0.30612535 7.66E-06 3.540256309 
PRDM1 0.881028851 8.35E-06 -1.977455557 
TUFT1 0.583721626 8.50E-06 -1.685928769 
PDE8B -0.633048043 9.44E-06 1.695406141 
PPL 0.498386877 9.52E-06 1.685272733 
MICALL2 0.276222936 1.12E-05 -1.783721875 
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TSPAN7 -0.942579321 1.20E-05 2.94515172 
SCNN1A 0.848353302 1.37E-05 1.919098426 
LCN2 1.301157545 1.43E-05 1.89747008 
ARHGEF1
8 
0.274045069 1.46E-05 -1.648109039 
CAMKK1 -0.244857618 1.51E-05 -1.803206905 
HILPDA 0.814936842 1.58E-05 1.524834127 
METTL7A -0.643098346 1.66E-05 2.575040609 
BMP4 0.481365837 1.74E-05 1.950526324 
SLC26A9 0.667944302 1.83E-05 3.964097015 
DDC -0.647526718 2.14E-05 3.224883912 
PIK3IP1 0.563708598 2.17E-05 -2.009855712 
CP 1.63173183 2.19E-05 3.473055741 
HOXB2 0.307422003 2.49E-05 1.792163418 
PMEPA1 0.728618312 2.58E-05 -2.000420888 
PTK7 0.523494817 2.67E-05 -1.665988711 
GSTA5 -0.235668617 2.82E-05 4.242025323 
MUC13 1.365925475 3.03E-05 3.228157864 
COL4A1 0.730282232 3.91E-05 -3.376822534 
AFAP1L2 0.435614933 4.10E-05 -1.864118655 
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ATP2A3 -0.497214868 4.13E-05 -1.703008128 
NUAK1 0.72011331 4.33E-05 -1.859515338 
TMEM154 0.56593613 4.87E-05 -1.979779236 
MYL9 0.498128263 5.01E-05 -1.672534661 
BMPR2 0.548297274 5.25E-05 -1.529804144 
XYLT1 0.346416732 5.35E-05 -2.985531061 
DPEP1 -0.930168662 5.60E-05 1.526998676 
SERPINB9 0.684137339 6.47E-05 1.574182648 
FHOD3 0.328892789 6.68E-05 -1.880275721 
ALOX5 0.539208754 6.97E-05 -1.69678209 
LTBP2 0.549249709 0.000103522 -2.030301572 
SPDEF 0.288783808 0.000104772 3.286049889 
SIM2 0.279525596 0.000106217 -1.788117685 
CYP2S1 0.379490564 0.000144563 1.939704225 
MMP2 0.932558908 0.000148334 -3.576303649 
NUAK2 -0.382756815 0.000161631 -1.545508864 
RFTN1 0.553682027 0.000185334 -1.68795723 
LOX 0.95004903 0.000191041 -3.764458134 
NCF2 0.697220205 0.000205094 -2.128605899 
ELK3 0.554845063 0.000218213 -1.644974392 
152 
APOH -0.704812241 0.0002363 2.74160215 
TAS2R1 -0.133767998 0.000254552 -2.84620907 
IRF6 0.681927538 0.00026601 -2.150244118 
KITLG 0.559299276 0.000270036 2.378362081 
FA2H 0.270711868 0.000312491 2.621986268 
TAGLN 0.739436423 0.000336684 -3.083113843 
HLF -0.464848851 0.000337291 1.85463561 
TGFB1I1 0.230271629 0.000340498 -1.703450892 
HIP1 0.38686329 0.000374897 1.667764504 
AREG 1.001547601 0.000378632 2.487657633 
TGFBR3 -0.557471634 0.000385339 1.821636176 
TSHZ3 0.416347175 0.000388172 -1.782696728 
TIMP3 0.550649319 0.000392 -3.273893857 
C4BPB 0.437964714 0.000403669 -2.715511658 
TNFAIP6 1.048675065 0.000428195 -4.390676521 
MMP1 1.094245123 0.000452658 -1.811326748 
EHF 0.747090293 0.000497861 3.082630332 
HAPLN3 0.236638248 0.000661948 -2.980034806 
FGFBP1 0.587019891 0.000761854 2.984017491 
LIMA1 0.451277966 0.000822742 -1.610009305 
153 
AMBP -0.801298857 0.000836225 2.150567764 
KIRREL 0.44918639 0.000904756 -1.651926384 
ELMO1 -0.464445647 0.000935111 1.62063807 
TNR -0.201222586 0.000958908 -1.501565974 
DACT1 0.348341883 0.000971095 -3.961207129 
TRPM6 -0.212309723 0.000973084 -1.536396397 
CYP3A5 0.867386978 0.00103882 1.958568469 
CYP4F3 0.310734048 0.001040339 3.329032147 
ZBED2 0.294506468 0.001270619 -4.100225975 
PCDH9 -0.335135395 0.001287402 -2.092551991 
LIMK2 0.259861717 0.001378115 -1.879298282 
CYP4F12 0.28338208 0.001435476 2.714273851 
CFH 0.693140308 0.001625682 1.939460217 
AREG 0.693162936 0.001677067 2.487657633 
CCKBR -0.421335222 0.001681073 3.244645452 
P2RY1 -0.239280135 0.001718288 1.904019104 
TC2N -0.725634888 0.001760112 1.84641133 
TM4SF18 -0.56289415 0.001873779 1.56974214 
DUSP26 -0.26381212 0.001905783 -2.740861662 
TGFBR1 0.50748759 0.002027592 -1.833301297 
154 
BEX4 -0.332725418 0.002110368 -1.527809395 
MEG3 -0.409377746 0.002278119 -3.014215036 
UACA 0.485077609 0.002410391 -1.554829931 
ARRDC3 0.457576126 0.002610096 -1.706578491 
HOOK1 -0.642034469 0.002814549 1.90408278 
ELF3 0.617512941 0.002994881 1.57922071 
SYT11 0.392968803 0.003046216 -1.596131606 
EREG 0.585404478 0.003114395 2.535201501 
TGFB2 0.650135487 0.003209205 -1.815530589 
PYGL 0.567483499 0.003877723 -1.697406124 
HSPB1 0.495723393 0.003900552 -1.817002997 
GJB1 -0.267295465 0.003915916 2.046861021 
ARSJ 0.232173017 0.003947339 1.639187694 
GCLC -0.30298635 0.00419904 1.555548709 
TSPAN12 -0.334452472 0.004314602 -2.127377044 
ASGR1 -0.205183187 0.004358131 2.23179198 
PPP1R13L 0.247333497 0.004442898 -1.55280512 
STK32B -0.18632671 0.004459746 2.256290031 
RIIAD1 -0.118414505 0.005000186 -1.849597445 
VAV3 -0.257477142 0.00518932 2.122149827 
155 
GPCPD1 0.379237014 0.005235482 2.218296643 
COLEC11 -0.226975516 0.005256437 1.646325943 
CA11 -0.184714824 0.005416679 1.71579784 
SLC23A1 -0.199651495 0.005481121 2.407606848 
TPM1 0.366559581 0.005600127 -2.40398745 
APAF1 0.287496786 0.005601495 -1.596911367 
ARHGEF4 -0.215745556 0.005666464 -2.139265882 
ROPN1L -0.185662835 0.005774355 1.63327287 
CXCL2 -0.54340524 0.005804707 1.751231715 
TFF3 0.479150156 0.006664249 1.611348443 
FLVCR2 0.2827053 0.006669499 1.633975526 
HRASLS2 0.384607296 0.006730425 1.981347329 
VEGFA 0.385459411 0.007006977 -1.733299719 
CSF2RA 0.414390116 0.00729303 2.656033482 
GALNT9 -0.170665815 0.007299509 -1.649962068 
TIMP3 0.434421282 0.008114515 -3.273893857 
TBXAS1 0.33313227 0.008519566 1.97515627 
GPR68 0.149112027 0.008996534 -3.471821356 
MEGF6 0.169605149 0.009474784 -2.525277559 
COL4A4 -0.164019572 0.009701733 -1.977800106 
156 
TRIM9 -0.174812235 0.009723045 -2.168372504 
COL24A1 0.185603487 0.009804752 1.699309435 
ANKS4B 0.299613791 0.009874766 2.057715712 
TJP2 0.257129574 0.010704573 1.776909982 
TMEM92 0.227652681 0.01106979 -1.740222502 
TMEM47 0.354955208 0.011495133 -2.125914393 
CYP1B1 0.60236247 0.011903708 1.810027115 
KCTD11 0.255413271 0.012330674 -2.227411819 
FGF1 0.128014067 0.012628227 -2.268292925 
FOSB -0.767734819 0.013093262 -2.308229922 
PHACTR3 0.140431563 0.013202524 -1.926725331 
TP53I3 0.211476264 0.013606297 -1.534797002 
GDA 0.621042941 0.015112439 2.885120996 
STK32A -0.233445612 0.015835331 -2.712324188 
TCEAL5 -0.108728946 0.016132055 -1.6146468 
SUCNR1 0.173573964 0.016998531 -2.073364187 
C14orf37 0.300000898 0.017044936 -1.717152925 
LPPR1 -0.194579997 0.017180624 1.98410087 
NECAB2 -0.206951858 0.017571132 2.895391716 
MMP10 0.391138485 0.019179961 -3.503883926 
157 
CRX -0.14744195 0.020173946 2.069995744 
CAMK2D 0.311893324 0.020255864 1.636270835 
ERBB3 0.38250676 0.02042191 2.627118391 
KDM6B -0.251947134 0.021547599 -2.122987441 
CORO2B -0.178503365 0.022565104 -1.649883539 
ARHGAP3
1 
0.3218602 0.022781959 -1.945706275 
SLC12A2 0.387419405 0.022933135 2.120195892 
SDPR -0.22300715 0.023597416 2.315158227 
TPPP3 -0.122692223 0.024488604 1.822408505 
VAMP1 0.168544225 0.025845602 1.613560243 
IL6R -0.210853406 0.026184057 1.641122582 
PIK3AP1 -0.283913324 0.026823639 -3.625712684 
RGS9 -0.187027779 0.028323708 -2.268310592 
RNF144B 0.261973485 0.028541859 2.747229973 
NDST1 -0.172142959 0.028740552 -1.552263051 
FAM71F1 -0.117914022 0.029004712 -1.880466701 
PTHLH 0.1954058 0.029650409 -1.712521717 
PACSIN1 -0.191219083 0.030005537 3.968080031 
P4HA3 0.300500447 0.031483439 -2.202860584 
158 
TSPAN13 -0.248473242 0.034974069 1.670632026 
NOX1 0.214701937 0.03628644 1.694493532 
BAAT -0.202371992 0.039161718 -1.541295066 
SERPINE1 0.579197407 0.041267413 -4.170443982 
TCEAL3 -0.158374891 0.046257647 -1.50992212 
CLIC3 0.223414147 0.046796378 -2.080875714 
FLRT3 0.351511789 0.046896843 2.779124899 
SYT13 0.33317043 0.04752032 -2.133300233 
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 Oral presentation titled, “Standardization of Cell Suspension of Melanocytes and 
Keratinocytes,” at the Research Scholar’s Meet (RSM – JIGYASA), 2008 Kishinchand 
Chellaram College, Mumbai, India. 
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